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Abstract 
Compelling data has demonstrated the fundamental role of regulatory T cells 
(Tregs) in immuno-regulation. In vivo animal models indicate that recipient’s 
CD4pos CD25pos T cells adoptively transferred can prevent or control graft versus 
host disease (GvHD) and allograft rejection. Furthermore, it has been 
demonstrated that CD4pos CD25pos T cells from a third party could also be used 
as an adoptive cell therapy to ameliorate allo-responses. Compelling data 
supports that CD45RApos Tregs represent the most homogenous population 
among the overall Treg pool. 
The objective of this study is to test the "Third party approach" using CB Tregs 
to suppress alloresponses. Herein is shown that CB Tregs were mainly 
CD45RApos CD31pos (>80%), which specifically depicts RTE cells that confer a 
wide TCR repertoire. This study shows an optimized one-step isolation method 
using anti-CD25 microbeads that achieves high purity (90%) for CD4pos CD25high 
CD127low T cells and decreases substantially the level of effector T cells (<9% of 
CD4pos CD127high). Due to the low frequency of Tregs (1% from overall 
lymphocytes), the modality of pooling mismatch CB units for Tregs isolation was 
tested. The pooled CB Tregs showed constitutively potent suppression ability in 
vitro. Interestingly, in 40% of the cases a better suppression was seen with pCB 
Tregs compared to individual CB Tregs suggesting a “synergetic effect”. In 
summary, this study suggests that CB units fulfill the optimal properties for the 
isolation of bona fide Tregs, which can be isolated with the highest purity using a 
single step isolation method under GMP standards. Moreover, this study 
suggests that CB Tregs can be intentionally pooled and tailored under the 
required HLA matches for clinical settings.  
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CHAPTER 1 
INTRODUCTION 
 
The grounding studies by Peter Gorer and George Snell discovered the 
involvement of the major histocompatibility complex (MHC) molecules in the 
rejection of transplanted tumors (Gorer, 1948; Snell et al., 1951).  Subsequently, 
it was shown by R. Zinkernagel and P. Doherty (Zinkernagel et al., 1975), that 
the nature of T cell-mediated immunity towards virus-infected cells was 
necessarily through the recognition of self-MHC, process called “self MHC 
restriction”. However, the adoptive transfer of cells or tissue between two 
genetically diverse individuals also evokes an adaptive and specific immune 
response towards non-self MHC/peptide complexes. As many as 10% of donor 
or host T lymphocytes, main participants in allo-response, can strongly 
recognize MHC molecules expressed on the transplanted cells or within the host 
(Lechler et al., 2005). Such recognition can evoke a by-directional immune 
response; 1) Host vs Graft and 2) Graft vs Host (Starzl et al., 2001). These 
immune responses will be dependent of the graft transplanted and the host 
immune-competency. 
 
1.1 Major Histocompatibility Complex 
The primary function of MHC molecules is to elicit an immune response by 
presenting antigenic peptides for recognition by T cell receptors (TCR). Each 
MHC molecule consists of an extracellular peptide-binding cleft, followed by an 
immunoglobulin-like domains and transmembrane and cytoplasmic domains. 
MHC genes are the most polymorphic genes present in the genome and 
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contains > 200 genes, which are located on the short arm of chromosome 6 at 
6p21.3 and mostly are related to immunity (Klein et al., 2000). In humans, these 
genes are called human leukocyte antigen (HLA). There are divided in: HLA 
class I (telomeric end), HLA class II (centromeric en d) and HLA class III (lying 
between class I and II). Class I contains the genes for HLA-A, -B, and –C and 
class II contains HLA-DR, -DP and –DQ (Figure 1). MHC molecules class I 
present peptides endogenously synthesized, wherein MHC molecules class II 
present extracellular antigens endocytosed into vesicles (Engelhard, 1994). 
Therefore, MHC class I molecules present peptides to and are recognized by 
CD8pos T cells, and MHC class II molecules present peptides to CD4pos T cells.        
 
 20 
 
Figure 1.1 MHC gene structure. Figure adapted from John Trowsdale (personal communication). 
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1.2 Innate and adaptive immune system  
The innate immune system provides the first critical mechanisms that allows, a 
rapid sensing and discrimination between self and non-self (Akira et al., 2006; 
Janeway et al., 2002; Medzhitov et al., 2002). The main effector cells of the 
innate immune system are the neutrophils, mononuclear phagocytes and natural 
killer (NK) cells. The pathogenic substances that stimulate innate immunity are 
called pathogen-associated molecular patterns (PAMPs), which are captured by 
pattern recognition receptors. The cellular effectors from innate immunity, mainly 
macrophages and NK cells, secrete a wide variety of cytokines (ie., IFN-!, TNF, 
IL-1, IL-12, etc) that elicit an inflammatory cascade (Janeway et al., 2002).  
However, this system is frequently overwhelmed due to the diverse antigenic 
exposure to which the human being is faced with throughout life. This has driven 
the evolution of the adaptive immune system, which is mediated by B cells and 
T cells. The capture of antigens by antigen presenting cells (APC) and 
subsequently their transportation to secondary lymphoid organs, are the first 
steps in adaptive immunity (Inaba et al., 1984; Steinman, 1991). In contrast to 
innate immunity, adaptive immunity effectors, primarily T cells, confers a wider 
repertoire for antigen recognition (Janeway et al., 2002)(103 molecular patterns 
and 107 distinct antigens, respectively). The major subsets of B cells are 
marginal zone B cells, follicular B cells and B-1 B cells, each subset is localized 
in different location within the lymphoid tissues (Hardy et al., 2000). Likewise, 
there are three main T cell subsets described as helper T lymphocytes (Th), 
cytotoxic T lymphocytes (CTLs) and CD4pos regulatory T cells (Tregs) 
(Mosmann et al., 1989; Sakaguchi et al., 2008). B and T cells have clonally 
distributed antigen receptors that have been created from recombination of DNA 
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segments during their maturation (Goldrath et al., 1999; Jung et al., 2006). For 
the purpose of this study I will only focus on the contribution of T cells in the 
adaptive immune system. 
  
1.2.1 T cell receptor 
TCRs are highly variable antigen-recognition structures. Most mature T cell 
present a disulfide-linked membrane-bound heterodimers consisting of " and # 
chains (Call et al., 2005). Each chain is the result of rearrangement of multiple 
copies of variable (V), joining (J) and in the case of the #-chain, diversity (D) 
segments during T cell maturation and subsequent joining to one of the constant 
(C) regions (Goldrath et al., 1999). The " and # chains within the TCR of a 
mature T cells, contains an amino-terminal variable (V) region and a constant 
(C) region, followed by a short hinge region, a transmembrane region and a 
cytoplasmic tail (Figure 1.2). 
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Figure 1.2 Structure of T cell receptor. This illustration was adapted and can be 
found on bioweb.wku.edu/courses/ biol328/TcR.htm.  
 
 
1.2.2 T cell activation 
T cells are activated through the interaction of their TCR with the antigenic 
peptides within the MHC molecule, process determined as Signal 1. CD8pos T 
cells interact with peptides on almost any cell expressing MHC class I. These 
MHC class I-restricted peptides are produced from proteins translated within the 
cell encoded either by the host or by infecting pathogens that are replicating 
inside the cell. Conversely, CD4pos T cells recognize peptides bearing MHC 
class II that derive from extracellular proteins that were internalized into the 
vesicles of APCs. MHC class II molecules are present on APCs and are 
inducible by the innate immune stimuli. In addition to TCR/MHC peptide complex 
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interaction, T cell activation also requires costimulatory signals, mainly via 
interactions between CD28 on T cells and CD80/CD86 molecules expressed on 
APCs (Signal 2) (Sharpe, 2009).  CD28-mediated signals, enhance T cell 
autocrine secretion of growth factor IL-2 and differentiation of naïve T cells into 
effector and memory T cells. In addition, CD28 favors T cell survival via the 
expression of the antiaoptotic protein Bcl-x. However, there have also been 
described certain homologues molecules that in contrast to CD28 confer 
inhibitory signals (CTLA-4 and PD-1 described later on).   
More recently, it has been shown that the presence of an inflammatory cytokine 
milieu (ie., IL-1, IL-6, IFN"/#, IL-12, IL-21) also plays a major role in T cell 
activation and differentiation (Signal 3) (Ben-Sasson et al., 2009; Curtsinger et 
al., 2010).         
 
 
1.2.3 CD4pos T cell lineages 
CD4pos naïve T cells upon encounter with their cognate antigen have the ability 
to respond in different ways, and to do so they differentiate into a variety of 
effector subsets (Zhou et al., 2009a) (Figure 1.3). This process of differentiation 
is influenced greatly by the cytokines in the microenvironment and the strength 
of TCR interaction with the antigen upon. Th1 cells are characterized by their 
production of IFN-! and are involved in cellular immunity against intracellular 
pathogens. The secretion of IL-12, produced by the innate immune cells as well 
as IFN-! produced by NK and T cells, polarize cells towards a Th1 response 
through the action of the signal transducer and activator of transcription 4 
(Stat4), Stat1, and T box transcription factor T-bet. In contrast, Th2 cells are 
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required for humoral immunity to control extracellular pathogens and their main 
features are the secretion of IL-4, IL-5 and IL-13. Th2 differentiation requires the 
action of GATA3 downstream of IL-4 and Stat6.  Recently it has been described 
a Th17 subset (Harrington et al., 2005), which main characteristic is the 
secretion of IL-17A, IL17F and IL-22. These cells play an important role in 
clearance of extracellular bacteria and fungi, specifically at mucosal surfaces. 
Th17 differentiation requires retinoid-related orphan receptor (ROR)!t (Ivanov et 
al., 2006), a transcription factor that is induced by TGF-# in combination with IL-
6, IL-21 and IL-23 all of which activate Stat3 phosphorylation. Follicular helper T 
(Tfh) cells are a subset that regulates the maturation of B cell responses. Tfh 
differentiation requires the cytokine IL-21 and it has been associated with the 
transcription factor Bcl-6 (Yu et al., 2009b). Lastly, the initial effector T cell 
responses, is often followed by a counter regulatory subset to limit potential 
collateral damage to the tissues. These cells are called induced Tregs (iTregs) 
and will be discussed later on.  
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Figure 1.3 CD4pos T cell lineages. This figure illustrates the differentiation pathway of helper T cells. The according transcription factors and 
cytokines from each subset are exemplified. Adapted from (O'Shea et al., 2010).
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1.2.4 CD4pos T cell plasticity 
As shown previously, it was common knowledge that T cell differentiation is 
irreversible and governed predominantly by the cytokines within the 
microenvironment and by the TCR strength interaction with their cognate 
antigen (Boyton et al., 2002). It is clear that Th1 cell cytokines supress Th2 cell 
differentiation through a feed-forward mechanism. IFN-! induces T-bet, which in 
turn induces Runx3 expression. Runx3 in addition of T-bet, promotes IFN-! 
production while silencing the Il4 gene in Th1 cells by binding to the IFN-! 
promoter and the Il4 silencer, respectively (Djuretic et al., 2007). However, 
current knowledge regarding two new lineages, induced Tregs and Th-17 T 
cells, has shown conflicting levels of plasticity. In a murine model  was shown 
that a scarce population, CD25neg FoxP3pos T cells, downregulated FoxP3 once 
adoptively transfered in vivo and was able to produce detectable levels of IL-17 
and IFN-! (Komatsu et al., 2008). Likewise, it has been shown in human naive 
Tregs CCR6pos population, the production of IL-17 once activated in the 
presence of the pro-inflammatory cytokines IL-1! and IL-6 (Berious et al., 2009).  
Noteworthy, the aforementioned plasticity between Tregs and Th-17 T cells, 
comes from studies performed at the population level. Moreover, since there is 
no specific marker for Tregs in able to achieve a 100% purity, a concise 
differenciation between plasticity or outgrowth of contaminant Th cells cannot be 
attained.  
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1.3 Allorecognition 
Allorecognition refers to the phenomenon by which the immune system from the 
host reacts to non-self MHCp complexes from the donor (Afzali et al., 2007). 
This phenomenon can be elicited through three main mechanisms (Figure 1.4).  
 
1.3.1 Direct-pathway  
It refers to the process when host T cells recognize intact donor MHC molecules 
presented at the surface of donor cells, mainly APCs that were transplanted 
within the graft. The structural basis of T cell direct-allorecognition has led to two 
main theories (Afzali et al., 2008; Archbold et al., 2008). The first one called 
“antigen density model “ proposed by Bevan. This model features the allo-MHC 
molecule as the cornerstone for allorecognition and suggests that engrafted 
cells contain high concentration of allo-MHC molecules, whereto an alloreactive 
T cell will recognize the inherent disparities within the MHC molecule as 
antigenic creating an immune response against the graft, all this independently 
of the bound peptide. This theory is supported by studies where blocking TCR 
contacting regions from allo-MHC inhibits alloresponses. In addition, 
alloreactivity can be elicited in the absence of a bound peptide to the all-MHC 
molecule (Smith et al., 1997). This peptide independent theory would explain the 
higher frequency of alloreactive T cells in contrast to the lower frequency of most 
antigen-specific T cells that focus their recognition upon peptide. The second 
theory called “multiple binary complexes”, suggests that allorecognition is mostly 
peptide-dependent (Matzinger et al., 1977). It assumes that different bound 
peptides in addition to an allo-MHC molecule could produce numerous antigenic 
determinants that will be recognized by a wider population of cross-reactive T 
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cells. Recognition could also be initiated due to peptide similarities between the 
host and the graft, but in spite of that, they appear as foreign due to the 
conformational modifications induced by the polymorphic residues within the 
allo-MHC molecule. More recent studies of alloreactive TCRs using crystal 
structure analysis shows that the bound peptide is involved in numerous close 
interactions with the alloreactive TCR (Housset et al., 2003; Macdonald et al., 
2009). However, both theories are non-mutually exclusive and it is very likely 
that both models take place during direct allorecognition.  
 
1.3.2 Indirect-pathway  
It illustrates the mechanism in which donor MHC molecules are processed and 
presented by host APC. Among the graft-derived peptides presented by the host 
APCs are the minor histocompatibility antigens and also peptides from the donor 
MHC molecules themselves, which are the Major source of polymorphic 
peptides whereto alloreactive T cells respond. The alloantigens scatter from the 
graft are mostly processed and presented by self-MHC class II, therefore CD4pos 
T cells play a Major role in indirect allorecognition.  
  
1.3.3 Semi-direct pathway 
Later on it was described a semi-direct pathway (Herrera et al., 2004), where 
recipient APCs trafficking within the graft are able to acquire intact donor 
MHC/peptide complexes in order to elicit an immune response. The exact 
mechanism that allows the transfer of intact MHC/peptide complexes between 
cells is still not fully elucidated. However, this pathway could also explain the 
described cross-talk between the two main allorecognition pathways (direct and 
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indirect), whereby host APCs acquire allogenic MHC/peptide complex through 
MHC transfer in addition to peptides from allogenic histocompatibility antigens, 
thus a single APC from the host is able to stimulate CD8pos T cells through the 
direct pathway and also recruit CD4pos T cells via indirect allorecognition.  
 
Figure 1.4 Allorecognition pathways. This illustration shows the three mechanisms 
involved in allorecognition. A) Direct-pathway; B) Indirect-pathway and; C) Semi-direct 
pathway. Adapted from (Caballero et al., 2006) 
 
 
 31 
The relative clinical contributions from these pathways in graft rejections are not 
clearly dissected. However growing evidence suggests that direct allorecognition 
plays a major role during the first phase post-transplant, this mostly in part to the 
presence of APCs derived from the graft that inherently evoke higher 
frequencies of alloreactive T cells responding during this initial phase. 
Conversely, indirect allorecognition is an oligoclonal T cell response, which is 
mediated by a selected set of alloreactive T cell clones recognizing a few 
dominant peptides presented by self-MHC (Benichou et al., 1994). This pathway 
has been mostly associated to chronic rejection, since it requires antigen 
processing and thus is less rapid than direct allorecognition. As post-transplant 
time passes, the more prominent indirect allorecognition takes over direct 
pathway. The relative contribution of semi-direct pathway and graft rejection is 
as yet unclear. 
 
1.4 Hematopoietic stem cell transplantation (HSCT) 
The use of HSCT has become an important modality in the management of 
hematological malignancies and inherited metabolic disorders (IMD) (Boelens et 
al., 2010; Hough et al., 2010; Jenq et al., 2010; Nowak, 2008; Socie et al., 
2009). The main complication of HSCT is acute or chronic graft versus host 
disease (GvHD). GvHD is an immunological mediated disease that affects 
substantially transplant-related morbidity and mortality in HSCT patients. The 
overall incidence is between 40 to 60%, with approximately a 50% mortality rate.  
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1.4.1 Acute Graft versus Host Disease 
There is currently a three-phase model to exemplify the process that leads to 
GvHD (Figure 1.5) (Ferrara et al., 2009). Phase 1 (conditioning/afferent phase): 
The conditioning regimen used in HSCT initiates the pathogenic process of 
GvHD. Therefore, the use of myeloblative regimens either with total body 
irradiation or high-dose of chemotherapy, elicit host tissue damage mainly in the 
liver, intestinal mucosa between other tissues, through the secretion of 
inflammatory cytokines (IL-1, TNF-", GM-CSF and IFN-!). In addition, this could 
lead to MHC up-regulation from the host, thus resulting in a wider repertoire of 
antigens for recognition by alloreactive T cells. Phase 2 (induction and 
expansion): The subsequent presentation of host antigens to donor T cells will 
evoke proliferation and differentiation towards effector T cells. Donor CD4pos T 
cells induce GvHD, directed to MHC II molecule disparities, likewise, donor 
CD8pos T cells will elicit GvHD responding to MHC I disparities. Moreover, 
disparities in minor histocompatibility antigens (miH) can elicit as well GvHD. 
Host APCs are essential in this phase, not only for providing host pMHC for 
recognition, but also via secretion of IL-1 and providing costimulatory signals to 
alloreactive T cells. Phase 3 (effector phase): this complex phase is responsible 
for the characteristic features of GVHD of end-organ dysfunction and tissue 
damage. Th-1 preponderance over Th-2 responses constitutively elicits GvHD. 
Although the cytolytic function of cytotoxic T lymphocytes (CTLs) are paramount 
in the effector phase of GvHD, NK cell’s effector properties have also been 
implied in GvHD pathology. In general, the cellular damages are caused through 
these main cellular contact-dependent pathways: TNF"-mediated cytotoxicity, 
perforin-granzyme B-mediated and Fas-FasL-mediated apoptosis.     
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Figure 1.5 Acute GvHD pathophysiology. Adapted from (Ferrara et al., 2009). This 
illustration exemplifies the three phases of acute GvHD. The main cell subsets as well 
as the cytokines involved in the process are also shown. In addition it illustrates the 
therapeutic potential of Tregs within this process.  
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1.5 Solid organ transplantation (SOT)  
The introduction of modern immunosuppressive agents has led to a great 
success achieving short-term allograft survival (Overall #92% 1-year graft 
survival) (Fehr et al., 2004; Lechler et al., 2005) in SOT. However, these agents 
have not been effective to avoid graft loss due to chronic rejection (Overall 
#65% 5-year graft survival). In addition to the correlation between HLA 
mismatches and graft-survival, alloantigen-independent mechanisms like 
ischemia-reperfusion injury and growth factors that drive tissue remodeling are 
also involved in the initiation and perpetuation of chronic rejection. Vascularized 
grafts like the heart and the kidney are bona fide targets for chronic rejection 
pathology. These grafts slowly develop arterial occlusion as a result of the 
proliferation of intimal smooth muscle cells and lastly fail due to ischemic 
damage. In addition and in contrast to HSCT, SOT requires the administration of 
constant immunosuppression. This leads to important side effects like an 
enhanced risk of opportunistic infections, cancer, nephrotoxicity, hypertension 
and cardiovascular disease.  
 
In view of the current results in HSCT and SOT, the common general consensus 
to address the aforementioned hurdles in both settings is the establishment of 
immunological tolerance. This approach should prevent GvHD and the 
development of chronic rejection and will avoid the secondary effects due to the 
requirement of long-term immunosuppression in SOT.       
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1.6 Immunological Tolerance 
Paul Ehrlich proposed in 1906, that the immune system is programmed to avoid 
the generation of autoreactive immune responses “horror autotoxicus”. Later on, 
F. Burnet based on his clonal selection theory, demonstrated that autoreactive 
clones are normally deleted at immature stages, however it was considered that 
some autoreactive clones could escape this process. Further on, P. Medawar 
coined the term “actively acquired tolerance” as: the state of indifference or non-
reactivity towards a substance that would normally be expected to initiate an 
immunological response (Billingham et al., 1953; Medawar, 1961). These 
groundbreaking experiments showed an early window in life wherein the 
adoption of foreign homologous cells can be accepted and included as part of 
the self-antigen repertoire and, hence allowing the acceptance of further grafts 
from the same donor strain.      
 
Immunological tolerance can be subdivided in two non-mutually exclusive 
mechanisms: Recessive and Dominant. Recessive tolerance refers to the cell-
intrinsic mechanisms that include elimination of self-reactive thymocytes or 
chronically stimulated peripheral T cell clones by apoptosis or their inactivation 
through anergy induction. Dominant tolerance is mediated by a specialized 
subset of cells that restrain pathogenic immune responses. The immunological 
mechanisms of tolerance to allo-antigens confer great similarity towards the 
ones involved to self-antigens. However, the greater frequency of alloreactive T 
cells compared to the lesser repertoire involved to self-antigens becomes a 
difficult task to outdo in clinical transplantation.  
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1.6.1 Recessive tolerance: The thymus plays a major role for the maintenance 
of self-tolerance. The repertoire of developing thymocytes is purged of cells 
withholding TCRs with high avidity to peptide-MHC (pMHC) complexes 
presented in the thymus, process called “thymic negative selection”. In addition, 
the nuclear factor named autoimmune regulator (Aire), aids this process by 
controlling the ectopic expression of “tissue restricted antigens” within the 
medullary thymic epithelial cells (mTECs). Therefore, the two main factors 
involved in thymic negative selection are: the self or non-self antigen 
concentration within the thymus and the affinity of the thymocytes TCR that 
recognizes the antigen. If such conditions occur, T cell deletion can be evoked 
from double-positive T cells in the thymic cortex or from newly generated single-
positive T cells in the medulla (Singh et al., 2006; von Boehmer et al., 2010). 
This process is important for both CD8pos and CD4pos T cells, since it affects 
both class I and class II MHC-restricted T cells, respectively. Recessive (also 
called central) tolerance can be induced experimentally by infusing donor 
antigens into the thymus. However, this process only achieves transient 
tolerance due to the lack of continuous administration of donor antigens. 
Conversely, if donor antigens are administered in a short window early in life or 
when a replacement of the immune system is attempted using hematopoietic 
stem cell transplantation based protocols, a continuous supply of donor antigens 
to the thymus allows life-long negative selection of donor-reactive thymocytes 
(Fehr et al., 2004; Medawar, 1961).  
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1.6.1.1 Anergy  
Full activation of CD4pos T cells requires the binding of pMHC complexes (signal 
1) in addition with co-stimulation provided by APCs (signal 2). However, 
aberrant activation of the TCR alone in a non-inflammatory scenario can elicit a 
long-term state of functional unresponsiveness known as Anergy (Fathman et 
al., 2007). This process was first described from in vitro studies, where CD4pos T 
cells were exposed to pMHC complexes on APCs devoid of B7 molecules. The 
resulting T cells remain viable whilst unresponsive even to further stimuli by 
competent APCs. The 2nd signal is required for an efficient TCR-induced 
transcription of the il2 gene, thus anergic T cells are unable to synthesize IL-2, 
resulting in an abortive proliferative response. Moreover, anergic T cells are 
unable to secrete inflammatory cytokines such as IFN-! and TNF". In addition, T 
cells can also become anergic when encounter with inhibitory receptors of the 
CD28 family. The two main inhibitory receptors described are the cytotoxic T 
lymphocyte-associated Ag-4 (CTLA-4) and programmed cell death-1 (PD-1) 
(Fife et al., 2008). A CTLA-4 and PD-1 knockout mice, results in uncontrolled 
multiorgan autoimmunity, suggesting their important role to keep T cells in 
check. CTLA-4 shows a higher affinity towards CD80 and CD86 on APCs 
compared to CD28, therefore it is suggested that APCs that express low levels 
of CD80 or CD86 will preferentially bind to CTLA-4 and therefore dampen the 
immune response. Costimulatory blockade using CTLA-4-Ig antibody has also 
been used to efficiently induce tolerance in pre-clinical models. However, T cell 
deletion and suppression can also be elicited through this approach. 
Interestingly, the ligands for PD-1, PD-L1 and PD-L2, are not exclusively and 
functional required to be presented on APCs, since parenchymal tissues can 
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also expressed these ligands and therefore allow PD-1 activation. It is 
suggested that CTLA-4-B7 interactions terminate proliferation and promote 
anergy induction during the initial response to pMHC, whereas PD-1-PD1-ligand 
interactions might restrain previously tolerized autoreactive T cells that 
encounter their pMHC complexes within the peripheral tissues. 
 
1.6.1.2 Deletion  
Cell death that occurs as a consequence of antigen recognition has been known 
as activation-induced cell death. This may occur through the activation of a pro-
apoptotic protein called Bim. Normal lymphocyte responses elicit anti-apoptotic 
proteins of the Bcl-2 family, however if T cells encounter antigen in the absence 
of costimulation, Bim may be activated and elicits death through the 
mitochondrial pathway. Furthermore, continuous stimulation of T cells can also 
result in expression of Fas (CD95) and its ligand FasL. Ligation of both 
receptors leads to the activation of caspase-8 and consequently the induction of 
apoptosis (Siegel et al., 1990; von Boehmer et al., 2010).  
 
1.6.1.3 Ignorance  
One barrier to self/non-self pMHC complex recognition is the physical separation 
of reactive T cells from the parenchymal cells that express their cognate antigen. 
This might occur either by the inability of donor antigens (within the graft) to 
reach the host lymphoid system (no priming), or by the inability of host 
lymphocytes to reach the graft (no effector function). This mechanism is only 
achieved in non-vascularized grafts (e.g. corneal allografts); therefore it is 
unlikely to apply to most of solid organ transplants in humans, since every 
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vascularized solid organ transplant can be reached by host lymphocytes and 
passenger leukocytes within the graft traffic to the host lymphoid tissues (Fehr et 
al., 2004). 
 
1.6.2 Dominant tolerance: Gershon in 1970 first showed the conception of 
having T cells that not only augmented, but also were able to dampen immune 
responses and called them “suppressor cells”. Further studies described 
peripheral immuno-regulatory mechanisms that are also in place withholding 
allo-reactive cells and allowing a state of tolerance (Dorsch et al., 1975; Roelen 
et al., 1998; Waldmann, 2008). At present compelling data supports that CD4pos 
FoxP3pos Tregs represent a known population acting as dedicated mediators of 
dominant tolerance (Sakaguchi, 2000).     
 
1.7 Types of regulatory T cells 
Even though several cells with suppressive capacities have been described (NK, 
B cells, CD8pos, !$ T cells, DCs, etc), for the purpose of this study I will review 
briefly the studies on Tr1, Th3, induce CD4pos FoxP3pos Tregs (iTregs) and lastly 
focus mainly on natural occurring Tregs cells (nTregs), which are the subjects of 
this study. 
 
1.7.1 Tr1 cells 
These specific cells are mainly induced regulatory T cells that have arisen from 
naïve CD4pos T cells stimulated with tolerogenic dendritic cells in the presence of 
IL-10 (Foussat et al., 2003; Groux, 2003; Roncarolo et al., 2001). Their main 
characteristic is high production of IL-10 with lesser secretion of TGF-%, 
 40 
endowing their capacity to suppress other naïve and memory T cells in vitro and 
in vivo, this suppressive effect could be reverted by adding IL-10 blocking 
antibody (Groux, 2003; Roncarolo et al., 2001). Noteworthy, since all the CD4pos 
T cells including Th1, Th2, Th17 and even nTregs are capable to secrete IL-10 
under certain circumstances, Tr1 may represent a certain state of each existing 
lineage. However, they do not express FoxP3 like nTregs. Therefore, currently 
there are no specific markers for these cells, thus it is difficult to track them and 
highly purified them ex vivo, and foremost guarantee their suppressive 
phenotype stability. 
 
1.7.2 Th3 cells 
Some experiments showed that specific non-reactivity to certain antigens can be 
induced when administered via oral route “ Oral tolerance “ (Faria et al., 2005). 
The responsible cells for this effect were reported as "%T cells restricted to class 
II with high secretion of TGF-%, IL-10, diminished IL-4 and no secretion of IFN-! 
or IL-2 (Chen et al., 2007). In addition, it has been shown that Th-3 cells TGF-
%’s secretion favors the transcription of FoxP3 and functionality of iTregs (Carrier 
et al., 2007). At present there are no specific markers available for Th-3 cells, as 
well as no certainty about their commitment to their suppressive phenotype once 
they are adoptively transferred in a pro-inflammatory scenario.  
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1.7.3 Induced CD4pos FoxP3pos Tregs (iTregs) 
The induction of FoxP3pos Tregs with suppressive capacity can be elicited from 
FoxP3neg T cells during homeostatic peripheral proliferation (Curotto de Lafaille 
et al., 2004). It has also been shown within a transplant tolerance model using a 
non-depleting CD4 antibody, the conversion from CD4pos naïve T cells into allo-
specific FoxP3pos Tregs (Cobbold et al., 2004). Moreover, CD103pos DCs 
present in the gut and mesenteric lymph nodes are optimal inducers of iTregs 
through the secretion of retinoic acid and TGF-% (Coombes et al., 2007). As 
previously mentioned, TGF-% plays an important role in FoxP3 transcription and 
stability in iTregs (Carrier et al., 2007; Chen et al., 2003; Chen et al., 2007; 
Horwitz et al., 2003, 2008; Zheng et al., 2002). Therefore, in contrast to nTregs 
the generation of iTregs, is done in the periphery under various conditions and 
are dependent of IL-2. Due to the great phenotype similarity between nTregs 
and iTregs, there is still uncertainty regarding the extent of contribution of each 
cell subset within an immune response. Nonetheless, it is very likely that 
wherein a correlation has been found between the presence of Tregs and 
chronic infections and poor prognosis in solid tumors is mainly due to iTregs 
(Cavassani et al., 2006; Menetrier-Caux et al., 2009; Piersma et al., 2008). 
However, nTregs and iTregs may also act synergistically to obtain optimal 
immune-regulation.   
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1.7.4 Natural occurring regulatory T cells (nTregs) 
The initial studies showing disruption of self-tolerance by mouse neonatal 
thymectomy, suggested that a thymus-derived cell subset was capable of 
mediating immune tolerance by withholding other cell subsets (Nishizuka et al., 
1969). Neonatal thymectomy between the 2nd and 4th day of life resulted in 
systemic T cell mediated lesions, which could be reverted by the adoptive 
transfer of splenocytes or thymocytes from an adult mice (Sakaguchi et al., 
1982). Subsequently, S. Sakaguchi in 1995 described a CD4pos T cell population 
in mice that co-express the IL-2 receptor " chain (CD25), which had the 
capacity to suppress in a dose dependant way to its counterpart population 
(CD4pos CD25neg)(Sakaguchi et al., 1995). In accordance, a similar population 
with the same suppressive ability was described in humans (Baecher-Allan et 
al., 2001).    
 
Mutations in the forkhead box P3 (FoxP3) transcription factor are associated 
with an autoimmune disorder in human patients called IPEX syndrome (immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked) and the murine 
homologue scurfy mice (Bacchetta et al., 2006; Bennett et al., 2001; Chatila et 
al., 2000; Wildin et al., 2001). The characteristic feature of this disorder is early 
lymphoproliferative immune-mediated disease affecting a variety of organs and 
tissues. Eventually, it was shown that FoxP3 is of great importance for Tregs 
development and functionality (Fontenot et al., 2003). However, later on, it was 
also shown that FoxP3 expression could also be upregulated transiently in 
effector T cells that confer no suppressive function (Morgan et al., 2005; 
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Roncarolo et al., 2008). Nonetheless, FoxP3 is the most accepted marker for 
nTreg characterization in a steady state of no inflammation. 
  
These regulatory T cells have been coined as natural occurring self-antigen 
driven emigrants from the thymus and normally constitute around 4 to 10% from 
the CD4pos T cells (Ito et al., 2008; Sakaguchi et al., 2008). FoxP3pos cells are 
detected with increased frequency since CD4pos CD8pos double-positive to 
CD4pos CD8neg single-positive stages (Fontenot et al., 2005c). Recently, it was 
suggested that nTreg selection is facilitated by TCRs that endow affinities 
towards self-peptides falling within a range between positive selection of 
conventional CD4pos T cells and negative selection of high-affinity self-reactive T 
cells (Wing et al., 2010). Therefore, FoxP3 development is difficult to be 
explained solely on TCR specificity. This notion supports the studies that have 
shown an important TCR overlap between conventional CD4pos CD25neg T cells 
and nTregs in humans (Pacholczyk et al., 2006). Besides TCR signaling 
contribution for nTreg development, it has been shown a marked decrease in 
frequencies of Tregs in CD28-deficient and CD80/CD86-deficient mice (Tai et 
al., 2005). Therefore, the costimulatory pathway has an essential cell-intrinsic 
role in nTregs differentiation. 
 
In addition, IL-2 is also essential for nTregs differentiation, since IL-2 or IL-2R" 
chain deficient mice, exhibit a marked decrease of FoxP3pos thymocytes 
(Fontenot et al., 2005a). Furthermore, activated STAT5, downstream of IL-2 
receptor signaling, regulates FoxP3 transcription (Burchill et al., 2007; Wuest et 
al., 2008). Therefore, IL-2 is paramount for Tregs differentiation and phenotype 
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stability. In contrast to in vitro studies, Tregs have shown the capacity of 
proliferating in vivo (Klein et al., 2003). Recently it has also been shown that the 
activation of the transcription factors Smad3 and NFAT, through the presence of 
TGF-%, is necessary for the histone-acetylation pattern in the Foxp3 5’ enhancer 
region, suggesting their involvement in nTreg development (Tone et al., 2008).  
It has been shown that induction of Tregs towards non-inherited HLA maternal 
antigens (NIMAs) are developed in early life in utero (Mold et al., 2008). These 
Tregs are maintained throughout life preserving their potent suppression ability 
against maternal antigens. However, during lifetime nTregs suffer phenotype 
changes, mainly starting with a naïve phenotype and eventually becoming 
central memory (Santner-Nanan et al., 2008). In reference some studies have 
explained that a subset of Tregs pool is maintained throughout life by 
homeostatic proliferation generated from highly differentiated memory CD4pos T 
cells (Vukmanovic-Stejic et al., 2006). This, in theory would allow having enough 
Treg cell numbers throughout life to maintain self-tolerance and counteract any 
possible deleterious immune response towards the host. nTregs also express 
the glucocorticoid-induced tumor necrosis factor receptor family-related gene 
(GITR). This receptor has been shown to have increased expression upon T-cell 
activation (Zhan et al., 2004), and it is thought to play a key role in dominant 
immunological self-tolerance. In accordance, signalling through this receptor 
abrogates nTregs suppressive capacity (McHugh et al., 2002; Nocentini et al., 
2005; Shimizu et al., 2002). 
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1.8 Mechanisms of suppression 
For the purpose of this study I will only focus on the mechanisms of suppression 
reported from CD4pos FoxP3pos Tregs (nTregs and iTregs). Most of the studies in 
vitro have shown that Tregs suppression is cell-contact dependent (Thornton et 
al., 2000). Although a more current consensus suggests that the activation 
process is cell-contact dependent, and once activated, the suppressive 
mechanisms will vary depending of the site, target cell and evolving factors of 
the immune response in hand (Vignali et al., 2008). The variety of Tregs 
suppressive mechanisms can be summarized into those that directly target T 
cells and those that primarily target APCs (Figure 1.6 A and B) (Shevach, 2009).  
 
1.8.1 Mechanisms that target conventional T cells 
Cytolysis: Some studies have shown that Tregs expressed granzyme A and that 
in conjunction with perforin and adhesion to CD18, they can mediate target-cell 
killing (Grossman et al., 2004). Moreover it was shown a lack of suppressive 
ability in Tregs from mice with granzyme-B-deficiency (Gondek et al., 2005).  
IL-2 consumption: Initial studies showed that IL-2 is also essential for Tregs 
suppressive function (Thornton et al., 2004a). Others have shown that Tregs 
compete for IL-2 secreted from effector T cells, resulting in effector T cell 
apoptosis (Pandiyan et al., 2007).  
 
Cytokine mediated: Several studies in vivo have also shown that different 
cytokines like IL-10, TGF-% and more recently IL-35 are involved in Tregs 
suppression ability. Although, there is still some controversy whether these 
cytokines are secreted by nTregs or iTregs (Vignali et al., 2008).  
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IL-10: A population characterized as CD4pos FoxP3pos ICOSpos, has shown to 
mediate suppression through contact with dendritic cells in an IL-10 dependent 
manner (Ito et al., 2008). Allergen-specific Tregs adoptively transferred to an 
asthma mouse model were able to control the disease (Roncarolo et al., 2001). 
This effect was reverted by blocking-IL-10 antibody. However, this effect was 
also seen when administered IL-10 deficient Tregs. In addition, it has been 
shown that the tumor microenvironment induces FoxP3+ T cells that mediate 
suppression through secretion of IL-10, affecting tumor immunosurveillance 
(Strauss et al., 2007). Moreover, IL-10 production by Tregs are essential for 
preventing immunopathology in mouse IBD models (Asseman et al., 1999). 
 
TGF-%: From current studies it has been shown that Tregs can mediate 
suppression either by soluble or membrane-tethered TGF-%. TGF-% secreted 
from Tregs has been shown in different scenarios like chronic infections, allergy, 
IBD models and tumors (Huber et al., 2006; Nakamura et al., 2001). Moreover it 
was shown that membrane-tethered TGF-% Tregs can control CD8pos T cells 
infiltration in a diabetes mouse model (Green et al., 2003).  
 
IL-35: Recently it was discovered a new regulatory cytokine: IL-35, which is a 
member of the IL-12 family. It was shown a preferential expression of IL-35 in 
FoxP3pos Tregs and not in resting or activated effector cells. In addition it was 
shown that ectopic expression of IL-35 in naïve T cells conferred them 
regulatory activity (Collison et al., 2007) (Figure 1.6 A).  
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1.8.2 Mechanisms directed towards APCs 
L-selectin (CD62L) acts as a "homing receptor" for leukocytes to enter 
secondary lymphoid tissues via high endothelial venules. CD62L-mediated 
lymphocyte recirculation is required for the proper distribution of both naïve and 
effector T cells between sites of inflammation and secondary lymphoid tissues 
(Grailer et al., 2009). In accordance, it has been demonstrated in a mice GvHD 
model, that only CD62Lhigh Tregs interfere with the activation and expansion of 
GvHD effector T cells within the secondary lymph nodes (Taylor et al., 2004). 
It has also been demonstrated using intravital miscroscopy that Tregs highly 
interact with dendritic cells (DCs) in vivo (Tang et al., 2006). Tregs constitutively 
express CTLA-4, which can elicit inhibitory signals to DCs, thus, diminishing 
effector T cell activation. CTLA-4 signal can activate indoleamine-2,3-
dioxygenase (IDO), which generates the immunosuppressive mediator 
kynurenin (Grohmann et al., 2002). Signaling through CTLA-4 also promotes the 
nuclear localization of Foxo transcription factors, which hampers the expression 
of genes encoding IL-6 and the phosphorylation of the tumor necrosis factor 
(Dejean et al., 2009), hence, blocking the cytokine-mediated inflammatory 
cascade. Secondly, it has been shown that Tregs expressed LAG3, which is a 
CD4 homologue that will bind to the MHC class II molecules blocking DC’s 
maturation (Huang et al., 2004). Likewise, it has been recently discovered that 
neuropilin (Nrp-1), receptor for class III semaphorins and a coreceptor for 
vascular endothelial growth factor (VEGF), promotes longer interactions 
between Tregs and immature DCs, thus inhibiting interactions between naïve T 
effector cells and DCs (Sarris et al., 2008).    
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Lastly, in the immune system, extracellular ATP functions as an indicator of 
tissue destruction and also favors APCs maturation. CD39 is the dominant 
ectoenzyme that has the capacity to hydrolyze ATP or ADP into AMP. CD39 
expression among Tregs has been associated with their suppressive function by 
inducing the immunoinhibitory molecule adenosine (Borsellino et al., 2007; 
Deaglio et al., 2007; Fletcher et al., 2009).  
 
In summary we can say that Tregs have a wide range of suppressive 
mechanisms. The context in which the immune response evolves will dictate the 
role of Tregs and their mechanisms of suppression (Figure 1.6 B).  
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A) 
 
B) 
 
Figure 1.6 Mechanism of suppression of CD4pos FoxP3pos Tregs. This illustration 
shows the mechanisms of suppression of Tregs and divide them in context of their 
target cell subset; A) Directed towards conventional T cells and B) directed towards 
APCs. These illustrations are adapted from (Shevach, 2009). 
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1.9 Clinical evidence and applications 
The initial identification of FoxP3 mutation in IPEX patients was solid evidence 
to support the existence and clinical relevance of nTregs (Bacchetta et al., 2006; 
Bennett et al., 2001; Chatila et al., 2000).  Interestingly, these patients confer a 
similar frequency of CD4pos CD25high T cells in comparison to healthy controls. 
However, the suppressive capacity of this Tregs is diminished and also the 
capacity of their conventional T cells to produce IL-2 and IFN-! upon activation 
(Bacchetta et al., 2006). Subsequently, compelling data has evolved around 
Tregs association with poor prognosis in solid organ tumors (Li et al., 2007; 
Perrone et al., 2008). It has been proposed that tumor cells induce Tregs that 
will create a tolerogenic microenvironment around the tumor that could restrain 
effector T cells response against them. Current cancer therapies for these 
tumors are focusing either on depleting Tregs or targeting key factors involved in 
Tregs mechanisms of suppression (Curiel, 2008). In concordance with these 
reports, it has also been shown correlation between higher Tregs frequency and 
chronic immunopathology by some pathogens (Cavassani et al., 2006; 
Hasenkrug, 2003).  
Recently, it has been proposed that recent thymic emigrants (RTE) naïve 
CD4pos T cells (CD4pos CD45RApos CD31pos) are important to prevent 
autoimmunity (Kohler et al., 2008). In concordance, it has been demonstrated in 
multiple sclerosis patients that a decrease of CD45RApos CD31pos Tregs could 
be associated with the immunopathology of these patients (Haas et al., 2007). 
Moreover, data has been reported about defective Tregs in type1 diabetes 
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(T1D) and rheumatoid arthritis (RA) patients (Brusko et al., 2008a; Nadkarni et 
al., 2007).  
In the area of solid organ transplantation, to my knowledge only one study has 
been able to correlate Tregs with good graft survival (Eljaafari et al., 2006). 
Conversely, in HSCT settings, it has been shown an association between GVHD 
and a reduced ratio between effector and Tregs cells (Matthews et al., 2009; 
Rezvani et al., 2006). Current data on cord blood used as a source for HSCT 
has suggested that the combination of naïve Tregs and naïve effector T cells, 
could be partly responsible for the lower degree of GvHD reported (Chang et al., 
2005; Hippen et al., 2008). In concordance, several studies have shown the 
potent suppressive ability of cord blood naïve Tregs (Bresatz et al., 2007; Ito et 
al., 2008; Porter et al., 2006; Santner-Nanan et al., 2008). Lately, evolving data 
has supported that CD45RApos Tregs represent the most homogenous 
population with superior suppressive capacity (Hoffmann et al., 2006b; Seddiki 
et al., 2006b). 
New strategies are currently ongoing to achieve adequate Treg cell numbers for 
cellular immuno-therapy with high purity and potent suppressive capacity 
(Baecher-Allan, 2006; Bresatz et al., 2007).  Since FoxP3 is an intranuclear 
marker it cannot be used for viable cell isolations. Furthermore, CD4 and CD25 
gating strategies are not specific enough to isolate pure Tregs from adults. 
Recent sorting techniques have been described using CD25high CD127low gate 
on CD4pos T cells, this shows a 90% correlation with FoxP3pos cells ex vivo and 
in vivo (Liu et al., 2006; Seddiki et al., 2006a). Most of the studies on Tregs 
isolation methods for clinical purposes have recommended multiple step 
protocols, mostly CD8, CD19 and most recently CD49d depletion (Kleinewietfeld 
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et al., 2009; Peters et al., 2008; Riley et al., 2009). Nevertheless, low purity 
(<60% FoxP3pos) continues to be an issue for stepping into bigger scale models 
and clinical trials. 
 
 Additionally, Tregs only constitute between 4 to 10% of peripheral CD4pos T 
cells, thus, expansion techniques have been created needing 3 to 4 weeks time 
of culture with >200 folds increase (Brusko et al., 2008b). Most of the expansion 
protocols have shown the need to add rapamycin to prevent outgrowth of 
effector contaminating cells (Battaglia et al., 2006). This mainly because of the 
higher level of contaminating effector cells (#40%) using current GMP isolation 
methods. Therefore, insufficient yield and low purity are still the main drawbacks 
to achieve a high purity product with clinical grade standards for cellular 
immunotherapy (Hoffmann et al., 2006a; Peters et al., 2008; Wichlan et al., 
2006).  
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1.10 Objective of this study 
The objective of this study is to test the "Third party approach" using CB Tregs 
to suppress alloresponses. In order to address this, the first objective is to fully 
characterize CB Tregs in comparison to adult Tregs. Secondly, optimize a one 
step CD25 Ab selection protocol for cord blood Tregs, which could be translated 
to large-scale isolations with high purity and clinical grade standards. Thirdly, 
test their suppressive potency in comparison with host adult Tregs. Fourthly, test 
the feasibility of mixing “Pooling” naive Tregs from cord blood units and evaluate 
their suppressive effect in vitro. The hypothesis is that by specifically pooling 
naive Treg cells from cord blood we could maintain their individual proliferative 
capacity as well as their naïve repertoire. Since these cells will be considered 
“third party”, it will be of great importance to have multiple repertoires to increase 
the chances of TCR engagement in vivo and thus activation.  
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  CHAPTER 2     
  MATERIAL AND METHODS 
2.1 Introduction 
 
The study described in this thesis focuses on the isolation of CD4pos CD25high 
CD127low T cells from cord blood mononuclear cells (CBMCs) employing 
magnetic particles coupled with specific antibodies. The results and 
translation from the two-step protocol recommended by the manufacturer 
employed in adult peripheral mononuclear cells (PBMCs) to a single-step 
protocol for CBMC’s will be shown in the relevant result chapter. This is to 
highlight the new optimized protocol that enable the study of highly purified 
CD4pos CD25pos CD127low T cells using a practical and reproducible one-step 
method. Results obtained during the optimization of different techniques and 
functional assays will be included within this chapter rather than in the results 
chapter, this with the only intention to focus more on the measurements 
regarding the actual effect in vitro or in vivo of CD4pos CD25pos CD127low T 
cells from cord blood rather than the results of the preliminary experiments.   
 
2.2 Samples and healthy donors 
CB units were collected from normal and cesarean full-term deliveries from 
the Barcelona cord blood bank with prior written consent and approval by the 
ethical committee. CB units were collected in sterile bags containing 25ml of 
citrate-phosphate-dextrose (CPD) using conventional techniques and 
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transported to the Anthony Nolan Research Institute (ANRI) in temperature 
between 4 and 21°C. 
 
To collect peripheral blood from healthy controls a qualified doctor under 
prior written consent and approval by the internal ethical committee took a 
range between 20 to 60ml of peripheral blood from members of the Anthony 
Nolan staff and was processed immediately as described in Section 2.3. 
 
2.3 Processing of blood samples 
CBU upon arrival to the ANRI were diluted 1:1 with transport medium (TM): 
RPMI 1640 (Lonza, Belgium) supplemented with trisodium citrate at a final 
concentration of 3.3% (w/v) and mercaptoethanol (BDH Biochemicals) at a 
final concentration of 5µM and used within 60hrs after collection. CBMC’s 
were isolated by density gradient by overlaying 35ml of cord blood onto 15ml 
Ficoll-Paque Premium (GE Healthcare, UK) in 50ml Falcon tubes and 
centrifugedd at 2,200 rpm (no break) for 35mins. Ficoll-Paque Premium with 
a density of 1.073 g/ml has been optimized to isolate mononuclear cells from 
CB units and is recommended in accordance with GMP (Good Manufacturer 
Practice) for the manufactured of cell therapy products. Centrifugation of cord 
blood over this reagent results in the formation of layers containing different 
cell types; the bottom layer contains erythrocytes, the layer immediately 
above contains mostly granulocytes and the mononuclear cells will be sitting 
just at the interface between plasma and the Ficoll. CBMC’s were carefully 
harvested and washed twice in RPMI 1640.  
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PBMCs from healthy volunteers were isolated with the same principle. 
Although, peripheral blood was not diluted with TM and Lympholyte  
(Cedarlane Laboratories, Canada) was used for the density gradient 
separation. In addition the initial centrifugation step was set up at 2,000rpm 
for only 20 minutes (no brake). 
 
2.3.1 Cell enumeration and viability 
Cell counts and viability were performed by dye exclusion method. Therefore 
10µl of the cell suspension were stained with an equal amount (10µl) of 0.4% 
trypan blue (BDH). Viable cells (non-stained) were counted in a 
haemocytometer (Neubaur Chamber, Weber) under a phase contrast Leica 
DM LB microscope (Meyer Instrument). Percentage of non-viable cells was 
also recorded with each measurement. Fresh samples always had >95% 
viability. 
 
2.3.2 Cryopreservation of cells 
The vast majority of the cellular experiments in this study were carried out 
using fresh blood samples. Cells that needed to be stored for use at later 
time points were cryopreserved in a pre-cooled freezing mix solution: 90% 
heat-inactivated fetal calf serum (hiFCS) and 10% dimethyl sulfoxide 
(DMSO) (BDH). Therefore 1ml aliquots containing a minimum of 1x107 cells 
were transferred to 1.5ml cryotube vials (Nunc) and immediately place in 
freezing containers (Sigma Aldrich) at -80°C for 24hrs for a recommended 
uniform cooling rate of 1°C per minute from ambient temperature (by indirect 
immersion in an isopropyl alcohol bath) before storage in liquid nitrogen. A 
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standard protocol was made to thaw the cells and placed into culture. 
Cryotubes were rapidly warm-up in a water bath at 37°C. Followed by 
transfer (drop wise) of the cell suspension into 10ml of pre-warmed RPMI 
1640 supplemented with 10% heat-inactivated human AB serum and 1U/ml 
penicillin and 1µg/ml streptomycin (all Bio Whittaker). This supplemented 
medium will be hereafter referred as culture medium. Subsequently, the cells 
were washed twice using centrifugation (with brake) at 1,600 rpm for 10 
minutes. Prior cell enumeration and viability measurement, cells were 
incubated in culture medium for at least 2hrs at 37°C/5%CO2 in a humidified 
incubator (IG 150,Jouan). The recovery rate was >75% with a viability >85%. 
 
2.4 Fluorescent cell surface staining and analysis 
Cells stained for cell surface markers using directly conjugated antibodies 
were visualized using flow cytometry. This is a commonly used technique 
based on the principles of light excitation, light scatter and emission of 
different fluorochromes, which generate specific data about particles or cells 
as they flow within a fluid stream through a beam of light. In general the 
properties that can be measured are cell relative size, granularity and 
fluorescence intensity. A FACSCalibur flow cytometer (Becton Dickinson) 
was used in this study.  
 
Cell surface staining was carried out using between 5x104 to 3x105 cells 
allocated in 96 well V bottom plates (Nunc) and centrifuged at 4°C/ 1700rpm 
for 6min (with brake) followed by two washes with pre-cooled PBS 
supplemented with 1% hiFCS. Subsequently, cell surface staining was done 
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adding 47µl (this taking into account a wet pellet of 3µl) of previously done 
antibodies cocktails (i.e CD4-APC, CD25-PE, CD127-Percp) at the 
recommended concentrations for 15 minutes in the dark at 4°C. This was 
followed by two more washes in the same manner. Samples were either 
immediately processed and acquired on the flow cytometer and analyzed 
using FlowJo software Version 6.0 (Tristar) or fixed in PBS/1 % (w/v) 
paraformaldeheyde (PFA) (BDH) and stored at 4°C in the dark until 
acquisition within 24hrs. 
 
Antibodies directed to different cell surface markers were purchased from BD 
Pharmingen, Ebiosciense, Miltenyi and R&D as detailed in table 2-1. Each 
antibody was titrated to acquire an optimal staining, as it will be described in 
section 2.4.2. 
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Table 2-1 List of surface markers antibodies used in flow cytometry 
Marker Format Concentration 
used 
Clone Company 
CD3 PE 1/10 SK7 BD 
CD4 PerCP/APC 1/25, 1/10 SK3,RPA-
T4 
BD, 
eBioscience 
CD8 PerCP 1/50 SK1 BD 
CD25 APC,PE 1/25,1/100 2A3,4E3 BD, Miltenyi 
CD31 APC 1/50 9G11 R&D 
CD39 APC 1/25 TU66 BD 
CD45RA PE 1/100 HI100 BD 
CD45RO APC 1/10 UCHL1 BD 
CD62L FITC 1/50 Dreg-56 BD 
ICOS PE 1/25 DX29 BD 
LAP PE 1/50 27232 R&D 
CTLA-4 PE 1/25 BNI3 BD 
GITR FITC 1/25 110416 R&D 
CXCR3 APC 1/5 1C6/CXCR
3 
BD 
CD127 FITC/PerC
P-Cy5.5 
1/10 eBioRDR5 Ebioscience 
HLA-DR FITC,PerC
P 
1/25 both L243 BD 
CD69 PerCP 1/50 L78 BD 
LAG-3 PE 1/25 AALE02 R&D 
CD103 PE 1/50 Ber-ACT8 BD 
CD132 PE 1/25 AG184 BD 
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2.4.1 Fluorescent intracellular staining  
A wide range of intracellular markers as well as the recognition of 
intracellular cytokines that are involved in immunological events can also be 
clearly depicted in a single cell level using flow cytometry. One of the main 
markers for proper study of Tregs is the intra-nuclear transcription factor 
FoxP3.   Intracellular staining for FoxP3 was carried out as recommended by 
the manufacturer (Ebioscience). Previously stained cells with cell surface 
markers (i.e. CD4-APC, CD25-PE and CD127-PerCP-Cy5.5) were fixed and 
permeabilized with Fix/Perm buffer for 30 minutes at 4°C in the dark, 
followed by two washing steps using permeabilization buffer (both 
Ebioscience). Cells were then incubated with the proper FoxP3 antibody at 
the following concentrations: FoxP3-FITC (1/20) or FoxP3-PerCP (1/50), for 
30 minutes at 4°C in the dark. In addition, cells were also stained with the 
proper isotype-matched control in the same manner. Cells were washed 
twice with permeabilization buffer and resuspended in 120µl of pre-cooled 
PBS 1% hiFCS until acquisition within 24hrs. Representative staining of 
Tregs characterization from PBMCs using the recommended markers are 
shown in Figure 2-1. 
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Figure 2.1 Example of Tregs characterization by flow cytometry: A) Gate on 
CD4pos cells from lymphocyte gate, B) Tregs gate described as CD4pos CD25high 
CD127low  (blue) cells and Effector cells described as CD4pos CD127high (red). C) 
Histogram showing their corresponding expression of FoxP3.   
 
The same protocol was used for intracellular cytokine staining. If the tested 
cells were also stained for FoxP3, Ebioscience’ reagents were used (since 
optimal FoxP3 staining is strictly dependent on the manufacturer protocol 
and reagents and does not jeopardized intracellular cytokine staining). BD 
reagents were used when no FoxP3 staining was required in the experiment. 
After proper stimulation with polyclonal stimuli (described in section 2.5.2), 
cells were incubated for at least 5hrs (5 to 7hrs) with 0.5µl BD Golgi-stop 
(aka monensin, final concentration of 2.0µM). Later on cells were harvested, 
washed and stained (with the proper concentration of each antibody) for 30 
minutes at 4°C as previously described. Additional cells were also stimulated 
and stained with the proper isotype-matched antibodies. Table 2-2 describes 
the monoclonal antibodies used in this study for intracellular staining. 
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Table 2-2 List of antibodies used for intracellular staining 
Marker Format Concentration 
used 
Clone Company 
FoxP3 FITC,PerCP-
Cy.5.5 
1/20,1/100 PCH101, 
236A/E7 
Ebioscience 
IFN-! APC 1/50 B27 BD 
IL-17a PE 1/50 TC11-
18H10 
BD 
IL-4 PE 1/50 MP4-25D2 BD 
IL-10 APC 1/50 JES3-19F1 BD 
  
 
2.4.2 Titration of directly conjugated antibodies 
For optimal staining and proper identification of the wanted cell subtypes, 
each antibody used was titrated using a standard protocol unless otherwise 
recommended by the manufacturer. Dilutions from 1/5 to 1/100 were done 
using the previously mentioned protocols for cell surface and intracellular 
staining in section 2.4 and 2.4.1 respectively. The optimal dilution was 
chosen using the following criteria: 1) Proper identification of the positive and 
negative population (when applicable) 2) no shift from the negative 
population mean fluorescence intensity (MFI) towards the positive population 
(compared to non-stained cells and 3) Ratio among the positive and negative 
populations within the range of what has been reported in previous studies or 
stated by the manufacturer. A representative titration using intracellular and 
cell surface markers is shown in Figure 2-2. 
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Figure 2.2 Representative example of titration of cell surface and intracellular 
antibodies: A) Lymphocyte gate shown by FSC and SSC. Histograms, shows the 
titration of surface markers B) CD3-PE, C) CD25-APC and D) CD45RO-PE) gated 
from lymphocyte gate. E) Overlay color graphs plotting on CD25 (y-axis) versus 
FoxP3-Percp (x-axis) using different antibody concentrations (1/100, 1/50 and 1/25). 
F) Stimulated PBMCs stained with IFN-!-APC and IL-17a-PE (1/100 and 1/50). 
Positive gates were done using isotype-matched controls.  
 
    
   2.4.3 Compensation and isotype controls 
Since flow cytometry uses different fluorochromes that emit a specific range 
of wavelengths, some overlap can be seen (FL1&FL2, FL-2&FL3, 
FL3&FL4). This spectral overlap was manually compensated using non-
stained cells, and stained cells with each of the different fluorochromes 
(FITC, PE, PerCP and APC) to clearly identify the positive and negative 
populations, either unstained cells or isotype-matched controls were used 
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each time to properly delineate the wanted population, an example of the use 
of isotype controls is demonstrated in Figure 2-3. 
      
 
Figure 2.3 Example of the use of isotype control for FoxP3 gating. A) PBMCs 
were gated on CD3pos CD4pos cells. B) In red cells were stained with isotype 
matched control, and plotted against CD25. C) Gate was set up to cover <1% of the 
events and use it on the cells stained with FoxP3. 
 
2.5 Functional assays 
    
   2.5.1 Mixed lymphocyte cultures (MLC) 
A one-way MLC was done to exemplify an allo-response in vitro. To get a 
reproducible allo-response and also to minimize the number of cells required 
for each functional assay, titration experiments were done to establish the 
optimal amount of cells needed as “responders” and “stimulators”. This was 
of specific interest for the suppression assays, since it was important to have 
a reproducible in vitro model that would allow us to titrate the number of 
Tregs needed to suppress an allo-response. Different cell numbers (104, 
2x104, 5x104, 1x105 and 2x105 cells) were placed either as “stimulators” or 
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“responders” in both directions (n=4). A representative experiment is shown 
in Figure 2-4.  
 
 
Figure 2.4 A representative experiment of MLC titration (n=4): Graph shows on the 
X-axis the number of irradiated PBMCs (stimulators) used to stimulate the different 
numbers of responder cells. Results are shown as mean c.p.m. SD. Red circle shows 
the combination selected for further experiments.  
 
The combination of 5x104 “responders” cells stimulated with 105 irradiated 
“stimulator” cells showed less variability and reproducible allo-response without 
over-crowding the system in 4 independent experiments. This combination was 
selected and used for further MLCs and set up as follow: PBMCs or previously 
isolated adult CD4pos CD25neg T cells were resuspended in culture medium at 
106 cells/ml. A total of 5x104 cells were used as “responders” and stimulated 
with mismatched 1x105 PBMCs that were fully irradiated with 10,000 Rad in a 
Cesium !-irradiator for 7 minutes. Cultures were placed on 96 well U bottom 
culture plates (SARSTEDT, USA) in a final volume of 200µl. Each experiment 
was set up in triplicates (unless mentioned otherwise) and incubated at 37°C/5% 
CO2. After 5 days of culture, each well was pulsed with 1µCi [H3] thymidine 
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(Amersham) for 16 to 18hrs. Cellular proliferation was quantified by thymidine 
uptake and incorporation into genomic DNA from dividing cells and measured 
using a liquid scintillation counter 1450 Microbeta (Perkin Elmer Wallac). Results 
were expressed as mean counts per minute (c.p.m.). Suppression was 
calculated using the following formula:  
% suppression = 1- [c.p.m. effector with Tregs/ c.p.m. effectors alone] x100. 
 
 2.5.2 Polyclonal stimulation assay 
In order to have a model non-dependent of antigen presenting cells (APC) and 
antigen non-specific, a polyclonal stimulation assay was carried out using 
soluble anti-CD3 human antibody (clone: HIT3a, BD) and soluble anti-CD28 
human antibody (clone CD28.2, BD). In vitro T lymphocyte stimulation is 
extensively used to study T cell function and for expansion protocols. Different 
mitogenic molecules such as lectins and monoclonal antibodies promote 
polyclonal proliferation whereas specific antigens yield an oligoclonal response. 
Antibodies specific for the TCR-CD3 complex provide an initial activation signal 
(aka Signal 1), but proliferation is dependent on a costimulatory signal, usually 
provided by cross-linking of CD28 (aka Signal 2).  
 
In order to optimize this method, previously isolated 5x104 CD4pos T cells 
(detailed in section 2.6) from CBMCs and PBMCs were incubated with different 
concentrations of anti-CD3 and anti-CD28 either alone or in combination. 
Autologous feeder cells (irradiated PBMC or CBMC) from both CD4pos T cells 
sources in combination with different concentrations of soluble anti-CD3 human 
antibody were also tested to elicit activation. As a positive control, CD4pos T cells 
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from CB and adult PBMC were also stimulated with 105 irradiated mismatched 
PBMCs. Each combination was set up in triplicates in 96 flat bottom culture 
plates (Becton Dickinson, New Jersey) and incubated at 37°C/ 5%CO2 in a final 
volume of 200µl. After 5 days of culture, cells were pulsed with 1µCi [H3] 
thymidine (Amersham) for 16 to 18hrs. Cellular proliferation was quantified by 
thymidine uptake as previously described using a liquid scintillation counter 
1450 Microbeta (Perkin Elmer Wallac). Results were expressed as mean counts 
per minute (c.p.m.). A representative experiment (n=3) is shown in Figure 2.5.  
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Figure 2.5 A representative experiment of polyclonal stimulation of CD4pos T cells 
from CB and PBMCs (n=3).  A) CB CD4pos and B) adult CD4pos cells were stimulated 
with soluble anti-CD3 human antibody at 2.5, 5 and 10µg/ml alone or in combination 
with anti-CD28 human antibody (at 2.5,5 and 10µg/ml) or with autologous irradiated 
feeder cells (105 cells). Both CD4pos T cells were also stimulated with mismatch (allo) 
irradiated PBMCs as a positive control. Dotted line delineates the mean proliferation of 
the MLR used as positive control.  
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CB CD4pos T cells showed less proliferation capacity compared to CD4pos T cells 
from adult PBMCs. In addition, CB CD4pos T cells were only able to respond 
appropriately to mismatched irradiated PBMCs, whereas adult CD4pos T cells 
responded to every combination of anti-CD3/anti-CD28 and anti-CD3+ 
autologous feeder cells in a reproducible fashion. Taking these results, every 
further suppression assay described in this thesis will be done using only adult 
CD4pos T cells or total PBMC as responder cells. Polyclonal stimuli for 
suppression assays will be done using soluble anti-CD3 at 2.5µg/ml and anti-
CD28 at 5µg/ml.  
 
2.5.3 Staining with 5,6-carboxyfluorescein diacetate succinimidyl ester 
(CFDASE) 
Staining with carboxyfluorescein diacetate succinimidyl ester (CFSE) has 
become, a routine technique in many laboratories since its first description by 
Lyons and Parish in 1994. CFSE has the ability to stably label molecules within 
cells, with each cell division resulting in a sequential dilution of fluorescence.  
Initially, CFDASE is non-fluorescent, due to the presence of two acetate groups, 
but these compounds enable the dye freely across the plasma membrane 
(Hawkins et al., 2007; Quah et al., 2007). Once inside the cell, the acetate 
groups are removed by intracellular esterases. This will yield the highly 
fluorescent CFSE trapped inside the cells. The fluorescent conjugates that 
persist within the cell will be diluted between daughter cells following cell 
division, which allows lymphocyte proliferation to be monitored by flow 
cytometry. 
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Optimal staining of the studied cells was accomplished using the following 
protocol: a total of 1 to 2x106/ml cells in PBS 5% hiFCS were stained with 2.5µM 
CFSE from a 5mM stock solution prepared in DMSO (Invitrogen Molecular 
Probes) at room temperature (RT) in the dark for 5 minutes. CFSE stained cells 
were centrifugedd at 1700 rpm for 5 minutes and washed three times with 10ml 
PBS 5% hiFCS. After washing steps, cells were resuspended at 106 cells/ml in 
culture medium and incubated at 37°C/ 5%CO2 incubator for subsequent 
stimulation. Figure 2.6 shows an example of CFSE proliferation after time 
course of polyclonal stimulation in correlation with [H3] thymidine uptake.
 
 
 
 
 
 
 
 71 
 
Figure 2.6 Polyclonal stimulation of CD4pos T cells measured with CFSE. CD4pos T 
cells were stained with 2.5µM CFSE and stimulated with soluble anti-CD3/CD28 human 
antibodies. Time course of A) 3, B) 4 and C) 5 days were set up in triplicates. Gates 
were done on lymphocytes set up by FSC and SSC. D) Parallel triplicates were also set 
for [H3] thymidine uptake at the same time points.  
 
 
CFSE assays were carried out for 4 days of culture when polyclonal stimulation 
was used and for 6 days when allo-response was measured. After culture, cells 
were spun at 1,700rpm for 5 minutes and washed twice in pre-cooled PBS 
supplemented with 1% hiFCS. Subsequently, cells were stained for surface 
markers and if needed eventually intracellular markers as described in section 
2.4 and 2.41.  
 
 72 
At last, cells were then immediately acquired on a FACSCalibur flow cytometer 
(BD). Suppression was calculated as follows:  
% suppression = %CFSEpos proliferating cells with Tregs/ % CFSEpos 
proliferating cells without Tregs x 100. 
 
2.5.4 Trans-well suppression assay 
To measure if Tregs were able to suppress in a cell-cell contact independent 
matter, MLCs (described in section 2.5.1) were done using 96 or 24 trans-well 
plates with inserts of 0.4µm pore size (Corning, Costar). Tregs resuspended at 
106cells/ml in culture medium were added in a 1:2 ratio (Tregs:Effectors) either 
in the lower chamber or in the upper chamber. When placed in the upper 
chamber they can be with or without irradiated PBMCs used as stimulators at a 
1:2 ratio (Tregs:Irradiated PBMCs). Cultures were placed on a final volume of 
200µl (96 well plates) or 500µl (24 well plates) of culture medium and set up as 
triplicates. After 5 days of culture, each well was pulsed with 1µCi [H3] thymidine 
(Amersham) for 16 to 18hrs. Cellular proliferation was quantified by thymidine 
uptake and measured using a liquid scintillation counter 1450 Microbeta (Perkin 
Elmer Wallac). Results were expressed as mean c.p.m. Suppression was 
calculated using the same formula described in section 2.5.1. 
 
2.6 Isolation of CD4pos CD25pos T cells from PBMCs using magnetic beads 
Isolation of untouched CD4pos T cells was done through negative selection using 
indirect magnetic labeling of non-CD4pos T cells as recommended by 
manufacturer (Miltenyi Biotec, Germany). Briefly, PBMC or CBMC were 
resuspended with 90µl per 107cells of chilled isolation buffer (1x PBS with 0.5% 
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BSA or hiFCS and 2mM EDTA) and stained with 10µl per 107cells of biotin-
antibody cocktail (which include anti-CD8, CD14, CD16, CD19, CD36, CD56, 
CD123, TCR!/$ and CD235a) for 10 minutes at 4°C. Subsequently, a second 
layer was done using anti-biotin microbeads at 20µl per 107cells and incubated 
for 15 minutes at 4°C. After incubation, cells were washed with 2ml of isolation 
buffer and centrifuged at 1400rpm for 10 minutes at 4°C. After discarding 
supernatant, cells were resuspended in 500µl of isolation buffer and passed 
through a LD column placed on a QuadroMACS isolation magnet (both Miltenyi). 
Two washing steps were carried out with 1ml of isolation buffer, and the effluent 
was collected containing the unlabeled pre-enriched CD4pos T cell fraction. This 
fraction was used in some experiments that required only CD4pos T cells. This 
method achieved >95% purity for CD3pos CD4pos T cells. For CD25 positive 
isolation, the cell suspension was counted (section 2.3.1), spun down and 
resuspended in 90µl per 107 cells of isolation buffer and stained with 10µl per 
107cells of directly conjugated CD25 microbeads (Miltenyi) and incubated at 4°C 
for 15 minutes. After a washing step with 5ml of isolation buffer, cell suspension 
was resuspended in 500µl of isolation buffer and passed through a LS column 
placed on the isolation magnet and rinsed with 2ml of isolation buffer. The 
negative fraction was collected and used as effector cells in functional assays.  
The CD25 positive fraction was collected after extracting the LS column from the 
magnet and rinse with 1ml of isolation buffer applying the plunger. This step was 
repeated to achieve better purity. After the second passage through an LS 
column, the cells were counted and resuspended in culture medium and 
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incubated at 37°C/ 5%CO2 upon their use. Figure 2-7 shows a representative 
isolation of CD4pos CD25pos T cells from adult PBMC. 
 
 
Figure 2.7 Characterization, of a CD4 enrichment and CD25 positive isolation from 
PBMC. Color plots showing gating strategy to characterize CD4pos CD25pos isolation 
from PBMC. A) Lymphocyte gate was set up from FSC and SSC. B) CD3pos CD4pos 
double positive population is taken from lymphocyte gate. C) CD4pos T cells are plotted 
against CD25 or D) using CD25 versus CD127 gating strategy. Tregs are depicted as 
CD4pos CD25high CD127low cells and effector cells as CD4pos CD127high. 
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2.7 IL-17 measurement by ELISA 
Noteworthy, IL-17 measurement from cell-culture supernatant was done in 
collaboration with Guy’s Hospital at their facilities using their standard protocol: 
ELISA for human IL-17 was carried out using the Duo-Set ELISA kits from R&D 
(R&D systems). Nunc Maxisorb™ plates were coated overnight at RT with 
100µl/well of anti-IL-17 at a final concentration of 4 µg/ml in PBS. Plates were 
washed three times with 0.05% Tween 20 (Sigma) in PBS and blocked for one 
hour at RT with 300ml/well freshly made, filtered, 1% bovine serum albumin 
(BSA) (Sigma) in PBS. Plates were washed three times as before and dry up 
before addition of 100µl/well of samples and standards in duplicate. Standard 
curves were prepared by serial two-fold dilutions of the manufacturer’s 
standards in 1% BSA v/v in PBS from a top concentration of 1000pg/mL to 
15.63pg/ml and one concentration of 0pg/ml (diluent alone). Plates were 
incubated for two hours and washed three times as before. A total of 100µl/well 
of the detection antibody was added at a final concentration of 75ng/ml of IL-17 
in 1% BSA v/v in PBS and incubated for two hours at RT. Plates were washed 
three times with 0.05% Twean/PBS and 100µl manufacturer’s streptavidin-HRP 
(horseradish peroxidase) diluted 1 in 20 (in 1%BSA/PBS) was added to each 
well and incubated for 20 minutes. Plates were again washed three times and 
dried up before the addition of 100µl substrate solution (TMB) (Zymed, San 
Francisco, CA) to each well. A further incubation for 20 minutes at RT in the 
dark was followed by acidic termination of the reaction through addition of 50ml 
0.5M sulphuric acid (H2SO4) to each well. Optical density at 450nm was 
measured on a Bio-Tek EL800 automatic plate reader (Wolf Laboratories, UK). 
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The concentration of IL-17 was calculated from standard curves constructed 
from the optical densities of the known concentrations. 
 
2.8 Determination of HLA type 
Healthy volunteer samples and cord blood units DNA-based HLA typing were 
performed at the Histocompatibility Laboratories at the Anthony Nolan Research 
Institute (ANRI). HLA class I and class II genotyping was performed using 
sequence-specific oligonucleotides (PCR-SSO), sequence-specific primers 
(PCR-SSP), or nucleotide sequencing. 
 
2.9 Analysis 
Statistical analysis and graphs were carried out using Prism 5 software for 
MAC OS X Graphpad package. In general, t test and one-way ANOVA were 
used when applicable to identify significance within functional assays and 
isolation 
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CHAPTER 3 
CB TREGS CHARACTERIZATION. 
 
Introduction 3.1 
A wide variety of markers have been ascribed to Tregs phenotype and 
functionality since the reborn studies of regulatory T cells (Sakaguchi et al., 
1995). Currently, FoxP3 is the most accepted marker for a proper identification 
of nTregs in a non-inflammatory state (Seddiki et al., 2006a). Strong correlation 
between the IL-2 receptor " chain (CD25) and FoxP3 expression has been 
widely described since the identification of FoxP3 in these cells (Fontenot et al., 
2003; Thornton et al., 2004a). However, currently it is widely known that adult 
CD4pos FoxP3pos T cells represent a small percentage from overall CD4pos 
CD25pos T cells, and also, latest studies have shown a scarce population of 
FoxP3pos cells among the CD4pos CD25neg T cells (Fontenot et al., 2005b; Miyara 
et al., 2009). Moreover, experiments intended to discover a more homogenous 
Treg population, had demonstrated that FoxP3pos cells are mainly CD4pos 
CD25high CD127low (IL-7 " receptor) whereas effector cells are CD4pos CD127high 
(Liu et al., 2006; Seddiki et al., 2006a). Compelling data has demonstrated that 
CD25pos CD45RApos Tregs represent the most homogenous population among 
the overall nTreg pool (Hoffmann et al., 2006b; Putnam et al., 2009). More 
recently (Miyara et al., 2009) classified nTregs into two main populations; resting 
Tregs (rTregs) CD45RApos CD25pos FoxP3low and activated Tregs (aTregs) 
CD45RAneg CD25high FoxP3high. Both populations showed stable Treg phenotype 
upon activation and proliferative capacity in vitro and in vivo. In summary, 
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regardless of the gating strategy, a level of FoxP3 expression is always 
assessed. Therefore, gating on FoxP3pos from total CD4pos T cells is the first 
step recommended to properly identify nTregs. Further characterizations should 
be measured from the double positive population (CD4pos FoxP3pos T cells). 
Noteworthy, this approach is only recommended in a steady state in vivo or 
freshly isolated ex vivo (Roncarolo et al., 2008). For characterization of Tregs in 
an inflammatory setting or post expansion cultures in vitro, measurements at the 
epigenetic level, specifically, methylation at the FoxP3 locus is required for a 
proper Treg identification (Baron et al., 2007; Polansky et al., 2008). 
 
Results 3.2 
The purpose of this chapter is firstly to characterize Tregs from CB in 
comparison to adult Tregs and, secondly, to measure the expression of different 
markers that have been shown to be important for Treg phenotype and 
functionality. 
 
3.2.1 Treg frequency is similar in adult PBMCs and CBMCs. 
As shown in Figure 3-1, gating on FoxP3pos cells, CB Tregs represented 
between 5 to 9% from overall CD4pos T cells (n=10). No major difference was 
seen when CD25high CD127low gate was used (5-8%). Likewise, gating on 
FoxP3pos cells, adult Tregs represented between 6 to 10% from CD4pos T cells 
(n=10). However, a slightly lower amount of FoxP3pos cells was depicted using 
CD25high CD127low gate (4 to 8%).  
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Figure 3.1 Tregs identification from adult PBMC and CB (n=10). Tregs were 
characterized as FoxP3pos cells and CD25highCD127low gate from CD4pos T cells. Red 
dots represent characterization from adult PBMCs and green dots from CBMCs. 
Results are shown with scatter plots, black line depicts the median value. 
 
 
3.2.2   CB Tregs are mainly naïve (CD45RApos). 
The main difference between CB Tregs and adult Tregs is their naïve 
phenotype. Gating on CD4pos FoxP3pos T cells, CB Tregs are 89% CD45RApos 
(range 68 to 92%), in contrast adult Tregs are 18% CD45RApos (range 8 to 40%; 
Figure 3-2). Accordingly, CB Tregs are 9% CD45ROpos (range 8 to 19%) and 
adult Tregs 80% CD45ROpos (range 48 to 91%). Furthermore, the expression of 
the lymphocyte chemokine receptor CCR7, which is also used to further 
characterize naïve T cells (Sallusto et al., 2000; Takada et al., 2009), showed no 
clear difference when measured between CB and adult Tregs (range 65 to 82% 
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and 56 to 72%, respectively). In contrast, a higher proportion of adult Tregs 
expressed the lymphocyte adhesion molecule L-selectin (CD62L) compared to 
CB Tregs (mean 79%, range 68 to 84%; mean 55%, range 38 to 57%, 
p=0.0001, respectively). CD62L-mediated lymphocyte recirculation is required 
for the proper distribution of both naïve and effector T cells between sites of 
inflammation and secondary lymphoid tissues (Grailer et al., 2009).  
 
To further characterize the CD45RApos Treg population, CD31 expression was 
measured to identify the recent thymic emigrant Treg (RTE) population (Haas et 
al., 2007; Junge et al., 2007). Noteworthy, there is a higher proportion of 
CD45RApos Tregs in CB compared to adult CD45RApos Tregs. Nonetheless, CB 
showed a higher proportion of CD31pos subset compared to adult (mean 80±4 vs 
64±3.3, p=0.008, respectively). In summary, the substantial difference depicted 
between CB and adult Tregs was mainly the naïve phenotype of the former. In 
addition, the majority of CD45RApos FoxP3pos CB Tregs are CD31pos, which will 
be considered as RTE Tregs that constitutively expressed a wide TCR 
repertoire. 
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Figure 3.2 CB and adult Tregs characterization. A) The upper histograms show a 
representative gating strategy for phenotype characterization of CB (depicted in green) 
and PBMCs (depicted in red) Tregs. B) The upper graph depicts expression of the 
mentioned markers from CD4pos FoxP3pos T cells from CBMCs in green (n=10) and 
adult PBMCs in red (n=10). The lower graph shows the level of CD31 expression from 
CD4pos FoxP3pos CD45RApos. Results are shown as mean values ± SEM. Statistical 
analysis was done using an unpaired two-tailed t Test (***p=<0.001).  
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As previously mentioned, currently it has been shown that Tregs can be 
characterized in two main subsets. aTregs which are CD25pos FoxP3high 
CD45RAneg and rTregs characterized as CD25pos Foxp3low CD45RApos (Miyara et 
al., 2009). Using this gating strategy and as expected, CB Tregs are mainly 
rTregs with a lower proportion of aTregs (mean 82%, range 79 to 86%; mean 
13%, range 11 to 16, respectively). Conversely, adult Tregs are mainly aTregs, 
with a scarce population being rTregs (mean 76.6%, range 69 to 83%; mean 
17.6%, range 15 to 20%, respectively) (Figure 3.3).  
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Figure 3.3 Representative rTregs and aTregs characterization from CB (n=3) and 
adult PBMC (n=3). A) The upper counter plots with their corresponding histogram 
overlay (right) shows a representative characterization of CB and adult CD4pos T cells 
using CD25 and CD45RA expression. Overlay histograms shows the level of FoxP3 
expression of each population depicted (I to VI). B) Lower graph shows the proportion 
of rTregs and aTregs from complete CD4pos FoxP3pos cells. Populations II and III were 
considered as aTregs and population I as rTregs (Miyara et al., 2009). Results are 
shown as mean ±SEM (***p=<0.0001).  
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3.2.3 CB Tregs constitutively express a wide variety of markers related to 
Treg functionality. 
In adult Tregs, a wide repertoire of markers has been correlated to their 
suppressive properties (Brusko et al., 2008b). CB CD4pos FoxP3pos (n=8) Tregs 
constitutively express most of these markers (Figure 3.4). Noteworthy, whilst 
Tregs are on a steady state in a non-inflammatory environment, most of these 
markers are expressed in lower levels. In contrast, once Tregs get activated, 
they start up-regulating most of these markers as it will be shown in details, 
when Treg activation pattern is described (Chapter 6). 
 
 
Figure 3.4 Representative characterization of CB Tregs (n=8). Histograms showing 
expression of different markers gated from CD4pos FoxP3pos population from CB. 
Results are shown as percentage of expression. 
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3.3 Discussion. 
It has been shown, that Tregs pool, suffer phenotypic changes in an age-
dependent fashion. Early in age, Tregs start with a naïve phenotype 
(CD45RApos) and undergo a preferential differentiation towards a central 
memory phenotype (CD45ROpos) (Akbar et al., 2007b; Seddiki et al., 2006b). 
However, certain functional properties have been suggested to diminish in 
correlation to these phenotypic changes (Ayyoub et al., 2009; Haas et al., 2007). 
Nonetheless, Treg frequency is remarkably stable throughout life in humans 
(Santner-Nanan et al., 2008). It has been shown that Tregs pool is maintained 
throughout life due to rapidly dividing CD4pos CD45ROpos T cells in vivo 
(Vukmanovic-Stejic et al., 2006).  
 
In agreement with what has been shown (Bresatz et al., 2007; Fritzsching et al., 
2006; Godfrey et al., 2005; Santner-Nanan et al., 2008), I showed that CB Tregs 
represented 5 to 10% from overall CD4pos T cells. No statistical difference was 
depicted when compared to adult Tregs (6 to 10% from CD4pos T cells). 
Furthermore, CB Tregs were mainly CD45RApos  (#89%) compared to adult 
(18%). In addition, CB FoxP3pos CD45RApos co-express CD31 (#80%), which 
has been shown to be a marker that together with CD45RA, specifically depicts 
cells that are RTE conserving a wide TCR repertoire (Haas et al., 2007; Junge 
et al., 2007). This has important considerations for their application in 
transplantation, since CD45RApos CD31pos Tregs TCR properties are more likely 
to resemble and counteract the high frequency (#7%) of allo-reactive naïve 
effector T cells that mount the strong response against the allograft (Suchin et 
al., 2001). In addition, herein is shown that CB Tregs are mostly rTregs (CD25pos 
 86 
CD45RApos FoxP3low), which have been shown to be bona fide Tregs in vitro 
and in vivo (Hoffmann et al., 2006b; Miyara et al., 2009; Seddiki et al., 2006b). 
Furthermore, rTregs are highly proliferative and apparently have a major role in 
overall Treg pool homeostasis. 
 
Additionally, CB Tregs constitutively express a repertoire of markers that has 
been shown to be important for their functionality. CB Tregs highly expressed 
CCR7 (#72%). It has been described that CCR7 expression on Tregs is 
paramount for their migration to lymph nodes and their allocation within the T-
cell zone (Forster et al., 2008; Zhang et al., 2009). This particular process has 
been of great importance for Tregs suppression in vivo (Zhang et al., 2009). 
Furthermore, I also showed that CB Tregs co-express the lymphocyte adhesion 
molecule CD62L (#57%). In accordance, it has been demonstrated in a mice 
GvHD model, that only CD62Lhigh Tregs interfere with the activation and 
expansion of GvHD effector T cells within the secondary lymph nodes (Taylor et 
al., 2004). 
 
In summary, CB has a higher frequency of the most homogenous population 
(CD45RApos) described so far of nTregs compared to adult PBMCs. 
Furthermore, they constitutively express homing receptors (CCR7 and CD62L) 
that will allow them to migrate in vivo to secondary lymph nodes. Lastly, most 
CB Tregs conserve the beneficial cellular properties of RTE T cells. As 
mentioned, this has major benefits for their application in vivo.  
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CHAPTER 4 
OPTIMIZED METHODOLOGY TO SPECIFICALLY ISOLATE 
CD4pos CD25high CD127low POPULATIONS FROM CB USING A 
SINGLE STEP PROTOCOL 
 
4.1 Introduction 
There is currently a lack of specific markers in order to characterize Tregs 
properly. Nevertheless, FoxP3 is the most accepted marker for their 
characterization in steady state of non-inflammation ex-vivo and in-vivo 
(Fontenot et al., 2005b; Seddiki et al., 2006a). Since FoxP3 is an intracellular 
marker it cannot be used for isolation of viable Tregs. Thus, CD4 and CD25 
have been used so far for Tregs isolation (Baecher-Allan, 2006; Hoffmann et al., 
2006a; Sagoo et al., 2008). The isolated populations have been demonstrated to 
be suppressive in models in vitro and in in vivo (Sakaguchi et al., 2008; 
Shevach, 2009). Later on, it was demonstrated that FoxP3pos cells are mainly 
CD127neg/low (IL-7 " receptor) whereas effector cells are CD127high (Liu et al., 
2006; Seddiki et al., 2006a). Depletion of CD127high cells from the isolated 
CD25pos fraction has been shown to improve substantially the purity of Tregs 
isolated from PBMCs (Hoffmann et al., 2009; Peters et al., 2008; Putnam et al., 
2009). Most of the studies on Tregs isolation methods for clinical purposes have 
recommended multiple step protocols, mostly CD8, CD19 and most recently 
CD49d depletion (Kleinewietfeld et al., 2009; Peters et al., 2008; Riley et al., 
2009). Nevertheless, low purity and yield continue to be an issue for further 
characterizations and stepping into bigger scale models and clinical trials. Latest 
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studies have shown that CD45RApos Tregs represent the most homogenous 
population among the Tregs pool (Hoffmann et al., 2006b). Unfortunately, less 
than 30% of adult Tregs are CD45RApos, resulting in a higher proportion of 
memory phenotype Tregs (CD45ROpos) (Santner-Nanan et al., 2008; 
Vukmanovic-Stejic et al., 2006). In contrast, cord blood Tregs are mainly naïve 
CD45RApos (>80%) and have also been shown to be highly suppressive 
(Godfrey et al., 2005; Porter et al., 2006; Wing et al., 2005). Interestingly, cord 
blood CD4pos CD25pos population is a well-defined population with a clearer gap 
between its counterpart negative fraction (CD4pos CD25neg) (Figure 4.1B). In 
addition, they express the same level of FoxP3 as CD4pos CD25highcells from 
PBMCs (Figure 4.1C,D). Moreover, the level of CD25 expression among the 
CD4neg population is barely evident (Figure 4.1B). Taking all this into 
consideration, cord blood makes a bona fide source for the isolation of Tregs 
using a single step CD25 isolation protocol.  
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A)                                                              B) 
 
                     Adult PBMCs                                         Cord Blood 
  
 
 
                    
Figure 4.1 A representative characterization of CD4pos CD25pos populations in 
PBMCs and CB (n=10). This figure shows CD4 vs CD25 expression on A) adult 
PBMCs and B) CBMCs, gated on live lymphocyte gate. Histograms below show the 
level of FoxP3 expression of CD4pos CD25high cells from PBMCs (in blue) and CB 
CD4pos CD25pos cells (in green). Isotype control is depicted red.  
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4.2 Results 
This chapter describes the optimization of the isolation of highly purified CD4pos 
CD25high CD127low T cells from cord blood using a single step protocol.  
 
4.2.1 Cell density modifications for specific Tregs selection 
Some groups have shown an increase in Tregs purity using lower concentration 
of CD25 microbeads with the intention to only capture the cells with the highest 
CD25 expression (CD25high) (Baecher-Allan, 2006). This study tested also the 
effect of modifying the cell density before CD25 microbeads staining. The 
staining conditions described by the manufacturer protocol (Miltenyi Biotec, 
Germany) will be mentioned throughout this chapter as “standard protocol”. 
Briefly, cells were resuspended in isolation buffer at 90µl per 107cells and 
stained with 10µl of anti-CD25 microbeads per 107cells leading to a cell 
concentration of #1.1x108cells/ml (standard protocol). In parallel, CD25 isolation 
was also done using three different cell densities with their corresponding anti-
CD25 microbeads concentration (1/9): A) #2.5x108cells/ml; B) #3.3x108cells/ml 
and C) #5x108cells/ml. After staining for 15 mins in the dark at 4°C, each cell 
suspension was washed and resuspended in 500µl of isolation buffer (described 
in section 2.6) and passed through two LS columns as suggested by the 
manufacturer (Miltenyi Biotec, Germany). In order to reduce sample bias, the 
initial isolations were carried out from the same CB unit and repeated three 
times in different CB units.  
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4.2.2 Purity for CD4pos CD25high CD127low and level of contaminating CD4pos 
CD127high cells. 
As mentioned in section 2.1 and in reference to previous studies (Liu et al., 
2006; Seddiki et al., 2006a), Tregs were characterized as CD4pos CD25high 
CD127low T cells and effectors as CD4pos CD127high T cells. The latter can also 
be sub-divided in function of CD25 expression as shown in figure 4.2 but for 
statistical analysis effector cells were defined as CD4pos CD127high without CD25 
subdivision. This study shows that high purity for CD4pos CD25high CD127low T 
cells can be achieved using a single step method (CD25 positive selection) and 
that cell density during anti-CD25 microbeads staining was found crucial factor 
for these results. Figure 4.2 shows purity of CD25 positive isolations using the 
same CB sample. These results show that a cell density of >2x108 cells/ml 
dramatically increases the purity of Tregs and therefore decreases the level of 
contaminating effector cells. Isolations using densities between #3.3x108cells/ml 
and #5x108cells/ml showed the highest purities for Tregs compared to the 
standard protocol (mean 89% and 90% vs 79%, respectively, n=3 p=0.001). 
This study did not show any statistical difference between #3.3x108cells/ml and 
#5x108cells/ml cell densities. Therefore, in order to have an easier translation to 
larger scale isolation, further isolations were carried out using a cell density of 
#3x108cells/ml and will be mentioned in this study as “new method”.  
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Figure 4.2 Flow cytometry analysis of CD25 positive isolations from the same CB 
unit using different cell densities (representative data, n=3). Contour plots gated on 
CD4pos cells, plotted against CD25 and CD127. Tregs are gated as CD25pos 
CD127low/neg, contaminating cells are subdivided in three sub-populations: CD25neg 
CD127neg, CD25neg CD127high and CD25pos CD127high. Numbers represent percentages 
of each sub-population. A) Cells were stained at #1.1x108cells/ml (standard protocol), 
B) at #2.5x108cells/ml, C) at #3.3x108cells/ml and in D) at #5x108cells/ml.  
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4.2.3 “New method” vs. standard protocol for large-scale Tregs isolation. 
In order to test if these modifications can be translated into larger scale isolation, 
complete CB units (a range between 1.8 to 2.2x108 CBMNCs) were used for 
CD25 positive isolation using either the standard protocol (#1.1x108cells/ml) or 
the new method (#3x108cells/ml). As shown in Figure 4.3, a higher proportion of 
Tregs (CD4pos CD25high CD127low) was observed with the new method 
compared to the standard protocol (mean 89% of the CD4pos cells, range: 86-
94% vs mean 72% range 54-89% respectively, p=0.03). Also the proportion of 
contaminating effector cells, was notably reduced by using this new method 
(CD4pos CD127high) (mean of 6% range: 3.6 to 9% vs mean 23% range: 7.3 to 
38%, p= 0.01). Although not significant, a noticeable difference was seen in the 
proportion of CD4pos cells (mean 86% vs 80% respectively, p=0.6) and/or the 
proportion of CD4pos CD25pos cells (mean 86% vs 76% respectively, p=0.1). 
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Figure 4.3 Percentage of different subpopulations using the two methods of 
isolations. Standard (std, black dots n=9) and the new method (red dots n=6).  The 
percentage of CD4pos was taken from the lymphocyte gate. The rest of the 
subpopulation percentages were taken from CD4pos cells. CD4pos CD25high CD127low 
was defined as Tregs and CD4pos CD127high as effectors. Mean values are shown of 
each subpopulation. Significance difference (p=<0.05) was done by Students t test.  
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4.2.4 Yield of isolated Tregs 
The final yield of Tregs was calculated as the percentage of CD4pos CD25high 
CD127low from the initial cell count used for the isolation. The new method 
resulted in a much higher yield of Tregs compared to the standard protocol 
(mean 0.4%, range: 0.3 to 0.6%, (n=6) vs mean 0.2%, range: 0.1 to 0.4%, (n=9), 
respectively, p=0.007) (Figure 4.4).   
 
 
Figure 4.4 Final yields of Tregs determined from the initial cell count. Shown is the 
mean proportion of defined Tregs in each method. The standard method is depicted 
with black dots (n=9) and the new method in red dots (n=6). Student t test was done to 
evaluate the difference between groups. 
 96 
4.2.5 Selected Tregs suppressive ability 
Since the main functional characteristic of Tregs is their suppressive ability, we 
tested the isolated populations in functional assays. Both methodologies 
generated populations that demonstrated suppression to allo-stimuli (p= <0.04). 
Overall the new method did not show a significant difference with the standard 
protocol regarding percentage of suppression (median 96% at 1:2 ratio 
(Tregs/effectors) vs 70%, p=0.1 and at 1:5 ratio of 60% vs 68%, respectively 
(n=4, p=0.7) (Figure 4.5). 
 
 
Figure 4.5 Suppressive ability of cell subsets isolated with both protocols. 
Percentage of suppression at different Tregs:effector ratios using CD25 positive 
isolations from both protocols tested in the same MLCs (n=4). Box and whisker plots 
are shown. 
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However, the standard protocol cohort had a coefficient of variation >31% (at 
1:2 or 1:5 Treg/effectors ratios) compared to the new method cohort which had a 
coefficient of <6%. To further elucidate if this was because of variable purity 
among isolations we conducted a Pearson test to evaluate correlation between 
purity and suppression (Figure 4.6). A good correlation was found between the 
proportion of CD4pos CD25high CD127low cells within isolations and percentage of 
suppression (r2=0.57; p=0.02) (Figure 4.6 A). In contrast, this was not observed 
when gated on CD4pos CD25pos cells (r2=0.26; p=0.5)(Figure 4.6 C). Consistent 
with the correlation of CD4pos CD25high CD127low cells with suppression, CD4pos 
CD127high effector cells showed an inverse correlation with suppression 
(r2=0.64; p=0.01)(Figure 4.6 B). 
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Figure 4.6 Correlation between CD4pos CD25high CD127low (A), CD4pos CD127low (B) 
and CD4pos CD25pos (C) percentages with suppression in MLC at 1/2 ratio 
(Tregs/effectors). Red dots represent isolations using the new method (n=4) and 
black dots using the standard protocol (n=4). Mean values and 95% CI are shown. 
Analysis was done using a Pearson test and two-tailed t test. 
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4.3 Discussion 
Several groups have described CB as a rich source of well-defined CD4pos 
CD25pos cells, which are mainly naïve Tregs (Chang et al., 2005; Godfrey et al., 
2005; Hippen et al., 2008; Porter et al., 2006). The lower proportion of effector 
cells (CD4pos CD127high) among the CD25pos as well as the scarce CD25pos cells 
among the CD4 negative fraction makes it an optimal source for a one step Ab 
clinical grade selection. 
 
FACs sorted isolations gating on the CD4pos CD25high have shown high levels of 
purity #98% but at the expense of low yields (<0.1%) (Baecher-Allan, 2006). 
Methods using microbeads conjugated Ab to CD25 have higher yields (0.3 to 
0.4%) but with purities that range from 72 to 92% gating on CD4pos CD25pos 
(Hoffmann et al., 2006a; Kleinewietfeld et al., 2009; Peters et al., 2008; Wichlan 
et al., 2006). However, assessing the purity by these criteria can be misleading 
especially with adult PBMCs, as there can be a substantial number of effector 
cells (CD4pos CD127high) among the CD25pos fractions. Employing CD25 vs 
CD127 gate on CD4pos cells is a more accurate Tregs characterization since it 
has been shown to have a strong correlation with FoxP3 ex-vivo and in-vivo in 
steady state (Liu et al., 2006; Seddiki et al., 2006a). These results were also 
confirmed phenotypically and functionally. This study describes a protocol for 
Tregs isolation from CB, which has led consistently to high CD4pos CD25high 
CD127low cell purity (mean 89%) using a single step CD25 selection. 
Additionally, this purity was achieved without a drop in yield. Furthermore, the 
yield was doubled (mean 0.4%) compared to the standard protocol (mean 0.2%) 
and even greater to FACs sorted isolation reported by others (0.1%) (Baecher-
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Allan, 2006). Another factor of great importance regarding Tregs isolation 
methods is the percentage of contaminating effector cells (CD4pos CD127high). 
This new method efficiently depletes this population to <9%. 
 
All CD25 positive isolations were suppressive when tested in functional assays. 
Nevertheless, the variability seen within the standard protocol isolations among 
the percentage of suppression was important. This effect was strongly 
correlated with the variability in the proportion of CD4pos CD25high CD127low cells. 
In concordance we observed an inverse correlation with suppression and the 
proportion of contaminating effector cells (CD4pos CD127high). In agreement with 
other groups (Liu et al., 2006; Seddiki et al., 2006a), gating on CD4pos CD25pos 
cells does not clearly characterize Tregs as we have shown no suppressive 
correlation when employed this gating strategy. 
 
 In summary we found that increasing the cell density >3 fold from the standard 
staining protocol in conjunction with suboptimal doses of anti-CD25 microbeads 
dramatically improves the purity and yield resulting in highly suppressive 
populations. These findings also suggests that a threshold of contaminating 
effector cells (>10% of CD4pos CD127high), within the cells isolated, may 
jeopardize the suppressive properties of Tregs. However, the inevitable level of 
contaminating CD4pos CD25pos CD127high effector cells (<10%), may also be 
required for Tregs activation and metabolic fitness (Shevach, 2009; Vignali et 
al., 2008).       
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CHAPTER 5 
SUPPRESSIVE FUNCTION OF INDIVIDUAL AND POOLED  
CB TREGS (pCB TREGS) 
 
5.1 Introduction 
It has been clearly demonstrated that Tregs from the host as wells as from the 
donor potently suppress allo-immune responses in vitro and in vivo (Edinger et 
al., 2003; Joffre et al., 2008; Taylor et al., 2004; Trenado et al., 2003; Tsang et 
al., 2009). However, in order to achieve an effective suppression in vivo, most of 
the experiments used host Tregs in a 1:1 and even 3:1 Treg:effectors cell ratios 
(Nomura et al., 2006; Sagoo et al., 2008; Taylor et al., 2004). 
 
Interestingly, it has also been shown that naïve Tregs from a third party donor 
can be used to prevent GvHD and helps bone marrow engraftment (Hippen et 
al., 2008; Steiner et al., 2006). Therefore, in the context of direct allorecognition, 
naïve Tregs are able to cross-react upon alloantigens, similarly as their 
counterpart conventional effector T cells. In accordance, a wide TCR repertoire 
overlap has been demonstrated between Tregs and their counterpart subset 
CD4pos CD25neg cells (Fazilleau et al., 2007; Hsieh et al., 2006; Pacholczyk et 
al., 2006; Vukmanovic-Stejic et al., 2006). Thus, if #7% of un-manipulated naïve 
T cells are able to respond to allo-stimuli (Suchin et al., 2001), likewise, naïve 
Tregs could be expected to react upon encounter to allo-antigens in vivo 
(Nomura et al., 2006). However, in spite of having nTregs that are able to 
suppress allo-responses, most of the studies emphasize the necessity to also 
outcompete effector T cells with at least an equivalent number of Tregs 
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(Hoffmann et al., 2006a; Riley et al., 2009; Sagoo et al., 2008) hence, skewing 
the balance towards a regulatory milieu is also of great importance. 
 
Tregs only constitute between 4 to 10% of the total CD4pos T cells in peripheral 
blood (Baecher-Allan et al., 2001; Santner-Nanan et al., 2008). Thus, the 
requirement to establish expansion protocols have been the only solution so far 
to achieve optimal cell numbers for Treg immunotherapy. Current expansion 
protocols either using polyclonal or antigen specific stimuli have shown 
encouraging results, with approximately >200 fold expansion in 2 to 3 weeks 
culture (Battaglia et al., 2006; Hoffmann et al., 2004; Peters et al., 2008; Putnam 
et al., 2009; Trenado et al., 2006). However, after 2 weeks of culture most of 
these protocols have shown down-regulation of FoxP3 and an important level of 
conversion or outgrowth of Th-17, Th-2 or Th-1 effector cells (Hoffmann et al., 
2009; Hoffmann et al., 2006b; Putnam et al., 2009). Infusion of effector T cells 
that may cause unwanted damages to the host or the graft is the main concern 
regarding Tregs immunotherapy, thus, emphasis has been allocated to this 
matter (Hoffmann et al., 2006a; Riley et al., 2009). 
 
5.2 Results 
The objectives of this chapter are firstly, to test the “third party” approach using 
CB Tregs to suppress alloresponses. Secondly, in order to acquire optimal cell 
numbers in a more practical approach, the modality of pooling multiple mismatch 
CB Tregs will be explored, hereafter called pCB Tregs. This approach not only 
would help to achieve optimal numbers for immunotherapy when requested, but 
also pooling naïve CB Tregs at their steady state prior activation will maintain 
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their wide TCR repertoire, cellular proliferative properties and will therefore 
increase the possibilities of an efficient suppression in vivo. In addition, since the 
number of cells is as important as their specificity, and in the context of acquiring 
the optimal cells and number for immunotherapy, I would also test the option of 
using pCB Tregs as an adjuvant to host Tregs. At last, since pooling CB units 
would imply more expression of alloantigens, I will also test their 
immunogenicity. 
 
5.2.1 CB Tregs effectively suppress alloresponses. 
As described in section 2.5.1, one-way MLCs were done to measure the 
capacity of Tregs to suppress alloresponses in vitro. This assay is intended to 
measure specifically the ability of Tregs to block direct allorecognition 
responses. A total of 8 MLCs were done, Tregs either from the host or CB were 
added at different Tregs:effectors cells ratios (1:2, 1:5 and 1:10).  All MLCs 
developed stimulation index >7. As shown on section 2.3 and 3-2.3, all Tregs 
isolated used for functional assays had purities >89% for CD25pos CD127low 
(range 89 to 96%).   
 
CB Tregs were effectively suppressive at all ratios. Although a tendency of 
better suppression can be seen when host Tregs are used, on overall there was 
no significant difference between host and CB Tregs suppression. (Figure 5.1) 
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Figure 5.1 Summary of suppression assays using host and CB Tregs. MLCs (n=8) 
were done with the addition of either Tregs from the Host (black bars) or CB (white 
bars) at different Tregs:effectors ratios (1:2,1:5 and 1:10). Results are shown as 
percentage of suppression, Mean ± SEM. Red lines shows the differences with 
statistical significance (* p=0.05, ** p=0.003 and *** p=<0.001) and black lines the 
ones with no statistical significance (NS).  A One-way ANOVA with Tukey’s post-test 
was done for statistical analysis. 
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5.2.2 pCB Tregs effectively suppress MLC without loosing their individual 
suppressive capacity. 
In order to establish if CB Tregs could be pooled without loosing their individual 
suppressive capacity, Tregs from 3 mismatch CB units were isolated and added 
to MLCs (n=10). Individual CB Tregs or pCB Tregs were added at different 
Tregs:effector cell ratios (1:2,1:5 and 1:10). As shown before, individual CB 
Tregs were efficiently suppressive and in addition, pCB Tregs were constitutively 
suppressive at all ratios. Most importantly, when CB Tregs were pooled, their 
suppressive ability was maintained (Figure 5.2). 
 
 
 
Figure 5.2 Representative suppression assay using individual vs pCB Tregs 
(n=10). Tregs isolated from 3 CB units (allocated as A, B and C) added either 
individually or as a pool (A+B+C) at different Tregs:effectors cell ratio (1:2,1:5 and 
1:10). Results are shown as Mean c.p.m ± SD. 
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Interestingly, in 4 out of the 10 experiments, pCB Tregs showed better 
suppression (synergy pattern, Figure 5.3 B) compared to individual CB Tregs, 
whereas the rest of the experiments showed an average level of suppression 
(Figure 5.3 A). 
 
 
 
Figure 5.3 Suppression patterns in MLC using individual vs pCB Tregs (n=10). A) 
Representative graph of the experiments (60%) showing an average suppression using 
pCB Tregs. B) A representative experiment showing synergy suppression using pCB 
Tregs (40%). Results are shown as % of suppression. Black lines represent the mean 
value of suppression of the three individual CB Tregs and green dotted lines represent 
the 95% CI. Red lines represent the mean value of suppression using pCB Tregs. 
 
 
In order to test further if “pooling” CB Tregs increases the cell frequency able to 
respond to alloantigens, CB Tregs were CFSE labeled and challenged either 
individually or pooled against a total of 1x105 irradiated PBMCs for 6 days. 
Parallel suppression assays were done with CFSE labeled CD4pos CD25neg and 
non-stained CB Tregs in order to also test their suppressive function. As shown 
in Figure 5.4 A, pCB Tregs proliferated greater than individual CB Tregs when 
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challenge with allo-stimuli. Moreover, both individual or pCB Tregs require allo-
stimuli for proper proliferation, since no proliferation was seen after 6 days 
without co-cultured with irradiated PBMCs. These results, suggest that pooling 
enables a wider repertoire for allorecognition. In addition, parallel suppression 
assays demonstrate CB Tregs and pCB Tregs suppressive efficiency (Figure 5.4 
B). 
A)                                                  
 
B) 
 
Figure 5.4 Representative histograms with CFSE labeled Tregs against allo-
stimuli and parallel functional assay (n=3). A) Individual CFSE stained CB Tregs 
(Tregs A, Tregs B) stimulated either individually or Pooled with 1x105 irradiated 
PBMCs for 6 days. Blue histograms represents, the cell subset cultured without stimuli. 
B) Functional assay using CFSE stained CD4pos CD25neg subset stimulated with soluble 
CD3/CD28 Ab at 1/2.5µg/ml for 4 days. CB Tregs were added in a 1:2 Tregs effector 
cell ratio (black histograms). Red histograms represent, 0:1 Tregs: effector cell ratio. 
Results are shown as percentage of non-proliferating cells. 
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5.2.3 Pooling CB units prior CD25 isolation does not affect Tregs 
suppressive function. 
As described in section 4.2.3 pooling of CB units, prior isolation is a feasible 
approach without affecting the purity post-isolation for CD4pos CD25pos CD127low 
cells. In order to complement these data and to test the suppressive function of 
the pCB Tregs, a series of CD25pos isolations were done from previously pooled 
CB units (range: 2 to 5 CB units) and used in MLCs at different Tregs:effectors 
cell ratio (1:2,1:5 and 1:10). Data was compared to all the suppression assays 
previously done using individual CB Tregs. In order to decrease variability, the 
same MLCs (n=15) were repeated using the same healthy controls used in the 
first experiments. 
 
As shown in Figure 5.5, this approach did not affect the suppressive function of 
the pCB Tregs. In agreement with the previous results, no statistical difference 
regarding overall percentage of suppression was found between pCB Tregs and 
individual CB Tregs at all ratios. 
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Figure 5.5 Suppression assays using previously pooled CB units Tregs vs 
individual CB Tregs (n=15). Results are shown as % of suppression ± SEM.  pCB 
Tregs are depicted in red bars and individual CB Tregs in black bars at different 
Tregs:effector cell ratios. Green lines shows the difference among groups that have 
statistical difference (*p=0.05, *** p=<0.001), whereas black lines shows the ones with 
no statistical difference (NS). 
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5.2.4 pCB Tregs suppression is diminished in a non-APCs system. 
As described in Chapter 1, we can summarize Treg mechanism of suppression 
whether they act directly on APC or effector cell subsets (Shevach, 2009). To 
further analyse in this context the mechanism of suppression of pCB Tregs, a 
non-APC system was done using a polyclonal stimuli. A total of 5x104 CD4pos 
CD25neg cells were stimulated with soluble CD3/CD28 Ab (1/2.5µg/ml) and pCB 
Tregs were added at different Tregs:effector cells ratio (1:2 and 1:5). As shown 
in Figure 5-1.5 pCB Tregs showed a reduced level of suppression compared to 
the suppression observed on previous MLCs. This may suggest that the 
suppression of pCB Tregs is at least dependent on the presence of APCs. 
However, it is important to take into consideration that different stimuli were 
used in the two assays (MLCs and polyclonal), hence, different levels of 
response.   
 
Figure 5.6 Suppression assay using polyclonal stimuli (representative of n=3). 
Adult CD4pos CD25neg were stimulated with soluble CD3/CD28 Ab at1/2.5µg/ml and co-
cultured with pCB Tregs at 1:2 and1:5 Tregs:effector cells ratio for 4 days. Results are 
shown as Mean cpm ± SD. 
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It has been suggested that Tregs suppression can be underestimated when 
measured by H3 thymidine uptake (Venken et al., 2007). Mainly because every 
proliferating cell, that is used in the assay will capture the radionuclide. In 
addition, since it has also been shown that Tregs can proliferate in vitro (Miyara 
et al., 2009), we cannot differentiate specifically the proliferation from each cell 
subset (Treg and effector T cells). To further test the suppression potency of 
pCB Tregs and to appreciate more the direct impact on effector T cells in the 
presence of pCB Tregs in a non-APC system, CFSE labeled CD4pos CD25neg T 
cells were stimulated with polyclonal stimulus (as previously described) with or 
without pCB Tregs (1:2 Tregs:effector cells ratio) for 4 days. Different activation 
markers as well as markers important for Tregs functions, were assessed from 
the CFSE+ population and correlated to their proliferative response. 
 
pCB Tregs  showed 52% suppression in agreement with the level detected with 
H3 Thymidine uptake (Figure 5.7 B). Even though less cells proliferated when 
co-cultured with pCB Tregs, effector T cells were able to up-regulate CD25, 
CD69 and HLA-DR (Figure 5.7 A). However, pCB Tregs potently inhibited 
effectors differentiation into cytokine secreting Th-1 cells, as they potently 
blocked IFN-! secretion (Figure 5.7 B). 
 
CTLA-4 and LAG-3 are normally up-regulated by activated T cells (Rudd et al., 
2009; Triebel, 2003). No difference on the expression of theses markers was 
observed when effector T cells were co-cultured with pCB Tregs. Interestingly, a 
greater amount of effector T cells became LAPpos when co-cultured with pCB 
Tregs, in spite of the reduced numbers of cells (Figure 5.7 A). These cells may 
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have been converted to iTregs, since it has been shown that iTregs can be 
developed from CD4pos CD25neg after activation in the presence of TGF-% (Chen 
et al., 2003). These cells constitutively up-regulate the latent associated peptide 
(LAP), which is the inactive form of TGF-% (Andersson et al., 2008). 
 
Furthermore, pCB Tregs highly up-regulated CD39 expression (Figure 5.8). 
CD39 expression among CD4pos FoxP3pos Tregs has been associated with their 
suppressive function by inducing adenosine, which is an immunoinhibitory 
molecule (Borsellino et al., 2007; Deaglio et al., 2007; Fletcher et al., 2009). 
Most importantly it has been postulated that Tregs that up-regulate CD39 may 
represent the memory subset required for long-term immunoregulation (Zhou et 
al., 2009b). Likewise, effector T cells highly up-regulated CD39 expression and 
barely any CD39neg population was detected upon co-cultures with pCB Tregs. 
Thus, in agreement with other studies, CD39 expression is not exclusive of 
Tregs, however, its expression on Tregs is associated with their suppressive 
functionality as well as with their differentiation to a memory Treg subset (Zhou 
et al., 2009b). In contrast, CD39 expression on effector T cells only represents 
the latter. More details regarding CTLA-4 and LAP expression on Tregs will be 
described in details in Chapter 6. 
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A) 
 
 
B) 
 
Figure 5.7 Representative suppression assay using CFSE staining (n=4). A) 
Histograms gated from CFSE+ population. Upper panel shows expression of activation 
markers (HLA-DR, CD69 and CD25), lower panel shows markers related to Treg 
function (CTLA-4, LAG-3 and LAP). Red color histogram depicts 0:1 and Gray depicts 
1:2 Tregs: effector cells ratio. B) Overlay counter plot graph showing cell divisions in 
different colors (gated from CFSE+ population). Left panel shows 1:0 and right panel 
1:2 Tregs: effector cells ratio. Percentage shown in white represents the level of IFN-! 
secretion. Percentage of suppression is shown in green.  
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Figure 5.8 Representative suppression assay measuring CD39 expression (n=3). 
Dot plot graph showing CFSE dilution compared to CD39 expression. Left panel shows 
0:1 and right panel 1:2 Tregs: effector cells ratio. Gates with percentages illustrates 
CD39 expression on non-proliferating and proliferating effector T cells. 
 
 
5.2.5 pCB Tregs suppression is cell-contact independent. 
To further test the capacity of pCB Tregs suppression and to elucidate if they 
require cell contact to regulate, MLCs (n=6) were done in 24 and 96 transwell 
plates. pCB Tregs were added either in the upper or lower chamber in a 1:1 
Tregs:effector cell ratio. pCB Tregs showed a potent suppression in a cell 
contact independent manner (Figure 5.9). Moreover, pCB Tregs did not require 
TCR engagement from the stimulator cells (irradiated PBMCs) to be 
suppressive. The same level of suppression was observed when pCB Tregs 
were co-cultured or not with irradiated PBMCs in the upper chamber. However, 
it is a common consensus that Tregs require TCR engagement for them to be 
suppressive (Thornton et al., 2000). More recently, it has been shown in a mice 
model using transgenic TCR Tregs that suppression can be achieved without 
Tregs TCR engagement (Szymczak-Workman et al., 2009). In addition, it has 
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also been shown that T cells can interact with other T cells, also called “T-T 
interactions” (Helft et al., 2008; LaSalle et al., 1992; Lee et al., 2009; Sidhu et 
al., 1992; Tsang et al., 2003). In accordance, and due to the general consensus 
that nTregs are considered to be an already pre-activated population as they 
exit the thymus, that, in addition to their expression of MHC-II and the specific 
fact that allorecognition is induced by pooling a variety of mismatch fully capable 
CD4pos T cells with a wide TCR repertoire, would confer the settings and the 
capacity for TCR interaction between each other.  
 
 
Figure 5.9 Representative Trans-well suppression assay (n=6). Normal MLCs were 
done in triplicates with the following settings: 1:0= Normal MLC in the lower chamber, 
1:1= Tregs:effector cells ratio co-cultured in the lower chamber, 1:1 TW= irradiated 
PBMC and responders in the lower chamber and pCB Tregs in the upper chamber 
ending in 1:1 Tregs:effector cells ratio, 1:1 TW+irr= the same as the previous with the 
addition of irradiated PBMC in the upper chamber with the pCB Tregs and 1:TW irr= 
normal MLC in the lower chamber and irradiated PBMCs in the upper chamber. Results 
are shown as Mean cpm ± SD. A One-way ANOVA with Tukey’s post-test was done for 
statistical analysis (*** p=<0001). 
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5.2.6 pCB Tregs can be used as an adjuvant to host Tregs. 
Current data regarding Treg immunotherapy for allo-transplantation suggest that 
specificity as well as cell numbers are important elements for effective 
suppression in vivo (Hoffmann et al., 2006a; Riley et al., 2009; Sagoo et al., 
2008). In agreement to this, I tested the feasibility of using host Tregs in addition 
with pCB Tregs, hereafter mentioned as host/CB pool. MLCs were carried out as 
described previously and Tregs were added at different Tregs:effector cell ratios. 
Host/CB pool was added only at a final 1:2 Treg:effector cells ratio. Within the 
host/CB pool, only 20% or 10% were host Tregs, with the rest being pCB Tregs. 
Interestingly, host/CB pool showed the same level of suppression compared to 
using only host Tregs. This effect was conserved even with the lowest 
proportion of host Tregs (10% host Tregs + 90% pCB Tregs) (Figure 5.10). As it 
has been shown, third party adult Tregs showed lower level of suppression 
compared to host Tregs (p=0.001). However, pCB Treg showed potent 
suppression with overall no statistical significance compared to host Tregs. As 
described on Chapter 3, CB Tregs are mainly naïve (#89%, CD45RApos) and 
most of them express CD31 (#80%), which is a marker correlated with recent 
thymic emigrants with a wide TCR repertoire (Junge et al., 2007). Conversely, 
adult Tregs are mainly central memory (CD45RAneg, CD62Lpos), with <15% 
being CD45RApos CD31pos. These phenotypic disparities among adult and CB 
Tregs could explain the different level of suppression achieved when used as 
“third party” in allo-responses. 
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Figure 5.10 Summary of suppression assays using pCB Tregs + host Tregs (n=3). 
Results are shown as mean % of suppression ± SEM. Host Tregs were added at 1:2, 
1:5 and 1:10 Tregs: effector cell ratios. Host/CB pool (pCB Tregs +host Tregs) was 
added at 1:2 Tregs:effector cells ratio with 20% and 10% being host Tregs, 
respectively. pCB Tregs and adult third party Tregs were added at 1:2 Tregs:effector 
cells ratio. Green lines, shows statistical differences (**p=0.001***p=<0.0001) and red 
lines no statistical difference (NS). A One-way ANOVA with Tukey’s post-test was done 
for statistical analysis. 
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5.2.7 pCB Tregs immunogenicity 
 
One of the main concerns regarding the use of third party cellular components in 
allo-transplantation may be increasing alloreactivity that may end up with a non-
beneficial effect to the host or to the graft. To address this issue, pCB Tregs 
were irradiated as described in section 2.5.1 either freshly isolated or after 48hrs 
of activation with soluble CD3/CD28 Ab. The latter was done to elicit higher 
expression of MHC II from pCB Tregs. Cultures were done in triplicates and 
follow up as a standard MLC. As shown on Figure 5.11, irradiated pCB Tregs 
did not elicit proliferation of CD4pos CD25neg T cells. The same results were 
shown when used activated pCB Tregs. 
 
 
Figure 5.11 pCB Tregs immunogenicity assay (n=2). Results are shown as mean 
cpm ±SD. CD4pos CD25neg T cells (effectors) stimulated either with soluble anti-
CD3/CD28 Ab or irradiated 1x105 pCB Tregs (freshly isolated or 48hrs post activation). 
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5.3 Discussion 
It has been widely shown that host or donor Tregs, are the most potent 
suppressors for allo-responses (Hoffmann et al., 2006c; Sagoo et al., 2008). On 
my understanding, the third party approach has not been fully explored. Few 
studies have actually used third party Tregs to suppress alloresponses and the 
vast majority have tested either donor or host Tregs expanded against third 
party antigens. Perhaps the caveats of some of these experiments could be due 
to the fact of using adult Tregs that in contrast to the murine models are mainly 
memory Tregs that have been induced within a heterologous immune system. In 
addition, expanding these memory Tregs towards alloantigens would imply a 
second selection process, which will inherently narrow the TCR repertoire of the 
ending Treg pool, hence lesser chances of suppressing alloresponses. This 
could explain the low suppressive potency of third party expanded Tregs shown 
in these reports and can also mislead the actual approach of using Tregs from a 
third party. In contrast, the only studies to my knowledge, using Tregs from a 
third party that have shown potent suppression of alloresponses, comes from a 
murine model study (Steiner et al., 2006) and others using human CB Tregs 
(Godfrey et al., 2005; Hippen et al., 2008). In accordance, herein is shown that 
CB Tregs are optimal for a third party approach. In addition, compelling data 
demonstrates that CD45RApos Tregs constitute the most homogenous and 
stable population among the overall Treg pool (Hoffmann et al., 2006b; Miyara 
et al., 2009). However, only a small proportion of adult Tregs are CD45RApos 
(#20%). In contrast, CB Tregs are mainly CD45RApos (#89%) and co-express 
CD31 which is a marker correlated with recent thymic emmigrants which also 
maintain a wide TCR repertoire (Kohler et al., 2008). As it was shown, CB Tregs 
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constitutively suppressed direct allo-recognition. Although a noticeable better 
suppression was detected using host Tregs, there was no statistical difference 
detected when compared to overall CB Tregs suppression. In contrast, a lesser 
level of suppression was seen when adult Tregs were used as third party. 
 
pCB Tregs showed in the same manner, constitutively potent suppression ability 
in MLC. Most importantly, pooling did not affect their suppressive capacity. 
Moreover, in 40% of the cases a better suppression was seen with pCB Tregs 
compared to individual CB Tregs suggesting a “synergy effect”. Noteworthy, no 
HLA matches (HLA-A,B,C and DR) were detected between the CB units pooled, 
responders and stimulators used in the MLCs. These results suggest that 
pooling could increase the repertoire for allo-recognition, and thus, induced 
better suppression. 
 
Lower levels of suppression were detected in a non-APC system. Effector T 
cells were able to up-regulate activation markers when co-cultured with pCB 
Tregs. However, pCB Tregs potently inhibited the differentiation of CD4pos 
CD25neg cells into cytokine secreting Th-1 cells, as they potently blocked IFN-! 
secretion. Interestingly, a higher percentage of effector cells became LAPpos 
when co-cultured with pCB Tregs. It has been shown that iTregs can be 
developed from activated CD4pos CD25neg T cells in the presence of TGF-% and 
upon activation they constitutively up-regulate LAP expression (Chen et al., 
2003).  
Furthermore, pCB Tregs highly up-regulated CD39, which has been shown to 
work in tandem with CD73 for their suppressive function (Borsellino et al., 2007; 
 121 
Fletcher et al., 2009). In addition, since CD39 expression also allows Tregs to 
be resistant to apoptosis, it has been postulated that CD39 expression on Tregs, 
is of great importance for the development of a memory pool to achieve long-
term immunoregulation (Zhou et al., 2009b). 
 
It has been widely believed that Tregs requires TCR engagement for proper 
functionality (Thornton et al., 2004b). pCB Tregs did not require cell contact with 
the stimulator cells in order to be suppressive. It has recently been shown 
suppression without the requirement of prior TCR engagement using transgenic 
TCR Tregs (Szymczak-Workman et al., 2009). Moreover, it has also been 
shown that T cells can get TCR engagement between T cells, called “T-T 
interactions” (Helft et al., 2008; LaSalle et al., 1992; Lee et al., 2009; Sidhu et 
al., 1992; Tsang et al., 2003).  Since, CB Tregs constitutively express MHC II 
and conserve a naïve wide TCR repertoire, and the specific fact that 
allorecognition is induced by pooling, it is more likely that T-T interactions may 
allow CB Tregs suppression without the traditional engagement within a T cell 
and an APC. Interestingly, this finding suggests that the process of pooling can 
elicit a higher Treg pool with already TCR engagement. This could be of great 
importance for their suppressive functionality once infused in vivo. Moreover, the 
majority of the experiments in vitro have shown that Tregs requires cell-contact 
to be suppressive (Shevach, 2009). Interestingly, pCB Tregs showed 
suppression in a cell contact independent manner. It has been described that 
Tregs can mediate suppression through the secretion of inhibitory cytokines, 
mainly TGF-%, IL-10 and recently IL-35 (Asseman et al., 1999; Nakamura et al., 
2004; Vignali et al., 2008). 
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From an in vivo model experiment, using cord blood polyclonal expanded Tregs, 
higher ratios (4:1 to 6:1 Tregs:effectors) are required to effectively suppress allo-
responses (Hippen et al., 2008). However, a lower purity of Tregs was used in 
this experiment, therefore, it is hard to elucidate if that higher dose is really 
required. Nonetheless, further experiments are still warranted to identify the 
optimal time for the adoptive transfer of Tregs, since this is an important factor 
that might influence greatly the cell dose required. Likewise the necessity of 
multiple infusions is also another option that has not been elucidated.   pCB 
Tregs showed to be a practical approach that could achieve optimal cell 
numbers with GMP standards using a single step isolation method when 
requested. They constitutively suppress allo-responses in vitro. Furthermore, 
pCB Tregs showed potent suppression ability when used as adjuvant to host 
Tregs suppression. 
 
It has been proven in preclinical models that donor polyclonal expanded Tregs 
are efficient to prevent GvHD in HSCT (Edinger et al., 2003). In contrast, it has 
been shown that Tregs with direct-alloantigen and indirect-alloantigen specificity 
are required for long-term graft survival in solid organ transplantation settings 
(Joffre et al., 2008; Tsang et al., 2008). However, the time period required in 
order to achieve optimal cell numbers with the specificity required in both clinical 
settings may not be feasible in time constrain scenarios. In addition, long-term 
(>2 weeks) Tregs expansion protocols have shown down-regulation of FoxP3 
expression and conversion/outgrowth to Th-1, Th-2 or Th-17 effector T cells 
(Hoffmann et al., 2009; Putnam et al., 2009). Therefore, pCB Tregs can be used 
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in addition to host Tregs expanded for shorter time periods in order to achieve 
optimal cell numbers for immunotherapy. This approach can address specificity 
and optimal cell numbers in a practical and safe fashion, and even help to save 
some additional host or donor Tregs, that might be required for multiple 
infusions. 
 
Irradiated pCB Tregs did not elicit any proliferation from effector T cells, further 
experiments using in vivo models are warranted to fully corroborate these 
results. 
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CHAPTER 6  
pCB TREGS ACTIVATION PATTERN AND REGULATORY 
PHENOTYPE STABILITY 
 
6.1 Introduction 
Evolving studies have correlated a wide repertoire of markers with Tregs 
differentiation, activation and their functional properties (Brusko et al., 2008b). 
These results have provided valuable data in order to elucidate a bona fide Treg 
for their proper translation into clinical settings. 
 
The majority of nTregs in the peripheral blood constitutively express high levels 
of the IL-2" receptor (CD25) (Baecher-Allan et al., 2001). It has also been 
described that the IL-2 second signal after TCR engagement, is of importance 
for Tregs differentiation in the thymus (Fontenot et al., 2005a). Furthermore, 
activated STAT5, downstream of IL-2 receptor signalling, regulates FoxP3 
transcription (Burchill et al., 2007; Wuest et al., 2008). Therefore, IL-2 is 
paramount for Tregs differentiation and phenotype stability. In addition, CTLA-4 
is constitutively expressed on nTregs (Baecher-Allan et al., 2001; Miyara et al., 
2009; Read et al., 2000), and it has been suggested to be a core mechanism 
through which nTregs harness APC function (Friedline et al., 2009; Shevach, 
2009). nTregs also express the glucocorticoid-induced tumor necrosis factor 
receptor family-related gene (GITR). Signalling through this receptor abrogates 
nTregs suppressive capacity (McHugh et al., 2002; Nocentini et al., 2005; 
Shimizu et al., 2002). Moreover, the expression of the lymphocyte activation 
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gene-3 (LAG-3) on Tregs, which is a homologue of CD4, modulates APCs 
function by interacting with their MHC II molecules (Liang et al., 2008). TGF-% 
plays an important role within the repertoire of Tregs cytokine-mediated 
suppression mechanisms (Huber et al., 2006; Nakamura et al., 2004; Nakamura 
et al., 2001). Usually TGF-% is detected in the inactive form associated with 
latency-associated peptide (LAP) and is constitutively expressed on activated 
Tregs with potent suppressive function (Nakamura et al., 2004; Tran et al., 
2009a; Tran et al., 2009b). It has also been described that the expression of 
different homing receptors like CD62L and CCR7 on Tregs, are predominant for 
their ability to migrate to different areas of importance within the body in order to 
suppress (Taylor et al., 2004; Zhang et al., 2009). In accordance, CXCR3 
signalling favours Tregs recruitment and interactions with T effector cells within 
Th-1 cell-mediated inflammation sites (Muller et al., 2007). 
 
Lastly, the awareness of possible Tregs plasticity (or outgrowth of the 
contaminating effector T cells) towards unwanted effector T cells (Th-1, Th-2 
and Th-17) is a main concern for the proper translation of Treg immunotherapy 
into clinical settings (Afzali et al., 2010; Hoffmann et al., 2009; Putnam et al., 
2009; Riley et al., 2009). Therefore, in addition to the functional assays that 
measure suppressive potency, different tests are warranted to confirm the 
regulatory phenotype stability of the cells intended to infuse. 
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6.2 Results 
In accordance to the aforementioned, the objective of this chapter is to measure 
the expression of different markers upon Tregs activation. This will allow us to 
clarify the changes in pCB Tregs following activation. pCB Tregs will be 
activated using polyclonal stimulation, this with the only intention to avoid the 
variability that will be inherent otherwise an allo-stimuli is used. In addition, pCB 
Tregs will be tested upon different conditions to ascertain their regulatory 
phenotype stability. 
 
6.2.1 pCB Tregs activation pattern is consistent with Treg phenotype and 
functionality. 
pCB Tregs were cultured with polyclonal stimuli for 96hrs in order to observe the 
initial activation process of pCB Tregs and whether they were able to convert or 
restrict the outgrowth of the initial contaminating effector T cells (#9%). In 
accordance, pCB Tregs up-regulated the wide repertoire of markers correlated 
with Treg phenotype and functionality (Figure 6.1 A,B). FoxP3 expression was 
upregulated within the first 24hrs (from #80% to "90% CD4pos FoxP3pos) of 
culture and hereafter, highly maintained throughout the culture (>90% CD4pos 
FoxP3pos). LAP expression was up regulated within the first 24 hrs and 
maintained the level of expression (#80% CD4pos LAPpos), with an apparent 
downslope after 72hrs of culture (72% CD4pos LAPpos). The expression of CTLA-
4 and GITR showed a slightly slower pace of up-regulation, with the highest 
expression achieved (67% CD4pos CTLA-4pos and 83% CD4pos GITRpos) at 72hrs 
of culture. The same activation pattern was seen for the expression of LAG-3, 
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HLA-DR, CXCR3, CD39 and ICOS. Lastly, pCB Tregs highly upregulated the 
expression of the !c chain receptor CD132 (>80%). It has been shown that Tregs 
requires the three components of the IL-2 receptor, which are CD25 (IL-2R"), 
CD122 (IL-2R%) and CD133 (IL-2R!c), for their functionality and homeostasis in 
vivo (Fontenot et al., 2005a; Thornton et al., 2004a; Yu et al., 2009a). 
 
In summary, pCB Tregs upregulated all the characteristic markers consistent 
with a regulatory phenotype that are important for their suppressive functionality. 
In accordance lower levels of CD127 (<4% CD127pos) were maintained 
throughout the culture and no IFN-! secretion was detected. Therefore, under 
this conditions pCB Tregs conserved a stable regulatory phenotype with an 
apparent control over the initial effector T cell population. 
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Figure 6.1 pCB Tregs activation pattern (n=2). A) pCB Tregs were activated with soluble CD3/CD28 antibodies. The expression of 
different markers, were measured at the estimated time points. Results are shown as percentage of expression gated from CD4pos cells. 
Positive fraction of each marker was depicted  using the specific isotype control as instructed in Material and Methods Chapter. 
B) Histograms of the different markers at the designated time points are shown. Results are shown as mean intense fluorescence intensity 
(MFI).    
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6.2.2 pCB Tregs differentiate upon activation from rTregs to aTregs with 
no sign of conversion/outgrowth to Th1, Th2 and Th-17. 
In order to test in a longer time frame the differentiation and stability of pCB 
Tregs, the cells were placed in 7 days culture with polyclonal activation using 
CD3/CD28 beads (1:2 bead:cell ratio) in addition to 400U/ml of IL-2, then rested 
for 24hrs in culture media for a posterior activation with PMA/Ionomycin. In 
agreement with a previous study (Miyara et al., 2009), in which rTregs were 
characterized as CD45RApos FoxP3low (prior culture !80% vs post activation 
<20%) became in their vast majority aTregs CD45RAneg FoxP3high (prior culture 
!12% vs post activation >65%, Figure 6.2 A,B). The expression of Ki-67, which 
is a nuclear marker used for proliferation (Scholzen et al., 2000), was not 
depicted from overall CD4pos T cells from fresh CB (Figure 6.2 A).  After 
activation of pCB Treg, Ki-67 expression was mostly up-regulated in the 
FoxP3pos population compared to the FoxP3neg (>30% vs <2% Ki67pos, 
respectively). In addition Ki-67 expression, among the FoxP3pos cells, was 
nonexclusive of their CD45RA expression. Ki-67 expression was expressed in 
the same proportion on the CD45RApos and CD45RAneg FoxP3pos T cells, 
suggesting a homeostatic balance between the overall Treg pool. 
 
Lastly, after a week of strong activation, pCB Tregs did not show any production 
of IFN-" (Th-1), IL-4 (Th-2) or IL-17a (Th-17) which suggests a lack of 
conversion or outgrowth towards unwanted effector T cells (Figure 6.2 C). 
Additionally, no IL-10 production was observed. 
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A) 
 
B) 
 
C) 
 
 
Figure 6.2 Representative activation culture using CD3/CD28beads and PMA/Io of 
pCB Tregs (n=3). Results are shown as percentage of expression gated from CD4pos 
population. A) Dot plots and histograms shows the initial purity and characterization of 
pCB Tregs using FoxP3, CD25, CD45RA and Ki-67. Gate I depicts rTregs and gate III 
shows aTregs (gates V and VI determine effector cells). B) Dot plots and histograms of 
pCB Tregs after activation showing percentage of expression of FoxP3, CD45RA and 
Ki-67. C) Dot plots of pCB Tregs after activation showing percentage of Ki-67 and 
FoxP3 and intracellular cytokine staining for IFN-", IL-4, IL-10 and IL-17a. 
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6.2.3 Overall CB CD4pos T cells are reluctant to Th-17 differentiation under 
the influence of IL-1b and IL-2. 
It has been shown that IL-1b and IL-2 can elicit Treg conversion towards Th-17 
cells (Beriou et al., 2009; Deknuydt et al., 2009). Therefore, to test this, adult 
CD4pos CD25pos, CD4pos CD25neg T cells, CB CD4pos CD25pos, CB CD4pos 
CD25neg and pCB Tregs were challenged by polyclonal activation using 
CD3/CD28 beads (1:2, bead:cell ratio) in the addition of IL-1# and/or IL-2 
(10ng/ml and 10U/ml final concentration, respectively) for 5 days. Proliferation 
was measured using thymidine incorporation, and the levels of IL-17, were 
measured from the supernatant (using ELISA, described in section 2.7).  
 
As expected, CD4pos CD25neg subsets from adult and CB showed higher 
proliferation at the end of culture compared to their counterpart CD25pos 
population. The addition of IL-1b and IL-2 into culture elicited higher proliferation 
rate compared to their individual effect upon each cell subtype from both 
sources (adult and CB, Figure 6.3 A). This finding also validates the viability of 
each cell subset. 
 
Overall, IL-17 was mostly detected from adult CD4pos cells compared to CD4pos 
from CB. Either IL-1b or IL-2 generated the secretion of IL-17 from both CD25neg 
and CD25pos CD4pos T cells in adult. The mixture of IL-1b and IL-2 within the 
same culture showed the best milieu for IL-17 secretion from both cell subtypes 
in adult. Conversely, overall CB CD4pos T cells showed barely any levels of IL-17 
hence no difference could be detected between individual CB CD4pos cell 
subsets or pCB Tregs (Figure 6.3 B).   
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6.3 Representative activation of CB and adult CD4pos cell subsets with IL-1b or/+ 
IL-2 (n=2) CD25pos and negative fractions from CD4pos cells of adult and CB were 
activated with CD3/CD28 beads (1:2 bead:cell ratio) with the addition of the described 
cytokine/s. A) Graph showing proliferation of each cell subtype with the described 
cytokines in culture. Results are shown as mean cpm±SD. B) Graph showing the level 
of IL-17 captured from the supernatant from each cohort as described. Results are 
shown as mean pg/ml ±SD. 
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6.2.4 Paucity of Th-17 conversion/outgrowth from expanded pCB Tregs, 
whilst maintaining their suppressive capacity. 
As mentioned before, Tregs expansion protocols have shown some important 
levels of conversion or outgrowth towards Th-1 or Th-17 effectors (Beriou et al., 
2009; Putnam et al., 2009; Riley et al., 2009). Herein, I showed that after long-
term culture (21 days), which will infer 3 steps of stimulation with CD3/CD28 
beads, pCB Tregs were able to expand (45 to 60 folds, Figure 6-4 A). However, 
around 10% of the FoxP3pos population showed IL-17a production with no level 
of IFN-" or IL-10 depicted (Figure 6-4 B). Noteworthy, the initial purity was !90% 
for CD4pos FoxP3pos, therefore, it is more likely that the 10% of CD4pos 
contaminating effector cells may be responsible for the level of IL-17a depicted. 
However, strict elucidation between conversion or outgrowth of Th-17 effector 
cells can not be assessed from this experiment. Nonetheless, expanded pCB 
Tregs maintain their suppressive capacity (Figure 6.4 C).                
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Figure 6.4 pCB Tregs expansion (n=2) A) Expansion of (1x105 cells) pCB Tregs with 
CD3/CD28 beads (1:2, bead:cell ratio) with 400U/ml of IL-2. Results are shown as total 
number of cells. B) Characterization of pCB Tregs at 21 days of culture. Results are 
shown as percentage of expression gated from CD4pos cells. C) Suppression assay 
(MLC) using the expanded pCB Tregs at different cell numbers as described. Results 
are shown as mean cpm ±SD. 
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6.3 Discussion 
Compelling data has shown that CD45RApos FoxP3pos Tregs also called rTregs, 
represent the most homogenous and stable population of the overall Treg pool 
(Hoffmann et al., 2006b; Miyara et al., 2009). In agreement, pCB Tregs, which 
are in there vast majority rTregs (>80%), behave as such upon activation. They 
showed a homeostatic proliferation balance upon activation, ending up with a 
reduced rTregs Ki-67pos pool and an increased population of aTregs. However, 
in contrast to Miyara’s study, the expression of Ki-67 on overall CB Tregs is only 
depicted once being activated, suggesting that overall naïve CD4 T cells from 
CB are in a clearly quiescent state in comparison to their similar population from 
adult PBMCs. Additionally, pCB Tregs upon polyclonal stimuli, constitutively up-
regulate and maintain their FoxP3, and GITR expression without any production 
of IFN-" or up-regulation of CD127 that would imply any effector T cell 
differentiation or outgrowth. Moreover pCB Tregs highly upregulate LAP 
expression. A similar pattern of LAP expression has been reported from sorted 
adult CD4pos CD25high T cells (Tran et al., 2009a). In this study they showed that 
an additional isolation of LAPpos cells specifically depicts activated CD4pos 
FoxP3pos T cells with potent suppressive capacity. In addition, pCB Tregs up-
regulate CTLA-4, which has been shown to be important inhibiting the 
inflammatory cascade through cell contact with CD80/86 expressed on APCs 
(Onishi et al., 2008). CTLA-4 signal can activate indoleamine-2,3-dioxygenase 
(IDO), which generates the immunosuppressive mediator kynurenin (Grohmann 
et al., 2002). Moreover, signalling through CTLA-4 promotes the nuclear 
localization of Foxo transcription factors, which hampers the expression of 
genes encoding IL-6 and the phosphorylation of the tumor necrosis factor 
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(Dejean et al., 2009). Therefore, CTLA-4 expression by Tregs is of great 
importance for their function in vivo. pCB Tregs also express LAG-3, which has 
been shown that CD4pos T cells transduced with LAG-3, confers them regulatory 
ability (Huang et al., 2004). Moreover, dendritic cell maturation and activation is 
hampered by the engagement between their MHC II molecules and LAG-3 from 
Tregs (Liang et al., 2008). 
 
As previously mentioned (Chapter 3), another important characteristic of Tregs 
is their capacity to migrate to sites of relevance of the immune response in hand, 
specifically the target tissue and the secondary lymph nodes. Accordingly, pCB 
Tregs constitutively express CD62L and CCR7, which are important for their 
ability to migrate to secondary lymph nodes, wherein they can inhibit APCs 
maturation and activation (Taylor et al., 2004; Zhang et al., 2009). Moreover, it 
has been shown that Tregs that upregulate the transcription factor T-bet and 
subsequently the expression of CXCR3, specifically have the capacity to migrate 
and suppress at sites of Th-1 cell-mediated inflammation (Koch et al., 2009; 
Muller et al., 2007).  The up-regulation of CXCR3 shown by pCB Tregs in 
combination with the absence of IFN-" secretion, suggest a stable suppressive 
phenotype and correlates with the functional assays where strong inhibition of 
IFN-" secretion from CD4pos CD25neg T cells was observed when they were co-
cultured with pCB Tregs (Chapter 5). In accordance, the expression of CD39 in 
pCBTregs correlates with their suppressive function (Chapter 5) and it has also 
been demonstrated that CD39pos Foxp3pos Tregs are potent suppressors of Th-
17 effectors (Fletcher et al., 2009). In addition, a population characterized as 
CD4pos FoxP3pos ICOSpos, mediates suppression through contact with dendritic 
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cells in an IL-10 dependent manner (Ito et al., 2008).  However, although pCB 
Tregs upregulated ICOS expression, no IL-10 secretion was observed. 
Noteworthy, the study that described secretion of IL-10 from this population 
used ICOS-L in addition to a polyclonal stimulation. Therefore, specific co-
stimulation or conditioning may be required to elicit detectable levels of IL-10 
secretion, thus the capacity of IL-10 secretion from pCB Tregs cannot be 
excluded from this experiment. 
 
It is known that activated T cells up regulate MHC class II expression (LaSalle et 
al., 1992). In agreement, pCB Tregs upregulate HLA-DR expression upon 
activation. It has been described that HLA-DRpos Tregs represents a mature 
population that achieves early cell-contact suppression (Baecher-Allan et al., 
2006). Additionally, the same group has shown that HLA-DRpos Tregs are less 
likely to convert towards Th-17 effectors (Beriou et al., 2009). Moreover, 
different levels of Th-17 conversion from nTregs have been reported (Beriou et 
al., 2009; Weaver et al., 2009). It has been shown that the presence of IL-1 
favours Tregs differentiation towards Th-17 effector T cells (Beriou et al., 2009; 
Deknuydt et al., 2009). Herein, is shown that CB CD4pos cell subsets are more 
reluctant to Th-17 differentiation under the influence of IL-2 and IL-1b, compared 
to adult CD4pos T cells. Nonetheless, due to the lower levels of IL-17 depicted 
among all CB CD4pos cell populations and in addition to the inevitable 
percentage of contaminating effector T cells within the CD25pos populations, a 
clear elucidation of the cell subset responsible for the paucity IL-17 depicted 
cannot be attained. However, higher cell proliferation was observed when both 
of these cytokines were used, independently of the source and the cell 
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population tested. The level of IL-17 observed from long-term expansion 
cultures of pCB Tregs correlates to some extent with what has been published 
from adult Tregs studies (Afzali et al., 2010; Beriou et al., 2009), although the 
levels of IL-17 shown on these studies were observed on shorter time cultures. 
Noteworthy, the level of IL-17 (!10%) expression among the FoxP3pos 
population from expanded pCB Tregs, correlates with the initial 10% level of 
contaminating effector T cells prior expansion. Therefore, it is more likely that 
the contaminating effector T cells are responsible for the IL-17 detected. 
Regardless, expanded pCB Tregs maintain their suppressive potency.  
 
In summary, pCB Treg, upon activation, showed a stable regulatory phenotype 
with beneficial properties for a proper suppressive function in vivo. However, 
long-term expansion protocols, in addition to an increase of contaminating 
effector T (>10% of CD4pos CD25pos CD127high) prior expansion, cells may affect 
this virtue. 
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CHAPTER 7 
pCB TREGS AMELIORATES SKIN TRANSPLANT  
REJECTION IN VIVO 
7.1 Introduction 
Currently the urge of stepping from bench to clinic, in terms of cellular 
immunotherapy, has elicited a scarcity of in vivo models that resemble better the 
clinical situation (Ishikawa et., al, 2005). Specifically, the preclinical models so-
called ¨ humanised models ¨ allow us to explore human tissues in immune-
depleted animals (Nadig et., al, 2010).  
In order to assess the functionality of pCB Tregs in vivo, a collaboration was 
established with Prof. Kathryn Wood’s group in Oxford. The entire process of 
cell preparation prior infusion and the humanized skin transplant model itself, 
was carried out by Issa Fadi and Joanna Wieckiewicz (members of Prof. 
Kathryn Wood´s group).  Noteworthy, the following experiment was done at their 
facilities (Nuffield Department of Surgery, John Radcliffe Hospital, University of 
Oxford, Oxford, UK.). The CD25 isolation of five pooled CB units used in this 
only preliminary experiment was done at the ANRI. After the isolation process, 
cells were transported immediately in cRPMI in a chilled sealed compartment to 
Nuffield Department of Surgery research department, Oxford, UK.  Once arrived, 
the cells were spun, placed in fresh cRPMI. Cell count and viability was 
performed by dye exclusion method. A total of 6.5x106 cells were counted with a 
95% viability. The phenotype of the resulting CD25 isolation showed similar 
results as described in chapter 3 with a 90% purity for CD4pos CD127low 
FoxP3pos (Figure 7.1).  
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Figure 7.1 FACs characterization of the pCB Tregs prior infusion. Percentage of 
populations gated from lymphocyte gate using FSC and SSC. 
 
In order to test the suppressive capacity of pCB Tregs, a previously optimized 
humanised mouse model of skin transplantation using healed-in human skin 
allografts in PBMC-reconstituted BALB.c Rag2-/- IL2rg-/- mice was used (Fadi 
et., al, 2010). A follow up of 100 days was done and graft survival was the end 
point of this preliminary experiment. From the total of mice used in the 
experiment group (n=4), one did not engrafted thus it was not included in the 
final analysis. Therefore, only three mice that fully engrafted from this group 
were included for a complete analysis. All the mice used for the positive control 
(n=3) showed full engraftment. As shown in figure 7.2, the positive control group 
rejected the skin graft as expected around 40 days post-infusion, in the other 
hand, the group with pCB Tregs had a median graft survival of >100 days. In 
addition, no GvHD was seen in the experiment group. 
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Figure 7.2 Graft survival graph (n=4). Humanised mouse model of skin transplantation using BALB.c Rag2-/- IL2rg-/- mice. A total of 
5x106 PBMC and 1x106 pCB Tregs were infused (5:1 ratio).  Control group were only infused with 5x106 PBMC (n=3). Results show 
percentage of survival in a 100 days follow up. Median survival time is also shown between groups. 
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Only one mouse presented a delayed skin graft rejection on day 73. Noteworthy, 
most of the current data suggest that a 1:1 ratio (Effectors: Tregs) has to be 
obtained in order to properly ameliorate graft rejection. This preliminary 
experiment using a much lesser dose of adoptively transfer Tregs (1:5 ratio) in 
addition of the novelty of using multiple mismatch CB Tregs, showed a potent 
protective effect in a humanized skin transplant model. This results goes in 
agreement with the in vitro data showed in previous chapters. In summary, pCB 
Tregs showed beneficial effects in this pre-clinical model, further experiments 
are warranted in order to validate this preliminary results.  
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CHAPTER 8 
GENERAL DISCUSSION 
 
The evolving knowledge in transplant immunology has given the basis for the 
current therapeutic approaches that enables graft engraftment in HSCT and 
overall good 5 years graft-survival in solid organ transplantation (SOT) (Fehr et 
al., 2004; Lechler et al., 2005; Nowak, 2008). However, the morbidity and 
mortality due to GvHD (Socie et al., 2009) and long-term immunosuppression 
required in SOT, in addition to the unsuccessful results so far to avoid chronic 
rejection (Kwun et al., 2009), are still main concerns that open the field for new 
therapeutic options. The compelling data from preclinical models using Tregs to 
prevent GvHD (Edinger et al., 2003; Hippen et al., 2008), likewise, to achieve 
long-term graft survival in SOT (Cobbold et al., 2003; Jiang et al., 2006; Joffre et 
al., 2008) without the requirement of constant immunosuppression has 
prompted Treg immunotherapy as a valuable option for their translation into 
clinical transplantation settings (Brusko et al., 2008b; Hoffmann et al., 2006c; 
Long et al., 2009). This study describes the phenotype and functional properties 
of CB Tregs and also tested their use as a “third party” approach in 
transplantation settings. 
 
Firstly, one of the main concerns is to identify the “bona fide” Treg from the 
overall Treg pool (Riley et al., 2009; Seddiki et al., 2006b). As mentioned, 
evolving studies supports that CD4pos CD45RApos FoxP3pos Tregs represent the 
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most homogenous and stable population among the overall Treg pool 
(Hoffmann et al., 2006b; Miyara et al., 2009; Seddiki et al., 2006b). However, the 
proportion of CD45RApos Tregs decreases in an age dependent manner 
(Santner-Nanan et al., 2008; Seddiki et al., 2006b; Vukmanovic-Stejic et al., 
2006). In agreement, CB Tregs are mainly CD45RApos (!89%) compared to 
adult Tregs (!18%). In addition, CB Tregs co-express CD31 (!80%), which will 
be considered as RTE Tregs (CD45RApos CD31pos FoxP3pos), which 
constitutively expressed a wide TCR repertoire (Junge et al., 2007; Kilpatrick et 
al., 2008). Recently it has been demonstrated that the natural wide TCR 
repertoire from Tregs is a mechanism non-redundant for the maintenance of 
self-tolerance (Adeegbe et al., 2010; Haas et al., 2007). Thus, the conserved 
wide TCR repertoire from the CD45RApos CD31pos population in CB Tregs may 
be in part responsible for their better suppression shown in this study, when 
compared to adult third party Tregs. In addition, naïve CD31pos CD4pos T cells 
have shown to have longer telomeres and higher telomerase activity (Akbar et 
al., 2007a; Kilpatrick et al., 2008), hence, and in agreement with a recent study 
(Miyara et al., 2009), these cells have more capacity for replication and survival 
in vivo. 
 
Secondly, this study shows an optimized method for CB Tregs isolation using a 
single step method with GMP standards that constitutively achieves high purity 
and yield. In addition, the inevitable level of contaminating effector T cells within 
Tregs isolation methods is another factor of safety-importance for the translation 
into clinical settings. Regardless of the great reduction in effector T cells (<9%) 
achieved with this method, it is evident that if a positive isolation step is done 
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using anti-CD25 microbeads and mostly due to the knowledge that CD25 
expression is non-exclusive to Tregs, it is very unlikely to avoid a contaminating 
CD25pos FoxP3neg population, this in a greater extent from adult PBMCs than 
CBMCs. However, the phenotype of that population in CB is mainly naïve, in 
contrast to adult, which would express in their totality a memory phenotype. It is 
known that memory T cells have a lower threshold for full activation (Surh et al., 
2008; Takada et al., 2009; Tough et al., 1999). More recent studies supports 
that an extent of virus-specific memory T cells can cross-react to allo-antigens, 
creating a significant barrier for transplantation and for the use of co-stimulation 
blockade protocols (Bingaman et al., 2004; Fairchild, 2006). Conversely, it has 
been shown that naïve CD4pos T cells are able to convert to a suppressive 
phenotype in the presence of TGF-". Moreover, this study shows that in an 
inflammatory milieu that highly induces Th-17 conversion from adult CD4pos T 
cells, overall CB CD4pos T cells were highly reluctant towards this effect. Lastly, 
it has been reported a low incidence of severe GvHD in CB transplantation in 
HSCT settings, this without increasing the relapse rate (Rocha et al., 2009). This 
effect may not only be attributed to the enriched population of Tregs within the 
CD4pos CD25pos fraction within CB, but also to the naïve effector T cells, which 
may be more easily controlled by their counterpart Treg population. Therefore, 
CB effector T cells in combination with a higher proportion of Tregs (9:1 Tregs: 
effectors) are less likely to cause an unwanted pathogenic effect once infused in 
vivo. 
 
Thirdly, specificity has been another matter of debate in regards to Tregs 
immunotherapy. Noteworthy, this may be really difficult to pinpoint since 
 146 
recipient T-cell allo-reactivity is a dynamic process that has the capacity to shift 
towards other epitopes within the allogeneic MHC molecule (epitope spreading) 
as well as to alloantigens expressed by the graft (Ford et al., 2009; Suciu-Foca 
et al., 1998). Therefore, expanding Tregs against donor APCs may not entirely 
produce a Treg population that will be able to suppress the variety of allo-
antigens encounter in vivo and the process itself, may even reduce the TCR 
repertoire towards only the allo-antigens encounter ex vivo by the APCs used in 
culture. In accordance, it has been shown that the requirement of both direct 
and indirect-alloantigen specific Tregs are indispensable to prevent acute and 
chronic rejection (Joffre et al., 2008; Tsang et al., 2008), likewise in HSCT 
settings, polyclonal expanded Tregs are required to prevent or suppress GvHD 
(Hoffmann et al., 2006c). Therefore, these results suggest that Treg TCR 
repertoire should be as wide as their counterpart allo-reactive effector T cells in 
able for them to properly hamper the dynamic pattern of allo-reactivity that 
evolves in vivo in the different settings. Nonetheless, alloantigen specific Tregs 
are also preferred in the context to avoid pan-immunosuppression within the 
host, which may hamper immune surveillance towards environmental pathogens 
and tumor cells. This statement is based on studies where chronic exposure to 
certain pathogens induces regulatory T cells that aid their survival within the 
host (Belkaid, 2008; Hasenkrug, 2003). Likewise, it has been shown that certain 
tumors escape immune surveillance due to the induction of regulatory T cells (Li 
et al., 2007; Menetrier-Caux et al., 2009; Perrone et al., 2008). However, it was 
demonstrated in a Treg dependent tolerance mice model, that the adoptive 
transfer of CD4pos CD25pos T cells did not affect the immune responses towards 
influenza virus within the recipient (Bushell et al., 2005). Moreover, it was shown 
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in a GvHD model, that the adoptive transfer of polyclonal expanded Tregs did 
not prevent the activation of donor allo-reactive T cells that endure effectively 
the Graft versus Tumor (GvT) effect, this, without compromising the beneficial 
effect of Tregs to abolish GvHD (Edinger et al., 2003). Thus, the risk of pan-
immunosuppression occurring due to adoptively transferred Tregs is not clearly 
grounded at the moment, although further measures might be necessary in 
clinical transplant settings where a risk of tumor relapse is increased. 
 
Additionally and in context of adoptive T cell therapy, it has been shown that a 
low clonal abundance within a polyclonal repertoire favors the survival and 
activation of naïve CD4pos T cells once adopted in vivo (Hataye et al., 2006). 
Hence, in support that an inverse relation between cell survival and clonal 
frequency occurs, it seems implausible the commitment towards protracted 
expansion protocols that achieves Tregs with higher TCR frequencies with the 
inherent inevitable outgrowth or conversion towards unwanted effector T cells 
that occur within these protocols. Therefore, it seems worth pursuing the 
modality tested in this study of pooling CB Tregs. Primarily because the risk of 
conversion or outgrowth from freshly isolated CB Tregs is lesser compared to 
adult Tregs, and also a low frequency repertoire would be enriched within the 
pooled CB Tregs that could resemble better and counteract the allo-reactive 
effector T cells. 
 
Lastly, the evolving data in cord blood transplantation has strengthened the 
relevance of the cellular components within HSCT. The immature phenotype of 
CB cell subsets has been suggested to be responsible for that beneficial effect 
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shown in clinical settings (Rocha et al., 2009). However and in spite of the less 
stringent requirement for HLA matching, a threshold of TNC or CD34pos cells 
infused, most be attain for a better outcome (Michel et al., 2003; Wagner et al., 
2002). To address this matter some groups have shown promising results using 
the modality of double unit cord blood (DCB) transplantation in HSCT 
(Fernandes et al., 2007; Gutman et al., 2010; Kang et al., 2009; Verneris et al., 
2009). Interestingly, it has been shown that after DCB transplantation, one CB 
unit fully engrafts and became dominant “single-unit dominance” (Rocha et al., 
2009). Regardless of the discovery of graft versus graft phenomena and the due 
elucidation involved in single-unit dominance, these results have shown that the 
type of cell subsets within the graft, are nonredundant for engraftment and to 
modulate the effector phase induced by allorecognition. Lastly and most 
important, these cell subsets and components allows the possibility to 
circumvent beyond HLA disparities in transplantation and grounds the 
convenience of a third or even multiple party approach in adoptive cellular 
therapy. In accordance, the modality of pooling CB Tregs tested in this study, 
showed that the HLA discrepancy within the CB units pooled can be intentionally 
used to induce allorecognition towards tolerance. Accordingly, it has been 
shown that matching donor and recipient on MHC II favors tolerance through the 
induction of Tregs (LeGuern et al., 2010). Furthermore, it has also been shown 
that induction of Tregs towards non-inherited HLA maternal antigens (NIMAs) 
takes place in early life in utero (Mold et al., 2008). These Tregs are maintained 
throughout life and preserved their potent suppression ability against maternal 
antigens. In agreement, it was demonstrated in CB transplantation an increased 
survival rate when donors are match to their NIMAs (van Rood et al., 2009). 
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Therefore, MHC II and NIMAs can initially be taken as selection criteria for 
optimizing CB Tregs suppression effect in vivo. 
 
The study reported by Trzonkowski et al., has shown the safety of adoptively 
transfer of donor polyclonal expanded CD4posCD25posCD127neg T cells as an 
adjuvant therapy to treat a patient suffering of chronic GVHD (Trzonkowski et 
al., 2009). Conversely they did not see the same effects in a patient undergoing 
acute GVHD (grade IV). In spite of using a currently non-GMP approved 
method, they showed an important decrease of FoxP3 expression from the 
expanded culture cells (from 90% to 40% FoxP3pos). Lastly, they showed that 
multiple infusions might be required for the proper treatment of acute and 
chronic GVHD. 
 
From an ongoing trial in nonmyeloablated or myeloablated recipients of two 
unrelated CB units transplantation, an infusion is given of !4x109 CB Tregs from 
an additional partially matched CB unit (Riley et al., 2009). Results are still 
pending, but from a recent presentation (Regulatory T cell meeting in Beijing, 
China 2008) from that group, no severe GvHD was reported with apparently no 
complications directly associated with the Treg infusion or the HLA mismatches 
from the three unrelated partially matched CB units used. 
 
In summary, findings from this study suggests that CB units fulfills the optimal 
properties for the isolation of bona fide Tregs, which can be isolated with the 
highest purity using a single step isolation method under GMP standards. 
Moreover, CB Tregs can be intentionally pooled and tailored under the required 
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matches for HLA and NIMAs for the clinical setting in hand. This strategy not 
only attains optimal cell numbers without the requirement of long term cultures, 
in addition, it allows to preserve their proliferative cellular properties and 
foremost, achieves a Treg pool with a wide TCR repertoire optimal for 
transplantation settings. Moreover, they can be either used as a first line therapy 
or as an adjuvant with host or donor Ag specific Tregs. 
 
 
 151 
REFERENCES 
Adeegbe, D., Matsutani, T., Yang, J., Altman, N.H., and Malek, T.R. (2010). 
CD4(+) CD25(+) Foxp3(+) T regulatory cells with limited TCR diversity in 
control of autoimmunity. J Immunol 184, 56-66. 
Afzali, B., Lechler, R.I., and Hernandez-Fuentes, M.P. (2007). Allorecognition 
and the alloresponse: clinical implications. Tissue Antigens 69, 545-556. 
Afzali, B., Lombardi, G., and Lechler, R.I. (2008). Pathways of major 
histocompatibility complex allorecognition. Curr Opin Organ Transplant 13, 
438-444. 
Afzali, B., Mitchell, P., Lechler, R.I., John, S., and Lombardi, G. (2010). 
Translational mini-review series on Th17 cells: induction of interleukin-17 
production by regulatory T cells. Clin Exp Immunol 159, 120-130. 
Akbar, A.N., and Vukmanovic-Stejic, M. (2007a). Telomerase in T 
lymphocytes: use it and lose it? J Immunol 178, 6689-6694. 
Akbar, A.N., Vukmanovic-Stejic, M., Taams, L.S., and Macallan, D.C. (2007b). 
The dynamic co-evolution of memory and regulatory CD4+ T cells in the 
periphery. Nat Rev Immunol 7, 231-237. 
Akira, S., Uematsu, S., and Takeuchi, O. (2006). Pathogen recognition and 
innate immunity. Cell 124, 783-801. 
Andersson, J., Tran, D.Q., Pesu, M., Davidson, T.S., Ramsey, H., O'Shea, 
J.J., and Shevach, E.M. (2008). CD4+ FoxP3+ regulatory T cells confer 
infectious tolerance in a TGF-beta-dependent manner. J Exp Med 205, 1975-
1981. 
 152 
Archbold, J.K., Macdonald, W.A., Burrows, S.R., Rossjohn, J., and 
McCluskey, J. (2008). T-cell allorecognition: a case of mistaken identity or deja 
vu? Trends Immunol 29, 220-226. 
Asseman, C., Mauze, S., Leach, M.W., Coffman, R.L., and Powrie, F. (1999). 
An essential role for interleukin 10 in the function of regulatory T cells that 
inhibit intestinal inflammation. J Exp Med 190, 995-1004. 
Ayyoub, M., Deknuydt, F., Raimbaud, I., Dousset, C., Leveque, L., Bioley, G., 
and Valmori, D. (2009). Human memory FOXP3+ Tregs secrete IL-17 ex vivo 
and constitutively express the T(H)17 lineage-specific transcription factor 
RORgamma t. Proc Natl Acad Sci U S A 106, 8635-8640. 
Bacchetta, R., Passerini, L., Gambineri, E., Dai, M., Allan, S.E., Perroni, L., 
Dagna-Bricarelli, F., Sartirana, C., Matthes-Martin, S., Lawitschka, A., et al. 
(2006). Defective regulatory and effector T cell functions in patients with 
FOXP3 mutations. J Clin Invest 116, 1713-1722. 
Baecher-Allan, C. (2006). Human CD25high Tregs: isolation by beads versus 
by FACS sorting. In Clin Immunol, pp. 234-235. 
Baecher-Allan, C., Brown, J.A., Freeman, G.J., and Hafler, D.A. (2001). 
CD4+CD25high regulatory cells in human peripheral blood. J Immunol 167, 
1245-1253. 
Baecher-Allan, C., Wolf, E., and Hafler, D.A. (2006). MHC class II expression 
identifies functionally distinct human regulatory T cells. J Immunol 176, 4622-
4631. 
Baron, U., Floess, S., Wieczorek, G., Baumann, K., Grutzkau, A., Dong, J., 
Thiel, A., Boeld, T.J., Hoffmann, P., Edinger, M., et al. (2007). DNA 
demethylation in the human FOXP3 locus discriminates regulatory T cells from 
activated FOXP3(+) conventional T cells. Eur J Immunol 37, 2378-2389. 
 153 
Battaglia, M., Stabilini, A., Migliavacca, B., Horejs-Hoeck, J., Kaupper, T., and 
Roncarolo, M.G. (2006). Rapamycin promotes expansion of functional 
CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 
diabetic patients. J Immunol 177, 8338-8347. 
Belkaid, Y. (2008). Role of Foxp3-positive regulatory T cells during infection. 
Eur J Immunol 38, 918-921. 
Ben-Sasson, S.Z., Hu-Li, J., Quiel, J., Cauchetaux, S., Ratner, M., Shapira, I., 
Dinarello, C.A., and Paul, W.E. (2009). IL-1 acts directly on CD4 T cells to 
enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci 
U S A 106, 7119-7124. 
Benichou, G., Fedoseyeva, E., Lehmann, P.V., Olson, C.A., Geysen, H.M., 
McMillan, M., and Sercarz, E.E. (1994). Limited T cell response to donor MHC 
peptides during allograft rejection. Implications for selective immune therapy in 
transplantation. J Immunol 153, 938-945. 
Bennett, C.L., Christie, J., Ramsdell, F., Brunkow, M.E., Ferguson, P.J., 
Whitesell, L., Kelly, T.E., Saulsbury, F.T., Chance, P.F., and Ochs, H.D. (2001). 
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27, 20-21. 
Beriou, G., Costantino, C.M., Ashley, C.W., Yang, L., Kuchroo, V.K., Baecher-
Allan, C., and Hafler, D.A. (2009). IL-17-producing human peripheral regulatory 
T cells retain suppressive function. Blood 113, 4240-4249. 
Billingham, R.E., Brent, L., and Medawar, P.B. (1953). Actively acquired 
tolerance of foreign cells. Nature 172, 603-606. 
Bingaman, A.W., and Farber, D.L. (2004). Memory T cells in transplantation: 
generation, function, and potential role in rejection. Am J Transplant 4, 846-
852. 
 154 
Boelens, J.J., Prasad, V.K., Tolar, J., Wynn, R.F., and Peters, C. (2010). 
Current international perspectives on hematopoietic stem cell transplantation 
for inherited metabolic disorders. Pediatr Clin North Am 57, 123-145. 
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., 
Giometto, R., Hopner, S., Centonze, D., Bernardi, G., Dell'Acqua, M.L., et al. 
(2007). Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis 
of extracellular ATP and immune suppression. Blood 110, 1225-1232. 
Bresatz, S., Sadlon, T., Millard, D., Zola, H., and Barry, S.C. (2007). Isolation, 
propagation and characterization of cord blood derived CD4+ CD25+ 
regulatory T cells. J Immunol Methods 327, 53-62. 
Brusko, T., and Bluestone, J. (2008a). Clinical application of regulatory T cells 
for treatment of type 1 diabetes and transplantation. Eur J Immunol 38, 931-
934. 
Brusko, T.M., Putnam, A.L., and Bluestone, J.A. (2008b). Human regulatory T 
cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 
223, 371-390. 
Burchill, M.A., Yang, J., Vogtenhuber, C., Blazar, B.R., and Farrar, M.A. 
(2007). IL-2 receptor beta-dependent STAT5 activation is required for the 
development of Foxp3+ regulatory T cells. J Immunol 178, 280-290. 
Bushell, A., Jones, E., Gallimore, A., and Wood, K. (2005). The generation of 
CD25+ CD4+ regulatory T cells that prevent allograft rejection does not 
compromise immunity to a viral pathogen. J Immunol 174, 3290-3297. 
Caballero, A., Fernandez, N., Lavado, R., Bravo, M.J., Miranda, J.M., and 
Alonso, A. (2006). Tolerogenic response: allorecognition pathways. Transpl 
Immunol 17, 3-6. 
 155 
Call, M.E., and Wucherpfennig, K.W. (2005). The T cell receptor: critical role 
of the membrane environment in receptor assembly and function. Annu Rev 
Immunol 23, 101-125. 
Carrier, Y., Yuan, J., Kuchroo, V.K., and Weiner, H.L. (2007). Th3 cells in 
peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 
cells derived from TGF-beta T cell-transgenic mice. J Immunol 178, 179-185. 
Cavassani, K.A., Campanelli, A.P., Moreira, A.P., Vancim, J.O., Vitali, L.H., 
Mamede, R.C., Martinez, R., and Silva, J.S. (2006). Systemic and local 
characterization of regulatory T cells in a chronic fungal infection in humans. J 
Immunol 177, 5811-5818. 
Chang, C.C., Satwani, P., Oberfield, N., Vlad, G., Simpson, L.L., and Cairo, 
M.S. (2005). Increased induction of allogeneic-specific cord blood CD4+CD25+ 
regulatory T (Treg) cells: a comparative study of naive and antigenic-specific 
cord blood Treg cells. Exp Hematol 33, 1508-1520. 
Chatila, T.A., Blaeser, F., Ho, N., Lederman, H.M., Voulgaropoulos, C., 
Helms, C., and Bowcock, A.M. (2000). JM2, encoding a fork head-related 
protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J 
Clin Invest 106, R75-81. 
Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., McGrady, G., 
and Wahl, S.M. (2003). Conversion of peripheral CD4+CD25- naive T cells to 
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor 
Foxp3. J Exp Med 198, 1875-1886. 
Chen, W., Perruche, S., and Li, J. (2007). CD4+CD25+ T regulatory cells and 
TGF-beta in mucosal immune system: the good and the bad. Curr Med Chem 
14, 2245-2249. 
Cobbold, S.P., Castejon, R., Adams, E., Zelenika, D., Graca, L., Humm, S., 
and Waldmann, H. (2004). Induction of foxP3+ regulatory T cells in the 
 156 
periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 
172, 6003-6010. 
Cobbold, S.P., Graca, L., Lin, C.Y., Adams, E., and Waldmann, H. (2003). 
Regulatory T cells in the induction and maintenance of peripheral 
transplantation tolerance. Transpl Int 16, 66-75. 
Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., 
Cross, R., Sehy, D., Blumberg, R.S., and Vignali, D.A. (2007). The inhibitory 
cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566-569. 
Coombes, J.L., Siddiqui, K.R., Arancibia-Carcamo, C.V., Hall, J., Sun, C.M., 
Belkaid, Y., and Powrie, F. (2007). A functionally specialized population of 
mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and 
retinoic acid-dependent mechanism. J Exp Med 204, 1757-1764. 
Curiel, T.J. (2008). Regulatory T cells and treatment of cancer. Curr Opin 
Immunol 20, 241-246. 
Curotto de Lafaille, M.A., Lino, A.C., Kutchukhidze, N., and Lafaille, J.J. 
(2004). CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral 
expansion. J Immunol 173, 7259-7268. 
Curtsinger, J.M., and Mescher, M.F. (2010). Inflammatory cytokines as a third 
signal for T cell activation. Curr Opin Immunol. 
Deaglio, S., Dwyer, K.M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, 
J.F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007). Adenosine generation 
catalyzed by CD39 and CD73 expressed on regulatory T cells mediates 
immune suppression. J Exp Med 204, 1257-1265. 
Dejean, A.S., Beisner, D.R., Ch'en, I.L., Kerdiles, Y.M., Babour, A., Arden, 
K.C., Castrillon, D.H., DePinho, R.A., and Hedrick, S.M. (2009). Transcription 
 157 
factor Foxo3 controls the magnitude of T cell immune responses by modulating 
the function of dendritic cells. Nat Immunol 10, 504-513. 
Deknuydt, F., Bioley, G., Valmori, D., and Ayyoub, M. (2009). IL-1beta and IL-
2 convert human Treg into T(H)17 cells. Clin Immunol 131, 298-307. 
Dorsch, S., and Roser, B. (1975). T cells mediate transplantation tolerance. 
Nature 258, 233-235. 
Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C.G., Strober, S., 
and Negrin, R.S. (2003). CD4+CD25+ regulatory T cells preserve graft-versus-
tumor activity while inhibiting graft-versus-host disease after bone marrow 
transplantation. Nat Med 9, 1144-1150. 
Eljaafari, A., Badet, L., Kanitakis, J., Ferrand, C., Farre, A., Petruzzo, P., 
Morelon, E., Dubosson, M., Tiberghien, P., Dubois, V., et al. (2006). Isolation of 
regulatory T cells in the skin of a human hand-allograft, up to six years 
posttransplantation. Transplantation 82, 1764-1768. 
Engelhard, V.H. (1994). Structure of peptides associated with class I and 
class II MHC molecules. Annu Rev Immunol 12, 181-207. 
Fadi I., Joanna H., Kathryn W (2010). Ex vivo-expanded human regulatory T 
cells prevent the rejection of skin allografts in a humanised mouse model. 
Transplantation, December Issue.  
 
Fairchild, R.L. (2006). Developing models to study the memory T cell barrier 
in transplantation. Am J Transplant 6, 1246-1247. 
Faria, A.M., and Weiner, H.L. (2005). Oral tolerance. Immunol Rev 206, 232-
259. 
Fathman, C.G., and Lineberry, N.B. (2007). Molecular mechanisms of CD4+ 
T-cell anergy. Nat Rev Immunol 7, 599-609. 
 158 
Fazilleau, N., Bachelez, H., Gougeon, M.L., and Viguier, M. (2007). Cutting 
edge: size and diversity of CD4+CD25high Foxp3+ regulatory T cell repertoire 
in humans: evidence for similarities and partial overlapping with CD4+CD25- T 
cells. J Immunol 179, 3412-3416. 
Fehr, T., and Sykes, M. (2004). Tolerance induction in clinical transplantation. 
Transpl Immunol 13, 117-130. 
Fernandes, J., Rocha, V., Robin, M., de Latour, R.P., Traineau, R., Devergie, 
A., Ribaud, P., Rea, D., Larghero, J., Gluckman, E., et al. (2007). Second 
transplant with two unrelated cord blood units for early graft failure after 
haematopoietic stem cell transplantation. Br J Haematol 137, 248-251. 
Ferrara, J.L., Levine, J.E., Reddy, P., and Holler, E. (2009). Graft-versus-host 
disease. Lancet 373, 1550-1561. 
Fife, B.T., and Bluestone, J.A. (2008). Control of peripheral T-cell tolerance 
and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224, 166-
182. 
Fletcher, J.M., Lonergan, R., Costelloe, L., Kinsella, K., Moran, B., O'Farrelly, 
C., Tubridy, N., and Mills, K.H. (2009). CD39+Foxp3+ regulatory T Cells 
suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J 
Immunol 183, 7602-7610. 
Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. (2003). Foxp3 programs the 
development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4, 
330-336. 
Fontenot, J.D., Rasmussen, J.P., Gavin, M.A., and Rudensky, A.Y. (2005a). A 
function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6, 
1142-1151. 
 159 
Fontenot, J.D., Rasmussen, J.P., Williams, L.M., Dooley, J.L., Farr, A.G., and 
Rudensky, A.Y. (2005b). Regulatory T cell lineage specification by the forkhead 
transcription factor foxp3. Immunity 22, 329-341. 
Fontenot, J.D., and Rudensky, A.Y. (2005c). A well adapted regulatory 
contrivance: regulatory T cell development and the forkhead family 
transcription factor Foxp3. Nat Immunol 6, 331-337. 
Ford, M.L., Kirk, A.D., and Larsen, C.P. (2009). Donor-reactive T-cell 
stimulation history and precursor frequency: barriers to tolerance induction. 
Transplantation 87, S69-74. 
Forster, R., Davalos-Misslitz, A.C., and Rot, A. (2008). CCR7 and its ligands: 
balancing immunity and tolerance. Nat Rev Immunol 8, 362-371. 
Foussat, A., Cottrez, F., Brun, V., Fournier, N., Breittmayer, J.P., and Groux, 
H. (2003). A comparative study between T regulatory type 1 and CD4+CD25+ 
T cells in the control of inflammation. J Immunol 171, 5018-5026. 
Friedline, R.H., Brown, D.S., Nguyen, H., Kornfeld, H., Lee, J., Zhang, Y., 
Appleby, M., Der, S.D., Kang, J., and Chambers, C.A. (2009). CD4+ regulatory 
T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 
206, 421-434. 
Fritzsching, B., Oberle, N., Pauly, E., Geffers, R., Buer, J., Poschl, J., 
Krammer, P., Linderkamp, O., and Suri-Payer, E. (2006). Naive regulatory T 
cells: a novel subpopulation defined by resistance toward CD95L-mediated cell 
death. Blood 108, 3371-3378. 
Godfrey, W.R., Spoden, D.J., Ge, Y.G., Baker, S.R., Liu, B., Levine, B.L., 
June, C.H., Blazar, B.R., and Porter, S.B. (2005). Cord blood CD4(+)CD25(+)-
derived T regulatory cell lines express FoxP3 protein and manifest potent 
suppressor function. Blood 105, 750-758. 
 160 
Goldrath, A.W., and Bevan, M.J. (1999). Selecting and maintaining a diverse 
T-cell repertoire. Nature 402, 255-262. 
Gondek, D.C., Lu, L.F., Quezada, S.A., Sakaguchi, S., and Noelle, R.J. 
(2005). Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory 
cells involves a granzyme B-dependent, perforin-independent mechanism. J 
Immunol 174, 1783-1786. 
Gorer, P.A. (1948). The significance of studies with transplanted tumours. Br J 
Cancer 2, 103-107. 
Grailer, J.J., Kodera, M., and Steeber, D.A. (2009). L-selectin: role in 
regulating homeostasis and cutaneous inflammation. J Dermatol Sci 56, 141-
147. 
Green, E.A., Gorelik, L., McGregor, C.M., Tran, E.H., and Flavell, R.A. (2003). 
CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-
beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S 
A 100, 10878-10883. 
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, 
A., Candeloro, P., Belladonna, M.L., Bianchi, R., Fioretti, M.C., et al. (2002). 
CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3, 1097-1101. 
Grossman, W.J., Verbsky, J.W., Tollefsen, B.L., Kemper, C., Atkinson, J.P., 
and Ley, T.J. (2004). Differential expression of granzymes A and B in human 
cytotoxic lymphocyte subsets and T regulatory cells. Blood 104, 2840-2848. 
Groux, H. (2003). Type 1 T-regulatory cells: their role in the control of immune 
responses. Transplantation 75, 8S-12S. 
Gutman, J.A., Turtle, C.J., Manley, T.J., Heimfeld, S., Bernstein, I.D., Riddell, 
S.R., and Delaney, C. (2010). Single-unit dominance after double-unit umbilical 
 161 
cord blood transplantation coincides with a specific CD8+ T-cell response 
against the nonengrafted unit. Blood 115, 757-765. 
Haas, J., Fritzsching, B., Trubswetter, P., Korporal, M., Milkova, L., Fritz, B., 
Vobis, D., Krammer, P.H., Suri-Payer, E., and Wildemann, B. (2007). 
Prevalence of newly generated naive regulatory T cells (Treg) is critical for 
Treg suppressive function and determines Treg dysfunction in multiple 
sclerosis. J Immunol 179, 1322-1330. 
Hardy, R.R., Li, Y.S., Allman, D., Asano, M., Gui, M., and Hayakawa, K. 
(2000). B-cell commitment, development and selection. Immunol Rev 175, 23-
32. 
Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., 
Murphy, K.M., and Weaver, C.T. (2005). Interleukin 17-producing CD4+ 
effector T cells develop via a lineage distinct from the T helper type 1 and 2 
lineages. Nat Immunol 6, 1123-1132. 
Hasenkrug, K.J. (2003). CD4+ regulatory T cells in chronic viral infection. 
Novartis Found Symp 252, 194-199; discussion 199-210. 
Hataye, J., Moon, J.J., Khoruts, A., Reilly, C., and Jenkins, M.K. (2006). Naive 
and memory CD4+ T cell survival controlled by clonal abundance. Science 312, 
114-116. 
Hawkins, E.D., Hommel, M., Turner, M.L., Battye, F.L., Markham, J.F., and 
Hodgkin, P.D. (2007). Measuring lymphocyte proliferation, survival and 
differentiation using CFSE time-series data. Nat Protoc 2, 2057-2067. 
Helft, J., Jacquet, A., Joncker, N.T., Grandjean, I., Dorothee, G., 
Kissenpfennig, A., Malissen, B., Matzinger, P., and Lantz, O. (2008). Antigen-
specific T-T interactions regulate CD4 T-cell expansion. Blood 112, 1249-1258. 
 162 
Herrera, O.B., Golshayan, D., Tibbott, R., Salcido Ochoa, F., James, M.J., 
Marelli-Berg, F.M., and Lechler, R.I. (2004). A novel pathway of alloantigen 
presentation by dendritic cells. J Immunol 173, 4828-4837. 
Hippen, K.L., Harker-Murray, P., Porter, S.B., Merkel, S.C., Londer, A., Taylor, 
D.K., Bina, M., Panoskaltsis-Mortari, A., Rubinstein, P., Van Rooijen, N., et al. 
(2008). Umbilical cord blood regulatory T-cell expansion and functional effects 
of tumor necrosis factor receptor family members OX40 and 4-1BB expressed 
on artificial antigen-presenting cells. Blood 112, 2847-2857. 
Hoffmann, P., Boeld, T.J., Eder, R., Albrecht, J., Doser, K., Piseshka, B., 
Dada, A., Niemand, C., Assenmacher, M., Orso, E., et al. (2006a). Isolation of 
CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant 
12, 267-274. 
Hoffmann, P., Boeld, T.J., Eder, R., Huehn, J., Floess, S., Wieczorek, G., 
Olek, S., Dietmaier, W., Andreesen, R., and Edinger, M. (2009). Loss of 
FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon 
repetitive in vitro stimulation. Eur J Immunol 39, 1088-1097. 
Hoffmann, P., Eder, R., Boeld, T.J., Doser, K., Piseshka, B., Andreesen, R., 
and Edinger, M. (2006b). Only the CD45RA+ subpopulation of CD4+CD25high 
T cells gives rise to homogeneous regulatory T-cell lines upon in vitro 
expansion. Blood 108, 4260-4267. 
Hoffmann, P., Eder, R., Kunz-Schughart, L.A., Andreesen, R., and Edinger, 
M. (2004). Large-scale in vitro expansion of polyclonal human 
CD4(+)CD25high regulatory T cells. Blood 104, 895-903. 
Hoffmann, P., and Edinger, M. (2006c). CD4+CD25+ regulatory T cells and 
graft-versus-host disease. Semin Hematol 43, 62-69. 
 163 
Horwitz, D.A., Zheng, S.G., and Gray, J.D. (2003). The role of the 
combination of IL-2 and TGF-beta or IL-10 in the generation and function of 
CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol 74, 471-478. 
Horwitz, D.A., Zheng, S.G., and Gray, J.D. (2008). Natural and TGF-beta-
induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of 
each other. Trends Immunol 29, 429-435. 
Hough, R., and Rocha, V. (2010). Transplant outcomes in acute leukemia. II. 
Semin Hematol 47, 51-58. 
Housset, D., and Malissen, B. (2003). What do TCR-pMHC crystal structures 
teach us about MHC restriction and alloreactivity? Trends Immunol 24, 429-
437. 
Hsieh, C.S., Zheng, Y., Liang, Y., Fontenot, J.D., and Rudensky, A.Y. (2006). 
An intersection between the self-reactive regulatory and nonregulatory T cell 
receptor repertoires. Nat Immunol 7, 401-410. 
Huang, C.T., Workman, C.J., Flies, D., Pan, X., Marson, A.L., Zhou, G., 
Hipkiss, E.L., Ravi, S., Kowalski, J., Levitsky, H.I., et al. (2004). Role of LAG-3 
in regulatory T cells. Immunity 21, 503-513. 
Huber, S., and Schramm, C. (2006). TGF-beta and CD4+CD25+ regulatory T 
cells. Front Biosci 11, 1014-1023. 
Inaba, K., Witmer, M.D., and Steinman, R.M. (1984). Clustering of dendritic 
cells, helper T lymphocytes, and histocompatible B cells during primary 
antibody responses in vitro. J Exp Med 160, 858-876. 
Ito, T., Hanabuchi, S., Wang, Y.H., Park, W.R., Arima, K., Bover, L., Qin, F.X., 
Gilliet, M., and Liu, Y.J. (2008). Two functional subsets of FOXP3+ regulatory T 
cells in human thymus and periphery. Immunity 28, 870-880. 
 164 
Ivanov, II, McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, 
J.J., Cua, D.J., and Littman, D.R. (2006). The orphan nuclear receptor 
RORgammat directs the differentiation program of proinflammatory IL-17+ T 
helper cells. Cell 126, 1121-1133. 
Janeway, C.A., Jr., and Medzhitov, R. (2002). Innate immune recognition. 
Annu Rev Immunol 20, 197-216. 
Jenq, R.R., and van den Brink, M.R. (2010). Allogeneic haematopoietic stem 
cell transplantation: individualized stem cell and immune therapy of cancer. Nat 
Rev Cancer 10, 213-221. 
Jiang, S., Tsang, J., and Lechler, R.I. (2006). Adoptive cell therapy using in 
vitro generated human CD4+ CD25+ regulatory t cells with indirect 
allospecificity to promote donor-specific transplantation tolerance. Transplant 
Proc 38, 3199-3201. 
Joffre, O., Santolaria, T., Calise, D., Al Saati, T., Hudrisier, D., Romagnoli, P., 
and van Meerwijk, J.P. (2008). Prevention of acute and chronic allograft 
rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 14, 88-
92. 
Jung, D., Giallourakis, C., Mostoslavsky, R., and Alt, F.W. (2006). Mechanism 
and control of V(D)J recombination at the immunoglobulin heavy chain locus. 
Annu Rev Immunol 24, 541-570. 
Junge, S., Kloeckener-Gruissem, B., Zufferey, R., Keisker, A., Salgo, B., 
Fauchere, J.C., Scherer, F., Shalaby, T., Grotzer, M., Siler, U., et al. (2007). 
Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T 
cells in normal individuals during aging and in lymphopenic children. Eur J 
Immunol 37, 3270-3280. 
 165 
Kang, H.J., Lee, J.W., Kim, H., Shin, H.Y., and Ahn, H.S. (2009). Successful 
first-line treatment with double umbilical cord blood transplantation in severe 
aplastic anemia. Bone Marrow Transplant. 
Kilpatrick, R.D., Rickabaugh, T., Hultin, L.E., Hultin, P., Hausner, M.A., Detels, 
R., Phair, J., and Jamieson, B.D. (2008). Homeostasis of the naive CD4+ T cell 
compartment during aging. J Immunol 180, 1499-1507. 
Klein, J., and Sato, A. (2000). The HLA system. First of two parts. N Engl J 
Med 343, 702-709. 
Klein, L., Khazaie, K., and von Boehmer, H. (2003). In vivo dynamics of 
antigen-specific regulatory T cells not predicted from behavior in vitro. Proc 
Natl Acad Sci U S A 100, 8886-8891. 
Kleinewietfeld, M., Starke, M., Di Mitri, D., Borsellino, G., Battistini, L., 
Rotzschke, O., and Falk, K. (2009). CD49d provides access to "untouched" 
human Foxp3+ Treg free of contaminating effector cells. Blood 113, 827-836. 
Koch, M.A., Tucker-Heard, G., Perdue, N.R., Killebrew, J.R., Urdahl, K.B., 
and Campbell, D.J. (2009). The transcription factor T-bet controls regulatory T 
cell homeostasis and function during type 1 inflammation. Nat Immunol 10, 
595-602. 
Kohler, S., and Thiel, A. (2008). Life after the thymus - CD31+ and CD31- 
human naive CD4+ T-cell subsets. Blood. 
Kwun, J., and Knechtle, S.J. (2009). Overcoming Chronic Rejection-Can it B? 
Transplantation 88, 955-961. 
LaSalle, J.M., Tolentino, P.J., Freeman, G.J., Nadler, L.M., and Hafler, D.A. 
(1992). Early signaling defects in human T cells anergized by T cell 
presentation of autoantigen. J Exp Med 176, 177-186. 
 166 
Lechler, R.I., Sykes, M., Thomson, A.W., and Turka, L.A. (2005). Organ 
transplantation--how much of the promise has been realized? Nat Med 11, 605-
613. 
Lee, Y.J., Jung, K.C., and Park, S.H. (2009). MHC class II-dependent T-T 
interactions create a diverse, functional and immunoregulatory reaction circle. 
Immunol Cell Biol 87, 65-71. 
LeGuern, C., Akiyama, Y., Germana, S., Tanaka, K., Fernandez, L., Iwamoto, 
Y., Houser, S., and Benichou, G. (2010). Intracellular MHC class II controls 
regulatory tolerance to allogeneic transplants. J Immunol 184, 2394-2400. 
Li, X., Ye, F., Chen, H., Lu, W., Wan, X., and Xie, X. (2007). Human ovarian 
carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral 
CD4(+)CD25(-) T cells through secreting TGF-beta. Cancer Lett 253, 144-153. 
Liang, B., Workman, C., Lee, J., Chew, C., Dale, B.M., Colonna, L., Flores, 
M., Li, N., Schweighoffer, E., Greenberg, S., et al. (2008). Regulatory T cells 
inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC 
class II. J Immunol 180, 5916-5926. 
Liu, W., Putnam, A.L., Xu-Yu, Z., Szot, G.L., Lee, M.R., Zhu, S., Gottlieb, 
P.A., Kapranov, P., Gingeras, T.R., Fazekas de St Groth, B., et al. (2006). 
CD127 expression inversely correlates with FoxP3 and suppressive function of 
human CD4+ T reg cells. J Exp Med 203, 1701-1711. 
Long, E., and Wood, K.J. (2009). Regulatory T cells in transplantation: 
transferring mouse studies to the clinic. Transplantation 88, 1050-1056. 
Macdonald, W.A., Chen, Z., Gras, S., Archbold, J.K., Tynan, F.E., Clements, 
C.S., Bharadwaj, M., Kjer-Nielsen, L., Saunders, P.M., Wilce, M.C., et al. 
(2009). T cell allorecognition via molecular mimicry. Immunity 31, 897-908. 
 167 
Matthews, K., Lim, Z., Afzali, B., Pearce, L., Abdallah, A., Kordasti, S., 
Pagliuca, A., Lombardi, G., Madrigal, J.A., Mufti, G.J., et al. (2009). Imbalance 
of effector and regulatory CD4 T cells is associated with graft-versus-host 
disease after hematopoietic stem cell transplantation using a reduced intensity 
conditioning regimen and alemtuzumab. Haematologica 94, 956-966. 
Matzinger, P., and Bevan, M.J. (1977). Hypothesis: why do so many 
lymphocytes respond to major histocompatibility antigens? Cell Immunol 29, 1-
5. 
McHugh, R.S., Whitters, M.J., Piccirillo, C.A., Young, D.A., Shevach, E.M., 
Collins, M., and Byrne, M.C. (2002). CD4(+)CD25(+) immunoregulatory T cells: 
gene expression analysis reveals a functional role for the glucocorticoid-
induced TNF receptor. Immunity 16, 311-323. 
Medawar, P.B. (1961). Immunological tolerance. Science 133, 303-306. 
Medzhitov, R., and Janeway, C.A., Jr. (2002). Decoding the patterns of self 
and nonself by the innate immune system. Science 296, 298-300. 
Menetrier-Caux, C., Gobert, M., and Caux, C. (2009). Differences in tumor 
regulatory T-cell localization and activation status impact patient outcome. 
Cancer Res 69, 7895-7898. 
Michel, G., Rocha, V., Chevret, S., Arcese, W., Chan, K.W., Filipovich, A., 
Takahashi, T.A., Vowels, M., Ortega, J., Bordigoni, P., et al. (2003). Unrelated 
cord blood transplantation for childhood acute myeloid leukemia: a Eurocord 
Group analysis. Blood 102, 4290-4297. 
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., 
Taflin, C., Heike, T., Valeyre, D., et al. (2009). Functional delineation and 
differentiation dynamics of human CD4+ T cells expressing the FoxP3 
transcription factor. Immunity 30, 899-911. 
 168 
Mold, J.E., Michaelsson, J., Burt, T.D., Muench, M.O., Beckerman, K.P., 
Busch, M.P., Lee, T.H., Nixon, D.F., and McCune, J.M. (2008). Maternal 
alloantigens promote the development of tolerogenic fetal regulatory T cells in 
utero. Science 322, 1562-1565. 
Morgan, M.E., van Bilsen, J.H., Bakker, A.M., Heemskerk, B., Schilham, 
M.W., Hartgers, F.C., Elferink, B.G., van der Zanden, L., de Vries, R.R., 
Huizinga, T.W., et al. (2005). Expression of FOXP3 mRNA is not confined to 
CD4+CD25+ T regulatory cells in humans. Hum Immunol 66, 13-20. 
Mosmann, T.R., and Coffman, R.L. (1989). TH1 and TH2 cells: different 
patterns of lymphokine secretion lead to different functional properties. Annu 
Rev Immunol 7, 145-173. 
Muller, M., Carter, S.L., Hofer, M.J., Manders, P., Getts, D.R., Getts, M.T., 
Dreykluft, A., Lu, B., Gerard, C., King, N.J., et al. (2007). CXCR3 signaling 
reduces the severity of experimental autoimmune encephalomyelitis by 
controlling the parenchymal distribution of effector and regulatory T cells in the 
central nervous system. J Immunol 179, 2774-2786. 
Nadig, S., Wieckiewicz, J., and Wood, K.J. (2010). In vivo prevention of 
transplantation arteriosclerosis by ex vivo-expanded human regulatory T cells. 
Nat Med 16, 809-813. 
Nadkarni, S., Mauri, C., and Ehrenstein, M.R. (2007). Anti-TNF-alpha therapy 
induces a distinct regulatory T cell population in patients with rheumatoid 
arthritis via TGF-beta. J Exp Med 204, 33-39. 
Nakamura, K., Kitani, A., Fuss, I., Pedersen, A., Harada, N., Nawata, H., and 
Strober, W. (2004). TGF-beta 1 plays an important role in the mechanism of 
CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 
172, 834-842. 
 169 
Nakamura, K., Kitani, A., and Strober, W. (2001). Cell contact-dependent 
immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell 
surface-bound transforming growth factor beta. J Exp Med 194, 629-644. 
Nishizuka, Y., and Sakakura, T. (1969). Thymus and reproduction: sex-linked 
dysgenesia of the gonad after neonatal thymectomy in mice. Science 166, 753-
755. 
Nocentini, G., and Riccardi, C. (2005). GITR: a multifaceted regulator of 
immunity belonging to the tumor necrosis factor receptor superfamily. Eur J 
Immunol 35, 1016-1022. 
Nomura, M., Plain, K.M., Verma, N., Robinson, C., Boyd, R., Hodgkinson, 
S.J., and Hall, B.M. (2006). The cellular basis of cardiac allograft rejection. IX. 
Ratio of naive CD4+CD25+ T cells/CD4+CD25- T cells determines rejection or 
tolerance. Transpl Immunol 15, 311-318. 
Nowak, J. (2008). Role of HLA in hematopoietic SCT. Bone Marrow 
Transplant 42 Suppl 2, S71-76. 
O'Shea, J.J., and Paul, W.E. (2010). Mechanisms underlying lineage 
commitment and plasticity of helper CD4+ T cells. Science 327, 1098-1102. 
Onishi, Y., Fehervari, Z., Yamaguchi, T., and Sakaguchi, S. (2008). Foxp3+ 
natural regulatory T cells preferentially form aggregates on dendritic cells in 
vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 105, 10113-
10118. 
Pacholczyk, R., Ignatowicz, H., Kraj, P., and Ignatowicz, L. (2006). Origin and 
T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity 25, 249-259. 
Pandiyan, P., Zheng, L., Ishihara, S., Reed, J., and Lenardo, M.J. (2007). 
CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated 
apoptosis of effector CD4+ T cells. Nat Immunol 8, 1353-1362. 
 170 
Perrone, G., Ruffini, P.A., Catalano, V., Spino, C., Santini, D., Muretto, P., 
Spoto, C., Zingaretti, C., Sisti, V., Alessandroni, P., et al. (2008). Intratumoural 
FOXP3-positive regulatory T cells are associated with adverse prognosis in 
radically resected gastric cancer. Eur J Cancer 44, 1875-1882. 
Peters, J.H., Preijers, F.W., Woestenenk, R., Hilbrands, L.B., Koenen, H.J., 
and Joosten, I. (2008). Clinical grade Treg: GMP isolation, improvement of 
purity by CD127 Depletion, Treg expansion, and Treg cryopreservation. PLoS 
ONE 3, e3161. 
Piersma, S.J., Welters, M.J., and van der Burg, S.H. (2008). Tumor-specific 
regulatory T cells in cancer patients. Hum Immunol 69, 241-249. 
Polansky, J.K., Kretschmer, K., Freyer, J., Floess, S., Garbe, A., Baron, U., 
Olek, S., Hamann, A., von Boehmer, H., and Huehn, J. (2008). DNA 
methylation controls Foxp3 gene expression. Eur J Immunol 38, 1654-1663. 
Porter, S.B., Liu, B., Rogosheske, J., Levine, B.L., June, C.H., Kohl, V.K., 
Wagner, J.E., Miller, J.S., and Blazar, B.R. (2006). Suppressor function of 
umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-
versus-host disease drugs. Transplantation 82, 23-29. 
Putnam, A.L., Brusko, T.M., Lee, M.R., Liu, W., Szot, G.L., Ghosh, T., 
Atkinson, M.A., and Bluestone, J.A. (2009). Expansion of human regulatory T-
cells from patients with type 1 diabetes. Diabetes 58, 652-662. 
Quah, B.J., Warren, H.S., and Parish, C.R. (2007). Monitoring lymphocyte 
proliferation in vitro and in vivo with the intracellular fluorescent dye 
carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2, 2049-2056. 
Read, S., Malmstrom, V., and Powrie, F. (2000). Cytotoxic T lymphocyte-
associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) 
regulatory cells that control intestinal inflammation. J Exp Med 192, 295-302. 
 171 
Rezvani, K., Mielke, S., Ahmadzadeh, M., Kilical, Y., Savani, B.N., Zeilah, J., 
Keyvanfar, K., Montero, A., Hensel, N., Kurlander, R., et al. (2006). High donor 
FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of 
GVHD following HLA-matched allogeneic SCT. Blood 108, 1291-1297. 
Riley, J.L., June, C.H., and Blazar, B.R. (2009). Human T regulatory cell 
therapy: take a billion or so and call me in the morning. Immunity 30, 656-665. 
Rocha, V., and Gluckman, E. (2009). Improving outcomes of cord blood 
transplantation: HLA matching, cell dose and other graft- and transplantation-
related factors. Br J Haematol 147, 262-274. 
Roelen, D.L., Bushell, A.R., Niimi, M., Young, N.T., Rust, N.A., Morris, P.J., 
and Wood, K.J. (1998). Immunoregulation by CD4 T cells in the induction of 
specific immunological unresponsiveness to alloantigens in vivo: evidence for a 
reduction in the frequency of alloantigen-specific cytotoxic T cells in vitro. Hum 
Immunol 59, 529-539. 
Roncarolo, M.G., Bacchetta, R., Bordignon, C., Narula, S., and Levings, M.K. 
(2001). Type 1 T regulatory cells. Immunol Rev 182, 68-79. 
Roncarolo, M.G., and Gregori, S. (2008). Is FOXP3 a bona fide marker for 
human regulatory T cells? Eur J Immunol 38, 925-927. 
Rudd, C.E., Taylor, A., and Schneider, H. (2009). CD28 and CTLA-4 
coreceptor expression and signal transduction. Immunol Rev 229, 12-26. 
Sagoo, P., Lombardi, G., and Lechler, R.I. (2008). Regulatory T cells as 
therapeutic cells. Curr Opin Organ Transplant 13, 645-653. 
Sakaguchi, S. (2000). Regulatory T cells: key controllers of immunologic self-
tolerance. Cell 101, 455-458. 
 172 
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., and Toda, M. (1995). 
Immunologic self-tolerance maintained by activated T cells expressing IL-2 
receptor alpha-chains (CD25). Breakdown of a single mechanism of self-
tolerance causes various autoimmune diseases. J Immunol 155, 1151-1164. 
Sakaguchi, S., Takahashi, T., and Nishizuka, Y. (1982). Study on cellular 
events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of 
Lyt-1 cells in normal female mice for the prevention of oophoritis. J Exp Med 
156, 1577-1586. 
Sakaguchi, S., Yamaguchi, T., Nomura, T., and Ono, M. (2008). Regulatory T 
cells and immune tolerance. Cell 133, 775-787. 
Sallusto, F., and Lanzavecchia, A. (2000). Understanding dendritic cell and T-
lymphocyte traffic through the analysis of chemokine receptor expression. 
Immunol Rev 177, 134-140. 
Santner-Nanan, B., Seddiki, N., Zhu, E., Quent, V., Kelleher, A., de St Groth, 
B.F., and Nanan, R. (2008). Accelerated age-dependent transition of human 
regulatory T cells to effector memory phenotype. Int Immunol 20, 375-383. 
Scholzen, T., and Gerdes, J. (2000). The Ki-67 protein: from the known and 
the unknown. J Cell Physiol 182, 311-322. 
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., 
Landay, A., Solomon, M., Selby, W., Alexander, S.I., Nanan, R., et al. (2006a). 
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between 
human regulatory and activated T cells. J Exp Med 203, 1693-1700. 
Seddiki, N., Santner-Nanan, B., Tangye, S.G., Alexander, S.I., Solomon, M., 
Lee, S., Nanan, R., and Fazekas de Saint Groth, B. (2006b). Persistence of 
naive CD45RA+ regulatory T cells in adult life. Blood 107, 2830-2838. 
Sharpe, A.H. (2009). Mechanisms of costimulation. Immunol Rev 229, 5-11. 
 173 
Shevach, E.M. (2009). Mechanisms of foxp3+ T regulatory cell-mediated 
suppression. Immunity 30, 636-645. 
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., and Sakaguchi, S. 
(2002). Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks 
immunological self-tolerance. Nat Immunol 3, 135-142. 
Sidhu, S., Deacock, S., Bal, V., Batchelor, J.R., Lombardi, G., and Lechler, 
R.I. (1992). Human T cells cannot act as autonomous antigen-presenting cells, 
but induce tolerance in antigen-specific and alloreactive responder cells. J Exp 
Med 176, 875-880. 
Siegel, R.M., Katsumata, M., Komori, S., Wadsworth, S., Gill-Morse, L., 
Jerrold-Jones, S., Bhandoola, A., Greene, M.I., and Yui, K. (1990). 
Mechanisms of autoimmunity in the context of T-cell tolerance: insights from 
natural and transgenic animal model systems. Immunol Rev 118, 165-192. 
Singh, N.J., and Schwartz, R.H. (2006). Primer: mechanisms of immunologic 
tolerance. Nat Clin Pract Rheumatol 2, 44-52. 
Smith, P.A., Brunmark, A., Jackson, M.R., and Potter, T.A. (1997). Peptide-
independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J Exp 
Med 185, 1023-1033. 
Snell, G.D., and Higgins, G.F. (1951). Alleles at the histocompatibility-2 locus 
in the mouse as determined by tumor transplantation. Genetics 36, 306-310. 
Socie, G., and Blazar, B.R. (2009). Acute graft-versus-host disease: from the 
bench to the bedside. Blood 114, 4327-4336. 
Starzl, T.E., and Zinkernagel, R.M. (2001). Transplantation tolerance from a 
historical perspective. Nat Rev Immunol 1, 233-239. 
 174 
Steiner, D., Brunicki, N., Blazar, B.R., Bachar-Lustig, E., and Reisner, Y. 
(2006). Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg 
cells. Exp Hematol 34, 66-71. 
Steinman, R.M. (1991). The dendritic cell system and its role in 
immunogenicity. Annu Rev Immunol 9, 271-296. 
Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J.T., and 
Whiteside, T.L. (2007). A unique subset of CD4+CD25highFoxp3+ T cells 
secreting interleukin-10 and transforming growth factor-beta1 mediates 
suppression in the tumor microenvironment. Clin Cancer Res 13, 4345-4354. 
Suchin, E.J., Langmuir, P.B., Palmer, E., Sayegh, M.H., Wells, A.D., and 
Turka, L.A. (2001). Quantifying the frequency of alloreactive T cells in vivo: new 
answers to an old question. J Immunol 166, 973-981. 
Suciu-Foca, N., Harris, P.E., and Cortesini, R. (1998). Intramolecular and 
intermolecular spreading during the course of organ allograft rejection. 
Immunol Rev 164, 241-246. 
Surh, C.D., and Sprent, J. (2008). Homeostasis of naive and memory T cells. 
Immunity 29, 848-862. 
Szymczak-Workman, A.L., Workman, C.J., and Vignali, D.A. (2009). Cutting 
edge: regulatory T cells do not require stimulation through their TCR to 
suppress. J Immunol 182, 5188-5192. 
Tai, X., Cowan, M., Feigenbaum, L., and Singer, A. (2005). CD28 
costimulation of developing thymocytes induces Foxp3 expression and 
regulatory T cell differentiation independently of interleukin 2. Nat Immunol 6, 
152-162. 
Takada, K., and Jameson, S.C. (2009). Naive T cell homeostasis: from 
awareness of space to a sense of place. Nat Rev Immunol 9, 823-832. 
 175 
Tang, Q., and Krummel, M.F. (2006). Imaging the function of regulatory T 
cells in vivo. Curr Opin Immunol 18, 496-502. 
Taylor, P.A., Panoskaltsis-Mortari, A., Swedin, J.M., Lucas, P.J., Gress, R.E., 
Levine, B.L., June, C.H., Serody, J.S., and Blazar, B.R. (2004). L-Selectin(hi) 
but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of 
GVHD and BM graft rejection. Blood 104, 3804-3812. 
Thornton, A.M., Donovan, E.E., Piccirillo, C.A., and Shevach, E.M. (2004a). 
Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ 
T cell suppressor function. J Immunol 172, 6519-6523. 
Thornton, A.M., Piccirillo, C.A., and Shevach, E.M. (2004b). Activation 
requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J 
Immunol 34, 366-376. 
Thornton, A.M., and Shevach, E.M. (2000). Suppressor effector function of 
CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 164, 
183-190. 
Tone, Y., Furuuchi, K., Kojima, Y., Tykocinski, M.L., Greene, M.I., and Tone, 
M. (2008). Smad3 and NFAT cooperate to induce Foxp3 expression through its 
enhancer. Nat Immunol 9, 194-202. 
Tough, D.F., Sun, S., Zhang, X., and Sprent, J. (1999). Stimulation of naive 
and memory T cells by cytokines. Immunol Rev 170, 39-47. 
Tran, D.Q., Andersson, J., Hardwick, D., Bebris, L., Illei, G.G., and Shevach, 
E.M. (2009a). Selective expression of latency-associated peptide (LAP) and IL-
1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory 
T cells allows for their purification from expansion cultures. Blood 113, 5125-
5133. 
 176 
Tran, D.Q., Andersson, J., Wang, R., Ramsey, H., Unutmaz, D., and 
Shevach, E.M. (2009b). GARP (LRRC32) is essential for the surface 
expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T 
cells. Proc Natl Acad Sci U S A 106, 13445-13450. 
Trenado, A., Charlotte, F., Fisson, S., Yagello, M., Klatzmann, D., Salomon, 
B.L., and Cohen, J.L. (2003). Recipient-type specific CD4+CD25+ regulatory T 
cells favor immune reconstitution and control graft-versus-host disease while 
maintaining graft-versus-leukemia. J Clin Invest 112, 1688-1696. 
Trenado, A., Sudres, M., Tang, Q., Maury, S., Charlotte, F., Gregoire, S., 
Bonyhadi, M., Klatzmann, D., Salomon, B.L., and Cohen, J.L. (2006). Ex vivo-
expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-
disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 
176, 1266-1273. 
Triebel, F. (2003). LAG-3: a regulator of T-cell and DC responses and its use 
in therapeutic vaccination. Trends Immunol 24, 619-622. 
Trzonkowski, P., Bieniaszewska, M., Juscinska, J., Dobyszuk, A., Krzystyniak, 
A., Marek, N., Mysliwska, J., and Hellmann, A. (2009). First-in-man clinical 
results of the treatment of patients with graft versus host disease with human 
ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol 133, 
22-26. 
Tsang, J.Y., Chai, J.G., and Lechler, R. (2003). Antigen presentation by 
mouse CD4+ T cells involving acquired MHC class II:peptide complexes: 
another mechanism to limit clonal expansion? Blood 101, 2704-2710. 
Tsang, J.Y., Tanriver, Y., Jiang, S., Leung, E., Ratnasothy, K., Lombardi, G., 
and Lechler, R. (2009). Indefinite mouse heart allograft survival in recipient 
treated with CD4(+)CD25(+) regulatory T cells with indirect allospecificity and 
short term immunosuppression. Transpl Immunol 21, 203-209. 
 177 
Tsang, J.Y., Tanriver, Y., Jiang, S., Xue, S.A., Ratnasothy, K., Chen, D., 
Stauss, H.J., Bucy, R.P., Lombardi, G., and Lechler, R. (2008). Conferring 
indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors 
transplantation tolerance in mice. J Clin Invest 118, 3619-3628. 
van Rood, J.J., Stevens, C.E., Smits, J., Carrier, C., Carpenter, C., and 
Scaradavou, A. (2009). Reexposure of cord blood to noninherited maternal 
HLA antigens improves transplant outcome in hematological malignancies. 
Proc Natl Acad Sci U S A 106, 19952-19957. 
Venken, K., Thewissen, M., Hellings, N., Somers, V., Hensen, K., Rummens, 
J.L., and Stinissen, P. (2007). A CFSE based assay for measuring 
CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific 
and polyclonal T cell responses. J Immunol Methods 322, 1-11. 
Verneris, M.R., Brunstein, C.G., Barker, J., MacMillan, M.L., DeFor, T., 
McKenna, D.H., Burke, M.J., Blazar, B.R., Miller, J.S., McGlave, P.B., et al. 
(2009). Relapse risk after umbilical cord blood transplantation: enhanced graft-
versus-leukemia effect in recipients of 2 units. Blood 114, 4293-4299. 
Vignali, D.A., Collison, L.W., and Workman, C.J. (2008). How regulatory T 
cells work. Nat Rev Immunol 8, 523-532. 
von Boehmer, H., and Melchers, F. (2010). Checkpoints in lymphocyte 
development and autoimmune disease. Nat Immunol 11, 14-20. 
Vukmanovic-Stejic, M., Zhang, Y., Cook, J.E., Fletcher, J.M., McQuaid, A., 
Masters, J.E., Rustin, M.H., Taams, L.S., Beverley, P.C., Macallan, D.C., et al. 
(2006). Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid 
turnover of memory populations in vivo. J Clin Invest 116, 2423-2433. 
Wagner, J.E., Barker, J.N., DeFor, T.E., Baker, K.S., Blazar, B.R., Eide, C., 
Goldman, A., Kersey, J., Krivit, W., MacMillan, M.L., et al. (2002). 
Transplantation of unrelated donor umbilical cord blood in 102 patients with 
 178 
malignant and nonmalignant diseases: influence of CD34 cell dose and HLA 
disparity on treatment-related mortality and survival. Blood 100, 1611-1618. 
Waldmann, H. (2008). Tolerance can be infectious. Nat Immunol 9, 1001-
1003. 
Weaver, C.T., and Hatton, R.D. (2009). Interplay between the TH17 and TReg 
cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 9, 883-889. 
Wichlan, D.G., Roddam, P.L., Eldridge, P., Handgretinger, R., and Riberdy, 
J.M. (2006). Efficient and reproducible large-scale isolation of human CD4+ 
CD25+ regulatory T cells with potent suppressor activity. J Immunol Methods 
315, 27-36. 
Wildin, R.S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J.L., Buist, N., 
Levy-Lahad, E., Mazzella, M., Goulet, O., Perroni, L., et al. (2001). X-linked 
neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the 
human equivalent of mouse scurfy. Nat Genet 27, 18-20. 
Wing, K., Larsson, P., Sandstrom, K., Lundin, S.B., Suri-Payer, E., and Rudin, 
A. (2005). CD4+ CD25+ FOXP3+ regulatory T cells from human thymus and 
cord blood suppress antigen-specific T cell responses. Immunology 115, 516-
525. 
Wing, K., and Sakaguchi, S. (2010). Regulatory T cells exert checks and 
balances on self tolerance and autoimmunity. Nat Immunol 11, 7-13. 
Wuest, T.Y., Willette-Brown, J., Durum, S.K., and Hurwitz, A.A. (2008). The 
influence of IL-2 family cytokines on activation and function of naturally 
occurring regulatory T cells. J Leukoc Biol 84, 973-980. 
Yu, A., Zhu, L., Altman, N.H., and Malek, T.R. (2009a). A low interleukin-2 
receptor signaling threshold supports the development and homeostasis of T 
regulatory cells. Immunity 30, 204-217. 
 179 
Yu, D., Rao, S., Tsai, L.M., Lee, S.K., He, Y., Sutcliffe, E.L., Srivastava, M., 
Linterman, M., Zheng, L., Simpson, N., et al. (2009b). The transcriptional 
repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 
31, 457-468. 
Yifan Zhan, David P. Funda, Alison L. Every, Petra Fundova, Jared F. Purton, 
Douglas R. Liddicoat, Timothy J. Cole, Dale I. Godfrey, Jamie L. Brady, Stuart 
I. Mannering, Leonard C. Harrison and Andrew M. Lew (2004). "TCR-mediated 
activation promotes GITR upregulation in T cells and resistance to 
glucocorticoid-induced death". International Immunology 16 (9): 1315–132 
Zhang, N., Schroppel, B., Lal, G., Jakubzick, C., Mao, X., Chen, D., Yin, N., 
Jessberger, R., Ochando, J.C., Ding, Y., et al. (2009). Regulatory T cells 
sequentially migrate from inflamed tissues to draining lymph nodes to suppress 
the alloimmune response. Immunity 30, 458-469. 
Zheng, S.G., Gray, J.D., Ohtsuka, K., Yamagiwa, S., and Horwitz, D.A. 
(2002). Generation ex vivo of TGF-beta-producing regulatory T cells from 
CD4+CD25- precursors. J Immunol 169, 4183-4189. 
Zhou, L., Chong, M.M., and Littman, D.R. (2009a). Plasticity of CD4+ T cell 
lineage differentiation. Immunity 30, 646-655. 
Zhou, Q., Yan, J., Putheti, P., Wu, Y., Sun, X., Toxavidis, V., Tigges, J., 
Kassam, N., Enjyoji, K., Robson, S.C., et al. (2009b). Isolated CD39 expression 
on CD4+ T cells denotes both regulatory and memory populations. Am J 
Transplant 9, 2303-2311. 
Zinkernagel, R.M., Dunlop, M.B., and Doherty, P.C. (1975). Cytotoxic T cell 
activity is strain-specific in outbred mice infected with lymphocytic 
choriomeningitis virus. J Immunol 115, 1613-1616. 
 
 180 
Appendix 
Source HLA-A HLA-B HLA-Cw HLA-DRB1 
HC1 02/3002 51/18  1602/03 
HC2 31/68 5101/5101 16/15 01/15 
HC3 03/23 0702/0702 0702/0702 1501/1501 
HC4 03/2901 44/44  11/07 
HC5 1101/68 3501/3503 04/04 0103/1201 
CB1 2601/3001 1302/3801 602/1202 1501/301 
CB2 2402/2402 1801/4901 701/701 1104/1302 
CB3 201/2402 4402/1402 202/501 1601/701 
CB4 101/3101 5101/801 701/1501 1501/301 
CB5 1101/3201 5701/4901 701/701 405/701 
CB6 2402/2501 5101/801 701/1504 407/1101 
CB7 201/3301 5101/4403 202/401 301/1101 
CB8 301/301 5101/3501 102/401 101/1302 
CB9 201/2402 5108/702 702/1602 1201/1302 
CB10 205/6802 1402/4101 701/802 102/701 
CB11 101/201 1517/5001 602/701 1302/806 
CB12 101/3301 1402/5701 701/802 301/701 
CB13 101/201 801/4402 501/701 101/1114 
CB14 201/6801 5002/3508 401/602 1301/701 
CB15 3002/6801 5201/5301 602/701 1102/1101 
CB16 201/2402 702/4001 302/702 101/101 
CB17 301/2901 5101/4501 303/602 404/701 
CB18 2011/2402 3901/3901 302/702 407/901 
CB19 101/201 5108/1517 701/1602  
CB20 201/3301 1401/3508 401/802 1501/701 
CB21 201/201 3501/4001 304/401 301/1301 
CB22 1101/3001 5101/1501 303/1502 1501/1103 
CB23 301/3201 1401/1402 802/802 102/701 
CB24 2301/2402 1302/4901 602/701 403/701 
CB25 2301/2601 4402/3801 501/1202  
CB26 2601/6801 4403/3503 202/401 301/701 
CB27 201/2402 702/4901 702/701 101/1501 
CB28 201/2301 4403/3901 401/1203 1601/1104 
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CB29 2301/2901 4403/1503 202/1601 405/701 
CB30 2402/2901 702/4901 702/701 1401/1001 
CB31 201/2901 4402/4403 501/1601 101/401 
CB32 301/2601 3801/3503 401/1203 1301/701 
CB33 201/2901 4403/3904 1202/1601 403/1104 
 
Appendix of section 2.8  
 182 
Publications 
-Figueroa-Tentori D, Querol S, et al. High purity and yield of natural Tregs 
from cord blood using a single step selection method: J Immunol Methods 
339,228-35 (2008). 
 
Abstract published 
--Figueroa-Tentori D, Duggleby R.C, Querol S, Madrigal J. A. Cord Blood 
Tregs can be pooled and effectively suppressive in mixed lymphocyte cultures. 
Oral Abstract 834.. Transplantation. 2008 Jul; 86(2s): 291. 
 
In preparation 
Regulation of allorecognition by HLA disparities of cord blood CD4+ CD25+ 
FoxP3+ T cells 
 
Presentations 
- Regulatory T cell immunotherapy: the more the merrier: UCL Cancer Institute 
Conference, London, UK July (2009) (Oral) 
 
- “Off the shelf” cord blood Tregs: practical and functional source for Regulatory 
T cells immunotherapy: The 2nd. Newcastle Therapeutic Tolerance Workshop, 
Newcastle, UK June (2009) (Best poster Award) 
 
 
 
 183 
-Pooling of naïve cord blood Tregs; a new approach to achieve good qualiy and 
cell numbers for cellular immunotherapy: International Conference on 
Regulatory T cells and Clinical Application in Human Diseases, Beijing, China, 
October (2008) (Poster) 
 
-Cord Blood Tregs can be pooled and effectively suppressive in mixed 
lymphocyte culture: XXII International congress of the Transplantation Society, 
Sydney, Australia, August (2008) (Oral) 
 
